<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1662-4548</issn>
<issn pub-type="epub">1662-453X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29867317</article-id>
<article-id pub-id-type="pmc">5964170</article-id>
<article-id pub-id-type="doi">10.3389/fnins.2018.00304</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Eissa</surname>
<given-names>Nermin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/489314/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Houqani</surname>
<given-names>Mohammed</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/533033/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sadeq</surname>
<given-names>Adel</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ojha</surname>
<given-names>Shreesh K.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/300729/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sasse</surname>
<given-names>Astrid</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/502007/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sadek</surname>
<given-names>Bassem</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/419903/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University</institution>, <addr-line>Al Ain</addr-line>, <country>United Arab Emirates</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University</institution>, <addr-line>Al Ain</addr-line>, <country>United Arab Emirates</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Clinical Pharmacy, College of Pharmacy, Al Ain University of Science and Technology</institution>, <addr-line>Al Ain</addr-line>, <country>United Arab Emirates</country></aff>
<aff id="aff4"><sup>4</sup><institution>School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin</institution>, <addr-line>Dublin</addr-line>, <country>Ireland</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Francisco Lopez-Munoz, Universidad Camilo José Cela, Spain</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Dr. Girish Kumar Gupta, Maharishi Markandeshwar University, Mullana, India; Mohamed M. Abdel-Daim, Suez Canal University, Egypt</p>
</fn>
<corresp id="c001">*Correspondence: Bassem Sadek <email>bassem.sadek@uaeu.ac.ae</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>12</volume>
<elocation-id>304</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>4</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Eissa, Al-Houqani, Sadeq, Ojha, Sasse and Sadek.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Eissa, Al-Houqani, Sadeq, Ojha, Sasse and Sadek</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Autistic Spectrum Disorder (ASD) is a complex neurodevelopmental brain disorder characterized by two core behavioral symptoms, namely impairments in social communication and restricted/repetitive behavior. The molecular mechanisms underlying ASD are not well understood. Recent genetic as well as non-genetic animal models contributed significantly in understanding the pathophysiology of ASD, as they establish autism-like behavior in mice and rats. Among the genetic causes, several chromosomal mutations including duplications or deletions could be possible causative factors of ASD. In addition, the biochemical basis suggests that several brain neurotransmitters, e.g., dopamine (DA), serotonin (5-HT), gamma-amino butyric acid (GABA), acetylcholine (ACh), glutamate (Glu) and histamine (HA) participate in the onset and progression of ASD. Despite of convincible understanding, risperidone and aripiprazole are the only two drugs available clinically for improving behavioral symptoms of ASD following approval by Food and Drug Administration (FDA). Till date, up to our knowledge there is no other drug approved for clinical usage specifically for ASD symptoms. However, many novel drug candidates and classes of compounds are underway for ASD at different phases of preclinical and clinical drug development. In this review, the diversity of numerous aetiological factors and the alterations in variety of neurotransmitter generation, release and function linked to ASD are discussed with focus on drugs currently used to manage neuropsychiatric symptoms related to ASD. The review also highlights the clinical development of drugs with emphasis on their pharmacological targets aiming at improving core symptoms in ASD.</p>
</abstract>
<kwd-group>
<kwd>autistic spectrum disorder</kwd>
<kwd>genetic factors</kwd>
<kwd>environmental factors</kwd>
<kwd>neurotransmitter dysfunctions</kwd>
<kwd>neurodegeneration</kwd>
<kwd>neuroprotection</kwd>
<kwd>cognitive deficits</kwd>
<kwd>pharmacological intervention</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">United Arab Emirates University<named-content content-type="fundref-id">10.13039/501100006013</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="4"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="249"></ref-count>
<page-count count="26"></page-count>
<word-count count="18993"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Autistic spectrum disorder (ASD) is a biologically based neurodevelopmental disorder affecting two major core behavioral symptoms, namely impairments in social skills and restricted /repetitive behavioral pattern or interest of ASD patients (Baronio et al., <xref ref-type="bibr" rid="B17">2015</xref>). These core symptoms can be observed before the age of three years and are lasting for the whole lifetime (Andres, <xref ref-type="bibr" rid="B7">2002</xref>). ASD has become high priority for scientists and health care providers, and has also attracted the public attention because of reported increase in its prevalence (Sheldrick and Carter, <xref ref-type="bibr" rid="B216">2018</xref>; Xu et al., <xref ref-type="bibr" rid="B247">2018</xref>). The worldwide estimated prevalence of individuals with ASD diagnosis is strikingly high with prevalence varying across numerous studies, but it is estimated that one in 160 children has an ASD worldwide, and it is expected to increase globally (Arvidsson et al., <xref ref-type="bibr" rid="B10">2018</xref>). Despite its increasing prevalence, the pathophysiology of ASD is still understood incompletely, and this can be attributed to challenges in identifying suitable animal models and the complexity of the neurobiology in brain function (Nestler and Hyman, <xref ref-type="bibr" rid="B171">2010</xref>). Several evidences suggest that strong genetic and environmental factors rise the occurrence of ASD in childhood (Baronio et al., <xref ref-type="bibr" rid="B17">2015</xref>). To date, there are no efficient therapeutic interventions that target the core symptoms of ASD, namely social communication impairments and restricted/repetitive behavior (Sheldrick and Carter, <xref ref-type="bibr" rid="B216">2018</xref>; Xu et al., <xref ref-type="bibr" rid="B247">2018</xref>). However, pharmacological interventions may be used to provide symptomatic control of associated comorbidities but not to treat core deficits (Wong and Smith, <xref ref-type="bibr" rid="B244">2006</xref>; Hanson et al., <xref ref-type="bibr" rid="B88">2007</xref>). Notably, it is nowadays believed that ASD and schizophrenia (SCH) are conceptualized as two separate disorders, despite the fact that both ASD and SCH were found to share multiple aetiologies, phenotypic feature similarities, and risk factors, and were reported to co-occur at elevated rates (Chisholm et al., <xref ref-type="bibr" rid="B41">2015</xref>).</p>
</sec>
<sec id="s2">
<title>Etiology of ASD</title>
<p>ASD is broadly considered to be a multi-factorial disorder that results from genetic as well as non-genetic risk factors. There is cumulative evidence for the involvement of genetic factors in the etiology of ASD, since siblings born in families with ASD are at 35–40% greater risk to develop ASD and with an increase in the current rate of approximately 1% from a rate of 0.05% in 1970s (Stubbs et al., <xref ref-type="bibr" rid="B224">2016</xref>). Moreover, genetic studies revealed that alteration in the developmental pathways of neuronal and axonal structures that are strongly involved in synaptogenesis emerge from single gene mutations (Geschwind, <xref ref-type="bibr" rid="B72">2011</xref>; Voineagu et al., <xref ref-type="bibr" rid="B232">2011</xref>; Chang et al., <xref ref-type="bibr" rid="B35">2015</xref>). It is likely that interactions between multiple genes, and variability in expression as a result of epigenetic factors and exposure to environmental factors are responsible for ASD (Muhle et al., <xref ref-type="bibr" rid="B165">2004</xref>). In a previous clinical study involving a twin, it was appraised that the risk of developing ASD was 35–40% due to genetic variability, and the remaining 60% was contributed to by prenatal, perinatal, and postnatal environmental factors (Hallmayer et al., <xref ref-type="bibr" rid="B85">2011</xref>). Accordingly, environmental factors implicated with ASD included prenatal and perinatal complications (Glasson et al., <xref ref-type="bibr" rid="B75">2004</xref>; Maramara et al., <xref ref-type="bibr" rid="B146">2014</xref>), birth and neonatal complications (Gardener et al., <xref ref-type="bibr" rid="B71">2011</xref>; Guinchat et al., <xref ref-type="bibr" rid="B83">2012</xref>), viral infection, autoimmune diseases, and exposure to teratogens and maternal anticonvulsants such as valproic acid (VPA) (Kern and Jones, <xref ref-type="bibr" rid="B123">2006</xref>; Kolevzon et al., <xref ref-type="bibr" rid="B128">2007</xref>). Therefore, an increased understanding of the interface between genetic and environmental factors in the pathogenesis of ASD may lead to an optimized therapeutic strategy.</p>
</sec>
<sec id="s3">
<title>Correlation of neurotransmitters dysfunction to ASD</title>
<p>Research has also focused on the study of neurotransmitters, in search of sensitive and specific markers of ASD as well as potential therapeutic interventions. The role of several central neurotransmitters (e.g., 5-HT, ACh, DA, GABA and Glu) in initial brain development may substantiate to be a significant area in studying the etiology of ASD. Certain disruption of brain neurotransmissions early during the development phase of the CNS may demonstrate early pharmacological intervention that helps to cure and maybe even preclude some of the severe behavioral symptoms of ASD. Ideally, the work in genetics may be able to explain these neurochemical defects at birth, providing possible appropriate medical treatment for infants who are at increased risk for ASD. This would completely exhibit new therapeutic tactic to the clinical control of ASD. Growing evidences suggest that a variety of several neurotransmitter systems such as ACh, 5-HT, DA, GABA, Glu, and HA are implicated in the onset and progression of ASD -along with genetic and environmental factors discussed below- (Shah and Wing, <xref ref-type="bibr" rid="B214">2006</xref>; Bacchelli et al., <xref ref-type="bibr" rid="B13">2015</xref>; Ellenbroek and Ghiabi, <xref ref-type="bibr" rid="B59">2015</xref>; Wang et al., <xref ref-type="bibr" rid="B238">2015</xref>; Chen et al., <xref ref-type="bibr" rid="B39">2017</xref>; Hellings et al., <xref ref-type="bibr" rid="B91">2017</xref>; Hellmer and Nystrom, <xref ref-type="bibr" rid="B94">2017</xref>; Naaijen et al., <xref ref-type="bibr" rid="B167">2017</xref>; Nakai et al., <xref ref-type="bibr" rid="B169">2017</xref>; Paval, <xref ref-type="bibr" rid="B184">2017</xref>; Paval et al., <xref ref-type="bibr" rid="B185">2017</xref>; Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Reported findings in different brains of ASD patients with altered central neurotransmitters.</p>
</caption>
<graphic xlink:href="fnins-12-00304-g0001"></graphic>
</fig>
<sec>
<title>Serotonin</title>
<p>Among all neurotransmitters investigated so far in ASD, 5-HT has motivated the most research efforts and investigations. 5-HT signaling facilitates several neural processes including neurogenesis, cell migration and survival, synaptogenesis, and synaptic plasticity. Interestingly, high 5-HT levels in the blood have been described for up to 45% of tested ASD subjects(Chen et al., <xref ref-type="bibr" rid="B37">2015</xref>, <xref ref-type="bibr" rid="B39">2017</xref>; Ellenbroek et al., <xref ref-type="bibr" rid="B58">2016</xref>). Moreover, preclinical investigations using ASD-like animal models reported that hyperserotonemia significantly reduced the motivation for social interest through inhibition of separation distress, potentially accounting for the social impairments found in ASD individuals (Ellenbroek et al., <xref ref-type="bibr" rid="B58">2016</xref>; Nakai et al., <xref ref-type="bibr" rid="B169">2017</xref>). Furthermore, 5-HT was found to accumulate mainly in platelets utilizing the specific 5-HT transporter. In line with these findings, genetic studies of linkage stated that the 17q11.2 region containing the 5-HT transporter gene <italic>SLC6A4</italic> polymorphisms appear to be associated with ASD, as Gly56 conversion to Ala56 in the transporter protein resulted in autistic phenotypic features combined with an amplified p38-mitogen-activated protein kinases (MAPK)-sensitive basal phosphorylation process. In addition and in a previous study, higher clearance rates of hippocampal 5-HT were observed and hence hyperserotonemia, which led to a significant hypersensitivity of brain 5-HT(1A) as well as 5-HT(2A) receptors, social impairment and repetitive behavior (Veenstra-VanderWeele et al., <xref ref-type="bibr" rid="B230">2012</xref>; Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
</sec>
<sec>
<title>Dopamine</title>
<p>Dopamine (DA) plays a fundamental role in brain functioning, and the pathophysiological role of dopaminergic system (DS) deficits in ASD is well recognized, with the wide clinical use of antipsychotics that mainly target the D2 receptors (D2Rs)(Seeman, <xref ref-type="bibr" rid="B213">2010</xref>; Baronio et al., <xref ref-type="bibr" rid="B18">2014</xref>) Interestingly, and in a very recent preclinical study, it has been shown that mice with increased dopaminergic neurotransmission in the dorsal striatum via the suppression of dopamine transporter expression in substantia nigra neurons or the optogenetic stimulation of the nigro-striatal circuitry exhibited significant deficits in sociability and repetitive behaviors relevant to ASD pathology in several rodent models, while these behavioral changes were blocked by using D1R antagonists (Lee et al., <xref ref-type="bibr" rid="B138">2017</xref>). Therefore, D1R agonists produced typical autistic-like behaviors in normal mice or the genetic knockout (KO) of D2Rs (Lee et al., <xref ref-type="bibr" rid="B138">2017</xref>). Furthermore, the siRNA-mediated inhibition of D2Rs in the dorsal striatum was shown to replicate ASD-like phenotypes in D2R KO mice (Lee et al., <xref ref-type="bibr" rid="B138">2017</xref>). With regard to the DS, genetic studies have demonstrated that mutations of DS-associated genes such as the DA transporter (DAT) (Hamilton et al., <xref ref-type="bibr" rid="B86">2013</xref>), DA receptors (Hettinger et al., <xref ref-type="bibr" rid="B96">2008</xref>; Qian et al., <xref ref-type="bibr" rid="B192">2013</xref>), and enzymes of DA biosynthesis (Nguyen et al., <xref ref-type="bibr" rid="B172">2014</xref>) are implicated in ASD. These studies expanded the evidences of genetically linking between DA transporter and ASD (Hamilton et al., <xref ref-type="bibr" rid="B86">2013</xref>; Bowton et al., <xref ref-type="bibr" rid="B23">2014</xref>). ASD is strongly associated with a mutation in the DA transporter gene <italic>SLC6A3</italic>, which codes for a protein that contributes to regulation of DA levels in the brain. In fact, DAT is the crucial regulator of DA homeostasis and alteration of this homeostasis as a consequence of DAT dysfunction is associated with ASD and other neuropsychiatric conditions (Hamilton et al., <xref ref-type="bibr" rid="B86">2013</xref>; Hellings et al., <xref ref-type="bibr" rid="B91">2017</xref>; Paval, <xref ref-type="bibr" rid="B184">2017</xref>; Paval et al., <xref ref-type="bibr" rid="B185">2017</xref>). Moreover, it has been found that the dopaminergic fibers arising from the ventral tegmental area (VTA) project to the prefrontal cortex (PFC) and to regions of the limbic system, such as the nucleus accumbens (NAcc), forming the mesocorticolimbic (MCL) circuit. This circuit was found to be involved in high order brain functions, such as emotional social behavior, reward, motivation and cognition (Paval et al., <xref ref-type="bibr" rid="B185">2017</xref>) (Hellings et al., <xref ref-type="bibr" rid="B91">2017</xref>; Figure <xref ref-type="fig" rid="F1">1</xref>). Notably, the DS has been related to behavioral skills belonging to executive functioning, such as analyzing, planning and prioritizing (Seeman, <xref ref-type="bibr" rid="B213">2010</xref>; Baronio et al., <xref ref-type="bibr" rid="B18">2014</xref>). In line with that, children diagnosed with ASD were found to show deficits in tasks linked to executive functioning, including response/selection, planning/working memory and flexibility (Hellings et al., <xref ref-type="bibr" rid="B91">2017</xref>; Paval et al., <xref ref-type="bibr" rid="B185">2017</xref>). Moreover, the DS has strongly been linked to social behavior, attentional skills and perception, and motor activity, while development abnormalities in these areas have all been linked to ASD as well (Hellings et al., <xref ref-type="bibr" rid="B91">2017</xref>; Paval et al., <xref ref-type="bibr" rid="B185">2017</xref>).</p>
</sec>
<sec>
<title>GABA and glutamate</title>
<p>Gabaminergic as well as glutaminergic systems are also proposed as potential mechanisms for ASD. Consequently, mutations in the respective synaptic proteins would lead to defective neurotransmissions at excitatory and inhibitory synapses, leading to disruption of excitatory-inhibitory balance of neurotransmissions in postsynaptic neurons, a key mechanism which has strongly been associated with ASD (Jamain et al., <xref ref-type="bibr" rid="B114">2002</xref>; Naaijen et al., <xref ref-type="bibr" rid="B167">2017</xref>). In addition to numerous reports stating the duplication of 15q11-13 locus in ASD populations, a majority of the cases do not show mutations at this locus. However, they do exhibit abnormalities in the expression of protein encoded by 15q11-13 gene, as reported. These results demonstrated the involvement of 15q11-13 locus in ASD, either directly by mutation or indirectly by epigenetic factors (Hogart et al., <xref ref-type="bibr" rid="B99">2007</xref>; Nakai et al., <xref ref-type="bibr" rid="B169">2017</xref>). This site employs numerous genes coding for particular subunits of GABA receptors, namely GABRB3, GABRA5 and GABRG3. There are numerous signaling and scaffolding proteins which are implicated in normal development and GABA synapse function. Therefore, mutations in the genes encoding these proteins consequently result in GABAergic dysfunction, hence inhibitory signaling deficits. For example, deletions in gene encoding a protein contactin-associated protein 2 (CNTNAP2) has been linked to ASD (Stephan, <xref ref-type="bibr" rid="B222">2008</xref>; Gregor et al., <xref ref-type="bibr" rid="B80">2011</xref>; Nord et al., <xref ref-type="bibr" rid="B176">2011</xref>). Moreover, deficiency in CNTNAP2 results in reduction in GAD1, parvalbumin and inhibitory interneurons along with impairments in inhibitory signaling (Peñagarikano et al., <xref ref-type="bibr" rid="B186">2011</xref>; Soghomonian et al., <xref ref-type="bibr" rid="B218">2017</xref>). This evidence suggests an association and the relation between mutations affecting the function of GABA and ASD. Furthermore, reduced expression of GABAergic genes and lower density of GABA related proteins have been found in individual brains of ASD patients. Consequently, alterations in GABA-A receptor genes and other genes expressed on GABA interneurons, as well as GABA biosynthesis enzymes (GAD 65 and GAD 67) in the cerebellum and parietal cortex, are strongly implicated in ASD (Fatemi et al., <xref ref-type="bibr" rid="B64">2002</xref>; Coghlan et al., <xref ref-type="bibr" rid="B46">2012</xref>). On the contrary, an increased level in the expression of excitatory Glu receptor AMPA, and of Glu transporter proteins were observed in individuals diagnosed with ASD, with highest expression abnormalities found in the cerebellum (Purcell et al., <xref ref-type="bibr" rid="B191">2001</xref>; Figure <xref ref-type="fig" rid="F1">1</xref>). Based on the aforementioned, altered expression of genes related to GABA and/or Glu might be linked to several ASD phenotypic features including cognitive deficits and/or hyperactivity (Jamain et al., <xref ref-type="bibr" rid="B114">2002</xref>; Naaijen et al., <xref ref-type="bibr" rid="B167">2017</xref>). Moreover, abnormalities in both neurotransmitters including an increase in the excitatory Glu and/or decrease in the inhibitory GABA were found to lead to epileptic seizure, a clinical feature which is commonly observed in ASD patients (Ballaban-Gil and Tuchman, <xref ref-type="bibr" rid="B16">2000</xref>; Levisohn, <xref ref-type="bibr" rid="B140">2007</xref>; Gillberg et al., <xref ref-type="bibr" rid="B73">2017</xref>).</p>
</sec>
<sec>
<title>Acetylcholine</title>
<p>The brain cholinergic neurotransmission system with ACh plays an essential role in regulating ASD-related behavioral symptoms including attention (Arnold et al., <xref ref-type="bibr" rid="B9">2002</xref>), cognitive flexibility (Ragozzino et al., <xref ref-type="bibr" rid="B193">1998</xref>), social interaction (Avale et al., <xref ref-type="bibr" rid="B12">2011</xref>) and stereotypical behaviors (McConville et al., <xref ref-type="bibr" rid="B151">1992</xref>; Bacchelli et al., <xref ref-type="bibr" rid="B13">2015</xref>; Wang et al., <xref ref-type="bibr" rid="B238">2015</xref>; Hellmer and Nystrom, <xref ref-type="bibr" rid="B94">2017</xref>). Mounting evidences suggest the involvement of cholinergic system dysfunction in the phenotypic outcomes of ASD-related behavioral features, in both humans and animal models - (Karvat and Kimchi, <xref ref-type="bibr" rid="B118">2014</xref>). In ASD patients, there are remarkable abnormalities in the cholinergic system. Anatomically there is irregularity in the number and structure of neurons in a basal forebrain cholinergic nucleus of patients diagnosed with ASD (Kemper and Bauman, <xref ref-type="bibr" rid="B122">1998</xref>). Also, a decrease in the level of choline, the precursor of the neurotransmitter ACh and the agonist for nicotinic-cholinergic receptor (nAChR), was determined in individuals diagnosed with ASD (Friedman et al., <xref ref-type="bibr" rid="B68">2006</xref>), with the severity of ASD related to the decreased level of cytosolic ACh (Sokol et al., <xref ref-type="bibr" rid="B219">2002</xref>). Moreover, and by using immunohistochemical analyses, abnormalities in nAChR were observed in several brain regions (e.g., neocortex, cerebellum, thalamus and striatum) of ASD patients, specifically with the major abnormalities being reduction in nAChR subunits and muscarinic receptors (M1 type) (Mukaetova-Ladinska, <xref ref-type="bibr" rid="B166">2017</xref>). Moreover, the brain ACh like several other brain neurotransmitters, e.g., DA, 5-HT and GABA, playing a key role in ASD are regulated by different central mechanisms including histamine H3 hetero-receptors (H3Rs), highlighting the attention to brain histaminergic system involvement in the ASD (Sadek and Stark, <xref ref-type="bibr" rid="B204">2015</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref>; Alachkar et al., <xref ref-type="bibr" rid="B1">2017</xref>; Eissa et al., <xref ref-type="bibr" rid="B56">2018</xref>). Genetically, studies reported duplications and mutations in <italic>CHRNA7</italic>, the gene encoding the α7nAChR subunit, in ASD patients (Mikhail et al., <xref ref-type="bibr" rid="B159">2011</xref>; Leblond et al., <xref ref-type="bibr" rid="B136">2012</xref>), whereas deletion of the <italic>CHRNB2</italic> gene, encoding the β2-subunit of nAChR was observed in other cases (Granon et al., <xref ref-type="bibr" rid="B79">2003</xref>). Furthermore, ASD related behavior may be linked to M1 type mAChR inhibition (McCool et al., <xref ref-type="bibr" rid="B152">2008</xref>) and cholinergic cell damage (Walker et al., <xref ref-type="bibr" rid="B236">2007</xref>; Figure <xref ref-type="fig" rid="F1">1</xref>). Consequently, social deficits and repetitive behaviors are the main phenotypic ASD features connected to disruption in cholinergic neurotransmission system (Wang et al., <xref ref-type="bibr" rid="B238">2015</xref>). Also, reduced attention (Arnold et al., <xref ref-type="bibr" rid="B9">2002</xref>), decreased cognitive flexibility (Ragozzino et al., <xref ref-type="bibr" rid="B193">1998</xref>), reduced social communications (Avale et al., <xref ref-type="bibr" rid="B12">2011</xref>) and conventional behaviors have been strongly linked to cholinergic neurotransmission dysfunction (McConville et al., <xref ref-type="bibr" rid="B151">1992</xref>; Bacchelli et al., <xref ref-type="bibr" rid="B13">2015</xref>; Wang et al., <xref ref-type="bibr" rid="B238">2015</xref>; Hellmer and Nystrom, <xref ref-type="bibr" rid="B94">2017</xref>).</p>
</sec>
<sec>
<title>Histamine</title>
<p>The brain histaminergic system was found to display a critical role in cognition, sleep and other neuropsychiatric disorders including schizophrenia (SCH) and Tourette syndrome that share comorbidity with ASD (Wright et al., <xref ref-type="bibr" rid="B245">2017</xref>). Moreover, alteration in gene expression was found for histamine-<italic>N</italic>-methyltransferase enzyme (HNMT, enzyme responsible for metabolism of central histamine (HA) and for histamine receptor (HR) subtypes H1-, H2-, and H3R (Wright et al., <xref ref-type="bibr" rid="B245">2017</xref>). Notably, there has in the last two decades been a rising interest in studying the role of brain HA on behaviors in both physiological conditions and psychiatric diseases, e.g., SCH (Sadek and Stark, <xref ref-type="bibr" rid="B204">2015</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref>). Interestingly and as revealed in several clinical reports, patients with SCH shared a variety of common symptoms and genetic factors with ASD (Konstantareas and Hewitt, <xref ref-type="bibr" rid="B131">2001</xref>; Carroll and Owen, <xref ref-type="bibr" rid="B33">2009</xref>). Moreover, a significant role for the brain HA has been projected, and a range of several H3R ligands has been developed so far for dual-targeting of both dopaminergic as well as histaminergic neurotransmissions (Bishara, <xref ref-type="bibr" rid="B20">2010</xref>; Baronio et al., <xref ref-type="bibr" rid="B18">2014</xref>). Furthermore and as discussed above, deficits in regulations of various other neurotransmitters including DA, 5-HT, GABA, and Glu are postulated (Witkin and Nelson, <xref ref-type="bibr" rid="B243">2004</xref>). Therefore, the role of central HA that influences behavior in CNS disorder sheds light on the histaminergic system as pharmacological target for therapeutic purposes (Haas et al., <xref ref-type="bibr" rid="B84">2008</xref>; Tiligada et al., <xref ref-type="bibr" rid="B227">2011</xref>; Shan et al., <xref ref-type="bibr" rid="B215">2012</xref>; Naddafi and Mirshafiey, <xref ref-type="bibr" rid="B168">2013</xref>). Interestingly, brain H3Rs act as auto-receptors or hetero-receptors that regulates the biosynthesis and release of HA and several other neurotransmitters, which consequently play a role in cognitive and homeostatic processes, as shown in Figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>. Therefore, there is an indirect indication that histaminergic neurotransmission may have a significant role in SCH and that potent and selective H3R antagonists could lead to therapeutic improvements of cognitive symptoms associated with SCH and ASD (Witkin and Nelson, <xref ref-type="bibr" rid="B243">2004</xref>; Esbenshade et al., <xref ref-type="bibr" rid="B61">2008</xref>; von Coburg et al., <xref ref-type="bibr" rid="B234">2009</xref>; Brown et al., <xref ref-type="bibr" rid="B27">2013</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref>). To date there are scarce literature studies concerning the association of H3R antagonists and treatment of ASD behavioral deficits. Accordingly and in a previous preclinical study, the imidazole-based H3R antagonists, namely thioperamide and ciproxifan, improved the decreased prepulse inhibition in an animal model of SCH (Brown et al., <xref ref-type="bibr" rid="B27">2013</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>, Table <xref ref-type="table" rid="T4">4</xref>). Thioperamide and ciproxifan are selective and potent imidazole-based H3R antagonists that are widely used in preclinical animal experiments (Ligneau et al., <xref ref-type="bibr" rid="B142">1998</xref>; Stark et al., <xref ref-type="bibr" rid="B220">2000</xref>). However, the preclinical use of numerous non-imidazole-based H3R antagonists, e.g., ABT-239 and A-431404, ameliorated ketamine- and/or MK-801-induced cognitive impairments in experimental rats, demonstrating enhanced results when compared with reference antipsychotics like risperidone or olanzapine (Brown et al., <xref ref-type="bibr" rid="B27">2013</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>, Table <xref ref-type="table" rid="T4">4</xref>). Interestingly, H3R antagonists possess antioxidant activity which could increase their potential clinical use, since oxidative stress is, also, considered as possible predictors of intensified symptoms of SCH and ASD (Mahmood et al., <xref ref-type="bibr" rid="B145">2012</xref>). Moreover, a study considering the effectiveness of the non-imidazole H3R antagonist ABT-288 in the treatment of cognitive deficits linked with SCH revealed that schizophrenic features remained constant during the whole time period of the study, with acceptable safety, tolerability and pharmacokinetics profile of ABT-288 at a 15-fold higher dose and 12-fold higher exposures in subjects with SCH than previously observed in healthy volunteers (Coruzzi et al., <xref ref-type="bibr" rid="B49">2012</xref>) (Hsieh et al., <xref ref-type="bibr" rid="B107">2010</xref>). Moreover, the use of a H3R antagonist ameliorated behavioral impairments in an animal model of SCH, including spatial working memory deficit, an abnormality which also characterizes patients with ASD (Steele et al., <xref ref-type="bibr" rid="B221">2007</xref>). Also, a recent preclinical study reported that an acute systemic administration of ciproxifan palliated some sociability impairments and stereotypic behavior in an animal model of VPA-induced ASD in mice (Baronio et al., <xref ref-type="bibr" rid="B17">2015</xref>). However, further research efforts are still necessary to magnify these observed initial data and to achieve enhanced understanding of pathophysiology and therapeutic management of ASD. Based on the aforementioned observations, numerous brain neurotransmitters, e.g., 5-HT, DA, GABA, Glu, ACh, and HA appear to be implicated in the pathophysiology of ASD, since disruption of genes encoding different proteins (receptors and/or catalyzing biosynthesis enzymes for respective neurotransmitter) that affect the respective neurotransmission functionality leads to a variety of phenotypic features of ASD. Interestingly, the above discussed dysfunctions of neurotransmitters, namely 5-HT, DA, GABA, Glu, ACh, and HA were, also, found to be influentially implicated in the clinical outcome features of SCH, a disorders that is comorbid and shares multiple etiologies and risk factors with ASD (Chisholm et al., <xref ref-type="bibr" rid="B41">2015</xref>; Devor et al., <xref ref-type="bibr" rid="B53">2017</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Schematic illustration of possible mechanisms of H3R antagonists on H3-auto receptors and hetero-receptors.</p>
</caption>
<graphic xlink:href="fnins-12-00304-g0002"></graphic>
</fig>
</sec>
</sec>
<sec id="s4">
<title>Current pharmacological intervention</title>
<p>Based on the aforementioned abnormalities in genes as well as various neurotransmitter systems, studying the effects of a given drug on core symptoms in ASD is very challenging. Despite advances in early diagnosis and intervention, efficacious reversal of core autistic symptoms is still not accomplished to date. At present time there is no definite pharmacological treatment for ASD but treatments for ASD are based on behavioral therapies and the use of highly controlled learning environments. The recent approaches to treatment of ASD set behavioral therapy and atypical language development, as keystone for ASD therapy along with other treatments that tends to ameliorate associated symptoms and not the core deficits (Sathe et al., <xref ref-type="bibr" rid="B209">2017</xref>; Weitlauf et al., <xref ref-type="bibr" rid="B240">2017</xref>). The heterogeneity of clinical and behavioral features in children diagnosed with ASD contributes to the difficulty in understanding the pathophysiology of this disorder, and consequently, no specific treatment can be effective for all ASD children. Therefore, subgrouping of children based on responses to intervention is essential (James et al., <xref ref-type="bibr" rid="B115">2009</xref>). As mentioned above, targeting ASD core symptoms for complete and effective treatment has been challenging and not yet achieved, however several pharmacological medications maybe effective in various associated symptoms that often cause significant impairments in ASD (Volkmar et al., <xref ref-type="bibr" rid="B233">1999</xref>). These associated symptoms of ASD include inattention, hyperactivity, anxiety, sleep disturbances, irritability, repetitive behavior, aggression and self-injury. Antipsychotics are often used for therapeutic management of ASD symptoms in children (Findling et al., <xref ref-type="bibr" rid="B66">2004</xref>). Currently, atypical antipsychotics risperidone and aripiprazole are the only two drugs which have so far been approved by FDA for improving behavioral symptoms associated with ASD (Matson et al., <xref ref-type="bibr" rid="B149">2011</xref>), however, there are several other pharmacological interventions that show effective clinical management of ASD symptoms. The most promising drugs reported for managing behavioral and neurological symptoms of ASD are acting on different brain targets and are summarized in Table <xref ref-type="table" rid="T1">1</xref>. Accordingly, therapeutic benefits have been observed and described with several classes of drugs including selective serotonin reuptake inhibitors (sertraline, citalopram, fluoxetine) for anxiety and repetitive behaviors, psychostimulant (methylphenidate) for hyperactivity, opioid antagonist (naltrexone) for hyperactivity, and atypical antipsychotics (risperidone, olanzapine, clozapine) for temper tantrums, aggression, or self-injurious behavior (Aman, <xref ref-type="bibr" rid="B3">2004</xref>; Moore et al., <xref ref-type="bibr" rid="B161">2004</xref>; Kumar et al., <xref ref-type="bibr" rid="B133">2012</xref>). Notably, numerous candidates of the classes discussed below have progressed to several phases of clinical trials as shown in Figure <xref ref-type="fig" rid="F3">3</xref>.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Selected medications of different classes that are currently used to manage different ASD symptoms.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Class</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Medication</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Structure</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Pharmacological effects</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Side effects</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Reference</bold>
</th>
</tr>
</thead>
<tbody>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Atypical Antipsychotics</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Clozapine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0001.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves hyperactivity and aggression in ASD patients</td>
<td align="left" colspan="1" rowspan="1" valign="top">Requires patient's hematological safety monitoring and it lowers seizure threshold</td>
<td align="left" colspan="1" rowspan="1" valign="top">Zuddas et al., <xref ref-type="bibr" rid="B249">1996</xref>; Chen et al., <xref ref-type="bibr" rid="B38">2001</xref>; Gobbi and Pulvirenti, <xref ref-type="bibr" rid="B76">2001</xref>; Sahoo et al., <xref ref-type="bibr" rid="B206">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Risperidone</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0002.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduces irritability, repetitive behavior, aggression, anxiety, and depression &amp; nervousness. It shows neuroprotective activity, modulates astroglia function, and increases the brain antioxidant activity.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mild sedation, increased appetite, fatigue, dizziness, drowsiness, tremor, and constipation</td>
<td align="left" colspan="1" rowspan="1" valign="top">McDougle et al., <xref ref-type="bibr" rid="B155">1998b</xref>; McCracken et al., <xref ref-type="bibr" rid="B153">2002</xref>; Hara et al., <xref ref-type="bibr" rid="B89">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Aripiprazole</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0003.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduces autistic symptoms in children such as irritability, stereotypy, and hyperactivity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fatigue, vomiting, weight gain, tremor, and extrapyramidal symptoms</td>
<td align="left" colspan="1" rowspan="1" valign="top">Marcus et al., <xref ref-type="bibr" rid="B147">2009</xref>; Owen et al., <xref ref-type="bibr" rid="B178">2009</xref>; Hirsch and Pringsheim, <xref ref-type="bibr" rid="B97">2016</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Selective Serotonin Reuptake inhibitor (SSRI)</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fluoxetine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0004.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reduces stereotyped and repetitive behavior in children and adolescents with ASD.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypomania. agitation, and hyperactivity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fatemi et al., <xref ref-type="bibr" rid="B65">1998</xref>; DeLong et al., <xref ref-type="bibr" rid="B52">2002</xref>; Hollander et al., <xref ref-type="bibr" rid="B102">2005</xref>; Hendriksen et al., <xref ref-type="bibr" rid="B95">2016</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Fluvoxamine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0005.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves compulsive repetitive behaviors, aggression</td>
<td align="left" colspan="1" rowspan="1" valign="top">Irritability, and increase risk of suicidal ideas</td>
<td align="left" colspan="1" rowspan="1" valign="top">McDougle et al., <xref ref-type="bibr" rid="B156">1996</xref>; Martin et al., <xref ref-type="bibr" rid="B148">2003</xref>; Brown et al., <xref ref-type="bibr" rid="B26">2017</xref>; Howes et al., <xref ref-type="bibr" rid="B105">2018</xref>; Lee et al., <xref ref-type="bibr" rid="B137">2018</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Sertraline</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0006.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">All SSRIs possess similar effects to fluoxetine and fluvoxamine. Sertraline shows improvements in repetitive and disruptive behavior in adults with ASD, paroxetine reduced aggression, and escitalopram shows improvements in irritability, stereotypy, hyperactivity and inappropriate speech.</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Hellings et al., <xref ref-type="bibr" rid="B92">1996</xref>; McDougle et al., <xref ref-type="bibr" rid="B154">1998a</xref>; AlOlaby et al., <xref ref-type="bibr" rid="B2">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Paroxetine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0007.jpg"></inline-graphic>
</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Davanzo et al., <xref ref-type="bibr" rid="B50">1998</xref>; Hellings et al., <xref ref-type="bibr" rid="B93">2015</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Escitalopram</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0008.jpg"></inline-graphic>
</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Owley et al., <xref ref-type="bibr" rid="B180">2005</xref>; Brown et al., <xref ref-type="bibr" rid="B26">2017</xref>; Viktorin et al., <xref ref-type="bibr" rid="B231">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Venlafaxine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0009.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves restricted behavior and interest, social and communication deficits, and hyperactivity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Irritability, and increase risk of suicidal idea</td>
<td align="left" colspan="1" rowspan="1" valign="top">Carminati et al., <xref ref-type="bibr" rid="B31">2006</xref>, <xref ref-type="bibr" rid="B32">2016</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Tricyclic Antidepressant</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nortriptyline</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0010.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves hyperactivity and aggressiveness in autistic children</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sedation, increase in aggression, irritability and hyperactivity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Kurtis, <xref ref-type="bibr" rid="B134">1966</xref>; Campbell et al., <xref ref-type="bibr" rid="B30">1971</xref>; Hong et al., <xref ref-type="bibr" rid="B104">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Clomipramine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0011.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves anger and compulsive and ritualized behavior</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Gordon et al., <xref ref-type="bibr" rid="B77">1993</xref>; Sanchez et al., <xref ref-type="bibr" rid="B208">1996</xref>; Hong et al., <xref ref-type="bibr" rid="B104">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Anticonvulsants</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lamotrigine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0012.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves overall autistic symptoms</td>
<td align="left" colspan="1" rowspan="1" valign="top">Life-threatening skin reactions, including Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, and toxic epidermal necrolysis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Uvebrant and Bauziene, <xref ref-type="bibr" rid="B229">1994</xref>; Jobski et al., <xref ref-type="bibr" rid="B117">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Valproic acid</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0013.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves receptive language, affective instability, aggression, and social skills</td>
<td align="left" colspan="1" rowspan="1" valign="top">Irritability, weight gain, anxiety</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anagnostou et al., <xref ref-type="bibr" rid="B5">2006</xref>; Hollander et al., <xref ref-type="bibr" rid="B103">2006</xref>, <xref ref-type="bibr" rid="B101">2010</xref>; Jobski et al., <xref ref-type="bibr" rid="B117">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Levetiracetam</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0014.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreases symptoms such as hyperactivity, impulsivity, aggression, and affective lability</td>
<td align="left" colspan="1" rowspan="1" valign="top">CNS effects such as somnolence, decreased energy, headache, dizziness, mood swings and coordination difficulties</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rugino and Samsock, <xref ref-type="bibr" rid="B202">2002</xref>; Jobski et al., <xref ref-type="bibr" rid="B117">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Glutamate antagonist</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Amantadine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0015.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves hyperactivity and speech disturbance</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nervousness, anxiety, agitation, insomnia, difficulty in concentrating, and exacerbations of pre-existing seizure disorders and psychiatric symptoms in patients with schizophrenia or Parkinson's disease.</td>
<td align="left" colspan="1" rowspan="1" valign="top">King et al., <xref ref-type="bibr" rid="B125">2001</xref>; Naaijen et al., <xref ref-type="bibr" rid="B167">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Memantine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0016.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves memory, hyperactivity, irritability, social behavior and communication, and self-stimulatory behavior</td>
<td align="left" colspan="1" rowspan="1" valign="top">Few autistic individuals experienced worsening of autistic symptoms</td>
<td align="left" colspan="1" rowspan="1" valign="top">Owley et al., <xref ref-type="bibr" rid="B179">2006</xref>; Chez et al., <xref ref-type="bibr" rid="B40">2007</xref>; Naaijen et al., <xref ref-type="bibr" rid="B167">2017</xref>; Vorstman et al., <xref ref-type="bibr" rid="B235">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Acetylcholinesterase inhibitors</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rivastigmine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0017.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves overall autistic behavior</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nausea, diarrhea, hyperactivity, and irritability</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vorstman et al., <xref ref-type="bibr" rid="B235">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Donepezil</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0018.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves irritability and hyperactivity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nausea and vomiting, decreased appetite and weight loss</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hardan and Handen, <xref ref-type="bibr" rid="B90">2002</xref>; Vorstman et al., <xref ref-type="bibr" rid="B235">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Galantamine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0019.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves several autistic symptoms in children such as irritability, hyperactivity, social interaction deficits, inappropriate speech, loss of attention, and anger</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Niederhofer et al., <xref ref-type="bibr" rid="B175">2002</xref>; Nicolson et al., <xref ref-type="bibr" rid="B174">2006</xref>; Vorstman et al., <xref ref-type="bibr" rid="B235">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Psycho-stimulant</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Methylphenidate</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0020.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves several autistic behavioral symptoms in children and adolescents such as hyperactivity, impulsivity, attention, social communication, and self-regulation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anorexia, aggression, and insomnia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Handen et al., <xref ref-type="bibr" rid="B87">2000</xref>; Di Martino et al., <xref ref-type="bibr" rid="B54">2004</xref>; Jahromi et al., <xref ref-type="bibr" rid="B113">2009</xref>; Kim et al., <xref ref-type="bibr" rid="B124">2017</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top"><bold>Adrenergic</bold> α<sub>2</sub>
<bold>receptor agonists</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">Clonidine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0021.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves hyperactivity, mood fluctuation, aggressiveness and agitation, sleeping pattern and night time awakenings</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sedation, dry mouth, and hypotension</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fankhauser et al., <xref ref-type="bibr" rid="B63">1992</xref>; Ming et al., <xref ref-type="bibr" rid="B160">2008</xref>; Nash and Carter, <xref ref-type="bibr" rid="B170">2016</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Guanfacine</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0022.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves attention, hyperactivity, and tics</td>
<td align="left" colspan="1" rowspan="1" valign="top">Insomnia, fatigue, blurred vision, mood instability, sedation, constipation, irritability, and aggression.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Posey et al., <xref ref-type="bibr" rid="B190">2004</xref>; Scahill et al., <xref ref-type="bibr" rid="B210">2006</xref>; Boellner et al., <xref ref-type="bibr" rid="B21">2007</xref>; Nash and Carter, <xref ref-type="bibr" rid="B170">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Opiate antagonist</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Naltrexone</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<inline-graphic xlink:href="fnins-12-00304-i0023.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Improves, hyperactivity, irritability, self- injuries. However, ineffective in social deficits.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gastrointestinal complaints such as diarrhea and abdominal cramping.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Panksepp and Lensing, <xref ref-type="bibr" rid="B181">1991</xref>; Bouvard et al., <xref ref-type="bibr" rid="B22">1995</xref>; Kolmen et al., <xref ref-type="bibr" rid="B129">1995</xref>; Elchaar et al., <xref ref-type="bibr" rid="B57">2006</xref>; Clifford et al., <xref ref-type="bibr" rid="B45">2007</xref>; Nash and Carter, <xref ref-type="bibr" rid="B170">2016</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Data were obtained from <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> last accessed 2017 August 20th</italic>.</p>
</table-wrap-foot>
</table-wrap>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Most promising drugs at different clinical trial phases for future therapeutic management of ASD behavioral and neurological symptoms.</p>
</caption>
<graphic xlink:href="fnins-12-00304-g0003"></graphic>
</fig>
<sec>
<title>Atypical antipsychotics</title>
<p>Clozapine belongs to the class of atypical antipsychotics because it shows capability of binding to 5-HT and DA receptors (Zuddas et al., <xref ref-type="bibr" rid="B249">1996</xref>; Chen et al., <xref ref-type="bibr" rid="B38">2001</xref>; Gobbi and Pulvirenti, <xref ref-type="bibr" rid="B76">2001</xref>). It is an atypical antipsychotic medication mainly used for SCH that does not improve following the use of other antipsychotic medications. In patients with SCH and schizoaffective disorder it may decrease the rate of suicidal behavior. It is possibly more effective than typical antipsychotics and in patients who are resistant to other medications. Clozapine was found to improve hyperactivity and aggression in ASD children, adolescents and adults, but has a limited clinical use because of it's hematological safety profile a potential of lowering the seizure threshold in epilepsy patients, necessitating monitoring procedures of patients taking this medication (Zuddas et al., <xref ref-type="bibr" rid="B249">1996</xref>; Chen et al., <xref ref-type="bibr" rid="B38">2001</xref>; Gobbi and Pulvirenti, <xref ref-type="bibr" rid="B76">2001</xref>). The antipsychotic medication with risperidone is mainly approached in ASD patients with SCH, bipolar disorder, and/or irritability symptoms, as this drug has revealed to be better than placebo in treating irritability, repetitive behavior, aggression, anxiety, depression and nervousness (McDougle et al., <xref ref-type="bibr" rid="B155">1998b</xref>; McCracken et al., <xref ref-type="bibr" rid="B153">2002</xref>). Moreover, risperidone has shown a neuroprotective effect and has enhanced the antioxidant and neuroprotective activity of astroglial cells in brain disorders such as ASD without clinical evidence of extrapyramidal side effects or seizures except mild sedative effects (McDougle et al., <xref ref-type="bibr" rid="B155">1998b</xref>; McCracken et al., <xref ref-type="bibr" rid="B153">2002</xref>). However, other side effects with use of risperidone were reported to include increased appetite, fatigue, dizziness and drowsiness (Table <xref ref-type="table" rid="T1">1</xref>; McDougle et al., <xref ref-type="bibr" rid="B155">1998b</xref>; McCracken et al., <xref ref-type="bibr" rid="B153">2002</xref>). Aripiprazole is another atypical antipsychotic primarily recommended for the treatment of SCH and bipolar disorder. Other uses include an add-on treatment for major depressive disorder, tic disorders, and irritability associated with ASD, as it shows a different mechanism of action from those of the other atypical antipsychotics (e.g., clozapine, and risperidone) by acting rather as a partial agonist on the D2Rs and 5-HT1A receptors (Marcus et al., <xref ref-type="bibr" rid="B147">2009</xref>; Owen et al., <xref ref-type="bibr" rid="B178">2009</xref>; Hirsch and Pringsheim, <xref ref-type="bibr" rid="B97">2016</xref>). However, it displays an antagonist profile at 5-HT2A and 5-HT7 receptors and acts as a partial agonist at the 5-HT2C receptor, both with high affinity (Marcus et al., <xref ref-type="bibr" rid="B147">2009</xref>; Owen et al., <xref ref-type="bibr" rid="B178">2009</xref>; Hirsch and Pringsheim, <xref ref-type="bibr" rid="B97">2016</xref>). The latter action may be the reason for the minimal weight gain observed during the course of therapy with aripiprazole.</p>
</sec>
<sec>
<title>Neurotransmitter reuptake inhibitors</title>
<p>The class of neurotransmitter reuptake inhibitors, e.g., fluoxetine (selective serotonin reuptake inhibitor, SSRI) has shown numerous prospective therapeutic benefits, including decreases in rituals, stereotyped and repetitive monotonous behaviors in ASD children and adolescents (Fatemi et al., <xref ref-type="bibr" rid="B65">1998</xref>; DeLong et al., <xref ref-type="bibr" rid="B52">2002</xref>; Hollander et al., <xref ref-type="bibr" rid="B102">2005</xref>). Fluoxetine belongs to the class of SSRI which does not significantly inhibit norepinephrine and dopamine reuptake at therapeutic doses (Fatemi et al., <xref ref-type="bibr" rid="B65">1998</xref>; DeLong et al., <xref ref-type="bibr" rid="B52">2002</xref>; Hollander et al., <xref ref-type="bibr" rid="B102">2005</xref>). Fluoxetine was found to produce some adverse effects including disinhibition, hypomania, agitation, and hyperactivity (Fatemi et al., <xref ref-type="bibr" rid="B65">1998</xref>; DeLong et al., <xref ref-type="bibr" rid="B52">2002</xref>; Hollander et al., <xref ref-type="bibr" rid="B102">2005</xref>). Fluvoxamine is a drug which functions as a SSRI and σ1 receptor agonist (Fatemi et al., <xref ref-type="bibr" rid="B65">1998</xref>; DeLong et al., <xref ref-type="bibr" rid="B52">2002</xref>; Hollander et al., <xref ref-type="bibr" rid="B102">2005</xref>). Fluvoxamine is used mainly for the treatment of obsessive-compulsive disorder, and is also used to treat major depressive disorder and anxiety disorders such as panic disorder and post-traumatic stress disorder. Notably, fluvoxamine is approved to treat social anxiety disorder (Fatemi et al., <xref ref-type="bibr" rid="B65">1998</xref>; DeLong et al., <xref ref-type="bibr" rid="B52">2002</xref>; Hollander et al., <xref ref-type="bibr" rid="B102">2005</xref>). Fluvoxamine has also shown similar potential effects as fluoxetine against ASD (Fatemi et al., <xref ref-type="bibr" rid="B65">1998</xref>; DeLong et al., <xref ref-type="bibr" rid="B52">2002</xref>; Hollander et al., <xref ref-type="bibr" rid="B102">2005</xref>). In a clinical trial, fluvoxamine was found to be well tolerated in ASD adults and it has improved compulsive as well as repetitive behaviors and aggression (Fatemi et al., <xref ref-type="bibr" rid="B65">1998</xref>; DeLong et al., <xref ref-type="bibr" rid="B52">2002</xref>; Hollander et al., <xref ref-type="bibr" rid="B102">2005</xref>). Other SSRIs, including sertraline, paroxetine and escitalopram, showed almost the same potential benefits and adverse effects as compared to fluoxetine and fluvoxamine (Hellings et al., <xref ref-type="bibr" rid="B92">1996</xref>; McDougle et al., <xref ref-type="bibr" rid="B154">1998a</xref>). Venlafaxine is another SSRI which has, also, shown improvements of restricted behaviors, decreased interests, social deficits, hyperactivity and communication problems in individuals with ASD, (Table <xref ref-type="table" rid="T1">1</xref>; Hellings et al., <xref ref-type="bibr" rid="B92">1996</xref>; McDougle et al., <xref ref-type="bibr" rid="B154">1998a</xref>).</p>
</sec>
<sec>
<title>Tricyclic antidepressants</title>
<p>The second-generation tricyclic antidepressant nortriptyline is used in the therapeutic management of major depression and childhood nocturnal enuresis (bedwetting), chronic fatigue syndrome, chronic pain and migraine, and labile affect in some neurological brain disorders (Kurtis, <xref ref-type="bibr" rid="B134">1966</xref>; Campbell et al., <xref ref-type="bibr" rid="B30">1971</xref>). Clomipramine is another tricyclic antidepressant used for the treatment of obsessive compulsive disorder, panic disorder, major depressive disorder, and chronic pain (Gordon et al., <xref ref-type="bibr" rid="B77">1993</xref>; Sanchez et al., <xref ref-type="bibr" rid="B208">1996</xref>). Interestingly, nortriptyline has been described to be effective in children with ASD as it improved the hyperactivity, aggressiveness, and ritualized behavior, while imipramine was not well tolerated in ASD children (Kurtis, <xref ref-type="bibr" rid="B134">1966</xref>; Campbell et al., <xref ref-type="bibr" rid="B30">1971</xref>). In a previous clinical trial, 58% of ASD subjects have found clomipramine to be superior to placebo and the antidepressant desipramine in improving ASD symptoms, anger, and compulsive and ritualized behaviors (Gordon et al., <xref ref-type="bibr" rid="B77">1993</xref>). In another clinical study, clomipramine has caused several adverse effects such as sedation and worsening of behaviors like aggression, irritability, and hyperactivity (Sanchez et al., <xref ref-type="bibr" rid="B208">1996</xref>; Table <xref ref-type="table" rid="T1">1</xref>).</p>
</sec>
<sec>
<title>Anticonvulsants</title>
<p>Lamotrigine, a member of the sodium channel blocking class of anticonvulsants clinically used in the treatment of children diagnosed with epilepsy, decreased symptoms in approximately 62% of the ASD individuals, and no considerable change among placebo-treated and lamotrigine-treated patients was observed in a study comprising 35 patients diagnosed with ASD (Uvebrant and Bauziene, <xref ref-type="bibr" rid="B229">1994</xref>). On the contrary, VPA with its anticonvulsant effect recognized based on its blockade of voltage-dependent sodium channels and increased GABA levels in the brain has shown -as an orphan drug- valuable effects in improving various symptoms and psychiatric comorbidities, e.g., receptive language, affective instability, and aggression, without appreciable clinical effects on core symptoms of ASD (Uvebrant and Bauziene, <xref ref-type="bibr" rid="B229">1994</xref>; Jobski et al., <xref ref-type="bibr" rid="B117">2017</xref>). Notably, VPA has been reported to be an inhibitor for histone deacetylase (HDAC), an enzyme which plays –together with other HDACs- an essential regulating role in gene transcription and phenotypic differentiation (Hsieh and Gage, <xref ref-type="bibr" rid="B108">2004</xref>, <xref ref-type="bibr" rid="B109">2005</xref>; Balasubramaniyan et al., <xref ref-type="bibr" rid="B15">2006</xref>; Jessberger et al., <xref ref-type="bibr" rid="B116">2007</xref>; Chomiak et al., <xref ref-type="bibr" rid="B42">2013</xref>). Accordingly, numerous studies reported that specific expression forms of HDAC1 and HDAC2, which are categorized as class I of HDACs, in the murine brain are existent at various developmental ages with HDAC1 expressed in neural stem cells/progenitors and glia, and HDAC2 being upregulated in postmitotic neuroblasts and various but not in fully differentiated glia (Chomiak et al., <xref ref-type="bibr" rid="B42">2013</xref>). Therefore, modulation of HDAC in diverse cell types and at several maturational time points may possibly lead to the observation of intensely diverse clinical outcomes and may explain why HDAC inhibition (for instance with VPA) in adulthood leads to improvement of ASD-like features in animals exposed prenatally to VPA (Chomiak et al., <xref ref-type="bibr" rid="B42">2013</xref>). In previous studies, in utero exposure to VPA in mice induced ASD-like behavioral social interaction deficits, anxiety and spatial learning incapacity (Kataoka et al., <xref ref-type="bibr" rid="B119">2013</xref>). However, all these behavioral impairments were ameliorated following chronic (5-week) treatment with VPA (30 mg/kg/d, i.p.) (Kataoka et al., <xref ref-type="bibr" rid="B119">2013</xref>; Takuma et al., <xref ref-type="bibr" rid="B226">2014</xref>), suggesting that dose (300-600/kg mg for acute induction of ASD or 30 mg/kg for chronic treatment goals) or time point (prenatal or 8-week old animals) of using VPA determines whether it is ASD-inducing or palliating cognitive dysfunction (Takuma et al., <xref ref-type="bibr" rid="B226">2014</xref>). VPA-induced ASD in rodents will be discussed in more details under section Non-genetic Animal Models of ASD. Moreover, the anticonvulsant drug levetiracetam was found to be valuable in decreasing hyperactivity, impulsivity, aggression, and emotional lability (Rugino and Samsock, <xref ref-type="bibr" rid="B202">2002</xref>) (Table <xref ref-type="table" rid="T1">1</xref>). These clinical observations for several antiepileptic drugs demonstrate that the prevalence of psychopharmacotherapy and polypharmacy in ASD patients is considerable, which is probably due to the treatment of non-core ASD symptoms and psychiatric comorbidities, despite a lack of pharmacological treatment options for ASD core symptoms.</p>
</sec>
<sec>
<title>Glutamate antagonists</title>
<p>Levels of glutamate have been found to be excessively increased in post-mortem brain samples of some ASD individuals (Owley et al., <xref ref-type="bibr" rid="B179">2006</xref>; Chez et al., <xref ref-type="bibr" rid="B40">2007</xref>). Numerous studies have publicized the effectiveness of several glutamate antagonists, e.g., amantadine and memantine, in ASD patients (Owley et al., <xref ref-type="bibr" rid="B179">2006</xref>; Chez et al., <xref ref-type="bibr" rid="B40">2007</xref>). In a controlled clinical trial, amantadine showed improving effects on hyperactive behavior and inappropriate speech in ASD children (Owley et al., <xref ref-type="bibr" rid="B179">2006</xref>; Chez et al., <xref ref-type="bibr" rid="B40">2007</xref>). Also, the clinical use of memantine in the treatment of ASD individuals has shown therapeutic progresses in regard to memory, hyperactivity, irritability, language, social behavior and self-stimulatory behavior (Owley et al., <xref ref-type="bibr" rid="B179">2006</xref>; Chez et al., <xref ref-type="bibr" rid="B40">2007</xref>; Table <xref ref-type="table" rid="T1">1</xref>).</p>
</sec>
<sec>
<title>Acetylcholinesterase inhibitors</title>
<p>Dysfunction of brain cholinergic neurotransmission has been described in several patients diagnosed with ASD (Perry et al., <xref ref-type="bibr" rid="B187">2001</xref>; Hardan and Handen, <xref ref-type="bibr" rid="B90">2002</xref>; Niederhofer et al., <xref ref-type="bibr" rid="B175">2002</xref>; Nicolson et al., <xref ref-type="bibr" rid="B174">2006</xref>). Therefore, acetylcholinesterase inhibitors, e.g., rivastigmine, donepezil, and galantamine, have in many studies been investigated for the use in ASD children (Hardan and Handen, <xref ref-type="bibr" rid="B90">2002</xref>; Niederhofer et al., <xref ref-type="bibr" rid="B175">2002</xref>; Nicolson et al., <xref ref-type="bibr" rid="B174">2006</xref>). Interestingly, the clinical application of rivastigmine in ASD children significantly relieved overall ASD behaviors, however, several adverse effects including nausea, diarrhea, hyperactivity and irritability were reported (Hardan and Handen, <xref ref-type="bibr" rid="B90">2002</xref>; Niederhofer et al., <xref ref-type="bibr" rid="B175">2002</xref>; Nicolson et al., <xref ref-type="bibr" rid="B174">2006</xref>). Among acetylcholinesterase inhibitors, donepezil has shown capability to improve irritability and hyperactivity of ASD children (Hardan and Handen, <xref ref-type="bibr" rid="B90">2002</xref>; Niederhofer et al., <xref ref-type="bibr" rid="B175">2002</xref>; Nicolson et al., <xref ref-type="bibr" rid="B174">2006</xref>). Moreover, galantamine produced substantial improvements in hyperactivity, irritability, social withdrawal, inappropriate speech, attention deficiency, and reduction in anger in children diagnosed with ASD (Hardan and Handen, <xref ref-type="bibr" rid="B90">2002</xref>; Niederhofer et al., <xref ref-type="bibr" rid="B175">2002</xref>; Nicolson et al., <xref ref-type="bibr" rid="B174">2006</xref>; Table <xref ref-type="table" rid="T1">1</xref>). These improvements observed for several acetylcholine esterase inhibitors strongly support the hypothesis that enhancing the cholinergic neurotransmission in ASD results in positive therapeutic effects.</p>
</sec>
<sec>
<title>Psychostimulants</title>
<p>Methylphenidate, the most commonly known CNS stimulant widely used in the therapeutic management of attention deficit hyperactivity disorder (ADHD) and narcolepsy, is commonly indicated for ASD children and adolescents (Handen et al., <xref ref-type="bibr" rid="B87">2000</xref>; Di Martino et al., <xref ref-type="bibr" rid="B54">2004</xref>; Jahromi et al., <xref ref-type="bibr" rid="B113">2009</xref>; Kim et al., <xref ref-type="bibr" rid="B124">2017</xref>). Methylphenidate mainly acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). In numerous controlled studies, methylphenidate palliated several behavioral ASD features including impulsivity, attention deficiency, and hyperactivity, but it correspondingly exhibited some initial adverse effects such as aggression, anorexia, and increased wakefulness (insomnia) (Handen et al., <xref ref-type="bibr" rid="B87">2000</xref>; Di Martino et al., <xref ref-type="bibr" rid="B54">2004</xref>; Jahromi et al., <xref ref-type="bibr" rid="B113">2009</xref>; Kim et al., <xref ref-type="bibr" rid="B124">2017</xref>; Table <xref ref-type="table" rid="T1">1</xref>).</p>
</sec>
<sec>
<title>Adrenergic alpha (α)<sub>2</sub> receptor agonists</title>
<p>Oral or transdermal administration of selective centrally acting α<sub>2</sub> adrenergic agonist, e.g., clonidine, have revealed to improve mood instability, hyperactive behavior, aggressiveness and nervousness in ASD individuals (Fankhauser et al., <xref ref-type="bibr" rid="B63">1992</xref>; Ming et al., <xref ref-type="bibr" rid="B160">2008</xref>). Clonidine is a drug used to treat high blood pressure, ADHD, anxiety disorders, tic disorders, withdrawal (from either alcohol, opioids, or smoking), migraine, and certain pain conditions, with largely tolerable adverse effects (Fankhauser et al., <xref ref-type="bibr" rid="B63">1992</xref>; Ming et al., <xref ref-type="bibr" rid="B160">2008</xref>). Also, previous clinical trials carried out with clonidine in ASD subjects delivered evidences for the clinical effectiveness and safety profile in ASD and related brain disorders (Fankhauser et al., <xref ref-type="bibr" rid="B63">1992</xref>; Ming et al., <xref ref-type="bibr" rid="B160">2008</xref>). Moreover, a retrospective study revealed that the use of guanfacine, a selective α<sub>2</sub> adrenergic receptor agonist used in the treatment of ADHD, anxiety, and hypertension, was accompanied with enhancements in insomnia, attention deficiency, hyperactivity, and tics (Posey et al., <xref ref-type="bibr" rid="B190">2004</xref>; Scahill et al., <xref ref-type="bibr" rid="B210">2006</xref>; Boellner et al., <xref ref-type="bibr" rid="B21">2007</xref>). However, the most common adverse effects observed with guanfacine were mood alteration fatigue, blurred vision, and headache (Posey et al., <xref ref-type="bibr" rid="B190">2004</xref>; Scahill et al., <xref ref-type="bibr" rid="B210">2006</xref>; Boellner et al., <xref ref-type="bibr" rid="B21">2007</xref>; Table <xref ref-type="table" rid="T1">1</xref>).</p>
</sec>
<sec>
<title>Opiate antagonists</title>
<p>Based on the reputed role of endogenous opioids such as β-endorphin and encephalin in the regulation of social behavior, the opiate antagonist naltrexone has been assessed in ASD (Panksepp and Lensing, <xref ref-type="bibr" rid="B181">1991</xref>; Bouvard et al., <xref ref-type="bibr" rid="B22">1995</xref>; Kolmen et al., <xref ref-type="bibr" rid="B129">1995</xref>; Elchaar et al., <xref ref-type="bibr" rid="B57">2006</xref>; Clifford et al., <xref ref-type="bibr" rid="B45">2007</xref>). The results observed in numerous studies for naltrexone showed that it might be able to treat behavioral aberrations perceived in ASD patients and induced by dysfunction of the brain opioid system (Panksepp and Lensing, <xref ref-type="bibr" rid="B181">1991</xref>; Bouvard et al., <xref ref-type="bibr" rid="B22">1995</xref>; Kolmen et al., <xref ref-type="bibr" rid="B129">1995</xref>; Elchaar et al., <xref ref-type="bibr" rid="B57">2006</xref>; Clifford et al., <xref ref-type="bibr" rid="B45">2007</xref>). Moreover, numerous studies revealed the significant improvements of various behavioral symptoms obtained with the use of naltrexone in ASD children (Panksepp and Lensing, <xref ref-type="bibr" rid="B181">1991</xref>; Bouvard et al., <xref ref-type="bibr" rid="B22">1995</xref>; Kolmen et al., <xref ref-type="bibr" rid="B129">1995</xref>; Elchaar et al., <xref ref-type="bibr" rid="B57">2006</xref>; Clifford et al., <xref ref-type="bibr" rid="B45">2007</xref>). Furthermore, these studies reported that naltrexone treatment provided substantial enhancements in self-injurious behavior, hyperactivity, social withdrawal, agitation and irritability in ASD patients (Panksepp and Lensing, <xref ref-type="bibr" rid="B181">1991</xref>; Bouvard et al., <xref ref-type="bibr" rid="B22">1995</xref>; Kolmen et al., <xref ref-type="bibr" rid="B129">1995</xref>; Elchaar et al., <xref ref-type="bibr" rid="B57">2006</xref>; Clifford et al., <xref ref-type="bibr" rid="B45">2007</xref>; Table <xref ref-type="table" rid="T1">1</xref>).</p>
<p>The aforementioned described drugs act on different targets to therapeutically manage the behavioral as well as psychiatric symptoms of ASD. However, several brain regions are altered in ASD individuals, resulting in loss of neuronal function, and behavioral and sensory impairments, including inattention, hyperactivity, mood fluctuations, aggressiveness, agitation, social deficits and repetitive and restricted behavior. In the brain, the plasticity of brain tissue, nerve tangling and imbalanced production of several neurotransmitters are all implicated on evolution in ASD individuals. Apart from environmental factors, other pathological conditions such as immunological problems, chronic neuroinflammation, oxidative stress, mitochondrial dysfunction are involved in etiopathogenesis of ASD (Kumar et al., <xref ref-type="bibr" rid="B133">2012</xref>).</p>
<p>Up until now, there is no approved drug existing in the market which is specific for treating symptoms associated with ASD, however, preclinical and clinical research and development are in progress to find new therapeutic entities. Currently, there are several candidates that successfully passed different clinical phases of drug development, with different pharmacological targets to palliate ASD behavioral and neurological symptoms (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F3">3</xref>). Interestingly, 10% of these clinical candidates are currently in phase 1, 46% have already progressed to phase 2, 27% advanced to phase 3, and 15% reached to phase 4 of clinical development, whereas 2% are currently of preclinical interest (Ruhela et al., <xref ref-type="bibr" rid="B203">2015</xref>; Table <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Drugs currently in phase 1–4 of clinical development for neurobehavioral manifestations, neurodevelopmental, and autistic disorders.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Name</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Class</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Clinical indication/condition (No. of trials in phase 2)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Clinical indication/condition (No. of trials in phase 3)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Clinical indication/condition (No. of trials in phase 4)</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Arbaclofen</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anticonvulsant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (3) Neurobehavioral Manifestations (2) Neurodevelopmental Disorders (3)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (2) Neurobehavioral Manifestations (3) Neurodevelopmental Disorders (1)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Aripiprazole</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antipsychotic drug</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (5) Neurobehavioral Manifestations (1) Neurodevelopmental Disorders (6)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (7) Neurobehavioral Manifestations (1) Neurocognitive Disorders (6) Neurodegenerative disease (11) Neurodevelopmental Disorders (13)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (5) Neurocognitive Disorders (3) Neurodegenerative disease (3) Neurodevelopmental Disorders (11)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Atomoxetine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Selective norepinephrine transporter</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (4) Neurocognitive Disorders (5) Neurodegenerative disease (4) Neurodevelopmental Disorders (14)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurocognitive Disorders (1) Neurodegenerative disease (1) Neurodevelopmental Disorders (29)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (3) Neurobehavioral Manifestations (5) Neurocognitive Disorders (1) Neurodegenerative disease (2) Neurodevelopmental Disorders (48)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Baclofen</td>
<td align="left" colspan="1" rowspan="1" valign="top">Central muscle relaxant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (2) Neurobehavioral Manifestations (1) Neurodegenerative Diseases (2) Neurologic Manifestations (9)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (1) Neurodegenerative Diseases (1)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bumetanide</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diuretic action</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurodevelopmental Disorders (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Buspirone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anxiolytic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (3) Neurodegenerative Diseases (1) Neurodevelopmental Disorders (4)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (1) Neurocognitive Disorders (1) Neurodegenerative Diseases (1)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Citalopram</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antidepressant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurocognitive Disorders (4) Neurodegenerative Diseases (2) Neurodevelopmental Disorders (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (3) Neurocognitive Disorders (7) Neurodegenerative Diseases (7)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (3) Neurocognitive Disorders (4) Neurodegenerative Diseases (6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CX516</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurocognitive Disorders (2) Neurodegenerative Diseases (1)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">D-Cyclocerine</td>
<td align="left" colspan="1" rowspan="1" valign="top">NMDA modulator</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dimercaptosuccinic acid</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antidote for lead, mercury, and arsenic poisoning</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Donepezil</td>
<td align="left" colspan="1" rowspan="1" valign="top">Acetylcholinesterase inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (4) Neurobehavioral Manifestations (7) Neurocognitive Disorders (62) Neurodegenerative Diseases (57)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (5) Neurocognitive Disorders (41) Neurodegenerative Diseases (33)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (1) Neurobehavioral Manifestations (6) Neurocognitive Disorders (49) Neurodegenerative Diseases (37) Neurodevelopmental Disorders (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fluoxetine</td>
<td align="left" colspan="1" rowspan="1" valign="top">SSRI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (3) Neurodegenerative disease (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (3) Neurocognitive Disorders (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurodegenerative Diseases (1) Neurodevelopmental Disorders (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fluvoxamine</td>
<td align="left" colspan="1" rowspan="1" valign="top">SSRI</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (1) Neurocognitive Disorders (1) Neurodevelopmental Disorders (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurodegenerative Diseases (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Galantamine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cholinesterase inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (2) Neurocognitive Disorders (12) Neurodegenerative disease (7)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurocognitive Disorders (28) Neurodegenerative disease (21) Neurodevelopmental Disorders (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (3) Neurocognitive Disorders (22) Neurodegenerative disease (21) Neurodevelopmental Disorders (2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lenalidomide</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anti-inflammatory</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurodegenerative Diseases (1)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Levetiracetam</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anticonvulsant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (1) Neurocognitive Disorders (2) Neurodegenerative disease (5)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurocognitive Disorders (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (2) Neurocognitive Disorders (1) Neurodegenerative disease (3) Neurodevelopmental Disorders (3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Methyl cobalamin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vitamin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (2) Neurocognitive Disorders (1) Neurodegenerative Diseases (4)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (2) Neurocognitive Disorders (1) Neurodegenerative Diseases (5) Neurodevelopmental Disorders (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurocognitive Disorders (4) Neurodegenerative Diseases (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Minocycline</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antibiotic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurobehavioral Manifestations (3) Neurocognitive Disorders (5) Neurodegenerative disease (5)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (3) Neurocognitive Disorders (2) Neurodegenerative disease (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurobehavioral Manifestations (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>N</italic>-Acetyl cysteine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antioxidant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (4) Neurobehavioral Manifestations (4) Neurocognitive Disorders (4) Neurodegenerative Diseases (7) Neurodevelopmental Disorders (5)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (1) Neurodegenerative Diseases (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurocognitive Disorders (1) Neurodegenerative Diseases (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Naltrexone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Opioid receptor antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurobehavioral Manifestations (2) Neurocognitive Disorders (1) Neurodegenerative disease (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (1) Neurodevelopmental Disorders (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurodegenerative disease (1) Neurodevelopmental Disorders (3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Olanzapine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Atypical antipsychotic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (2) Neurocognitive Disorders (1) Neurodegenerative Diseases (1) Neurodevelopmental Disorders (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurobehavioral Manifestations (2) Neurocognitive Disorders (3) Neurodegenerative Diseases (2) Neurodevelopmental Disorders (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (2) Neurocognitive Disorders (6) Neurodegenerative Diseases (2) Neurodevelopmental Disorders (5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Oralgam</td>
<td align="left" colspan="1" rowspan="1" valign="top">human immunoglobulin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Child Development Disorders, Pervasive (1) Neurodevelopmental Disorders (1)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Oxytocin hormone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hormone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (5)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Paliperidone ER</td>
<td align="left" colspan="1" rowspan="1" valign="top">Atypical antipsychotic</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurocognitive Disorders (1) Neurodevelopmental Disorders (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (1) Neurocognitive Disorders (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pioglitazone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antihyperglycemic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurocognitive Disorders (2) Neurodegenerative Diseases (4)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurocognitive Disorders (2) Neurodegenerative Diseases (3)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RG 1068</td>
<td align="left" colspan="1" rowspan="1" valign="top">Synthetic human secretin</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (2)</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Riluzole</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sodium channel blocker</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (3) Neurocognitive Disorders (2) Neurodegenerative Disorders (34)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (1) Neurocognitive Disorders (1) Neurodegenerative Diseases (11)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (2) Neurodegenerative Diseases (3) Neurodevelopmental Disorders (1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Risperidone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Atypical antipsychotic drug</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (4) Neurocognitive Disorders (3) Neurodegenerative disease (1) Neurodevelopmental Disorders (7)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (6) Neurobehavioral Manifestations (4) Neurocognitive Disorders (6) Neurodegenerative disease (5) Neurodevelopmental Disorders (12)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (4) Neurobehavioral Manifestations (8) Neurocognitive Disorders (11) Neurodegenerative disease (5) Neurodevelopmental Disorders (10)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Saproterin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Enzymatic cofactor</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sertraline</td>
<td align="left" colspan="1" rowspan="1" valign="top">SSRI</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (2) Neurobehavioral Manifestations (2) Neurocognitive Disorders (1) Neurodegenerative disease (2) Neurodevelopmental Disorders (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (2) Neurodegenerative disease (1) Neurodevelopmental Disorders (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurocognitive Disorders (2) Neurodegenerative disease (1) Neurodevelopmental Disorders (2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Valproic acid</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anticonvulsant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (3) Neurobehavioral Manifestations (2) Neurocognitive disorders (1) Neurodegenerative Diseases (7)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (1) Neurobehavioral Manifestations (2) Neurocognitive Disorders (3) Neurodegenerative Diseases (3) Neurodevelopmental Disorders (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (1) Neurobehavioral Manifestations (3) Neurocognitive Disorders (3) Neurodegenerative Diseases (1) Neurodevelopmental Disorders (6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Valproic acid + sodium valproate</td>
<td align="left" colspan="1" rowspan="1" valign="top">Anticonvulsant</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (1) Neurocognitive Disorders (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ziprasidone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Atypical antipsychotic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic Disorder (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autistic disorder (1) Neurobehavioral Manifestations (3) Neurocognitive Disorders (3)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurobehavioral Manifestations (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s5">
<title>Animal models of ASD</title>
<p>For the understanding of the etiology and pathogenesis of any human disease, e.g., ASD, experimental rodent models are of substantial meaning. Modelling of human neuropsychiatric diseases with animals is very challenging due to the multifaceted nature of these disorders, combined with the absence of effective diagnostic biomarkers and objective tests for accurate diagnosis (Nestler and Hyman, <xref ref-type="bibr" rid="B171">2010</xref>). Moreover, neuropsychiatric diseases, such as ASD, are multifactorial with genetic, medical and neurodevelopmental conditions associated with the disease (Hoffman et al., <xref ref-type="bibr" rid="B98">2017</xref>; Lyall et al., <xref ref-type="bibr" rid="B144">2017</xref>; Xie et al., <xref ref-type="bibr" rid="B246">2017</xref>). Generally, there are two types of rodent models for ASD, namely the genetic and non-genetic animal models. Accordingly, ASD genetic animal models are highly applicable when they reproduce the ASD features that are existent in an individual human genetic disease such as tuberous sclerosis and fragile X syndrome. Therefore, the ASD genetic models induced in mice should be established on an identified genetic cause of a disease, reflect key aspects of the human symptoms and respond to pharmacotherapies that are operational in the human diseases (Chadman et al., <xref ref-type="bibr" rid="B34">2009</xref>).</p>
<sec>
<title>Genetic animal models of ASD</title>
<p>A considerable advancement in detecting the genetic basis of several human diseases has been achieved by geneticists. These achievements include Alzheimer's disease, Huntington's disease, and some forms of breast cancer. However, more difficulties were associated with the detection of genetic factors for multifaceted diseases such as SCH, diabetes, bipolar disorder, and also ASD (Rao et al., <xref ref-type="bibr" rid="B195">2013</xref>; Wei et al., <xref ref-type="bibr" rid="B239">2015</xref>; Fregeac et al., <xref ref-type="bibr" rid="B67">2016</xref>; Hu et al., <xref ref-type="bibr" rid="B110">2017</xref>). In the case of ASD, extensive research efforts elucidated underlying mechanisms of the disorder and concluded that these mechanisms might include dysfunctions of neuronal microRNAs (miRNAs), which are regulators of gene expression, and which have gained much attention in pathophysiology of various psychiatric illnesses (Andolina et al., <xref ref-type="bibr" rid="B6">2017</xref>). Accordingly, about half of all identified miRNAs in humans are expressed in the CNS and exhibit modulatory functions crucial for numerous biological processes associated to the development of the CNS (Hu et al., <xref ref-type="bibr" rid="B110">2017</xref>). Consequently, disruptions in miRNA biogenesis and miRNA-target interaction have been linked with CNS diseases, including ASD (Hu et al., <xref ref-type="bibr" rid="B110">2017</xref>). Moreover, three miRNA (miRNA-7, miRNA-9, and miRNA-106b) were found to be associated with neurodegenerative diseases and only one, namely miRNA-9, with intellectual disability (Doxakis, <xref ref-type="bibr" rid="B55">2010</xref>; Wang et al., <xref ref-type="bibr" rid="B237">2010</xref>; Xu et al., <xref ref-type="bibr" rid="B248">2011</xref>; Hu et al., <xref ref-type="bibr" rid="B110">2017</xref>). Furthermore, it was recognized that the intellectual disability in Down syndrome which is a neurodevelopmental disorder, was caused by an extra-copy of chromosome 21 (Lejeune et al., <xref ref-type="bibr" rid="B139">1959</xref>). However, it is now being firmly established that deletions in the chromosome 21 are commonly discovered in some patients with intellectual disability including ASD (Hogart et al., <xref ref-type="bibr" rid="B100">2010</xref>). Similarly, increased risk of delayed development, intellectual disability and neurological as well as psychiatric problems associated with ASD, SCH, epilepsy and hypotonia was found to be the result of micro deletions in the long (q) arm of the chromosome in a region designated q21.1 (Knight et al., <xref ref-type="bibr" rid="B127">1999</xref>; Ravnan et al., <xref ref-type="bibr" rid="B196">2006</xref>; Mefford et al., <xref ref-type="bibr" rid="B158">2009</xref>). Moreover, chromosome 15 has been described to be as one of seven several chromosomes enriched in segmental low copy repeats or duplicons (Bailey et al., <xref ref-type="bibr" rid="B14">2002</xref>). These duplicons were revealed to strongly contribute to a mechanism in which low copy repeats facilitated misalignment during meiosis I, leading to unequal recombination of nonallelic homologes and developing a sequence of common cut-off point along the 15q11.2-q13 region (Robinson et al., <xref ref-type="bibr" rid="B197">1993a</xref>,<xref ref-type="bibr" rid="B198">b</xref>,<xref ref-type="bibr" rid="B199">c</xref>; Christian et al., <xref ref-type="bibr" rid="B43">1999</xref>). Previous reports suggested, also, several cases of ASD with cytogenetic abnormalities in the 15q11–13 region (Cook et al., <xref ref-type="bibr" rid="B47">1998</xref>), and the frequency of cytogenetic abnormalities in this region was found to be around 0-3% in ASD, and in fact, the most frequent cytogenetic abnormality in this population (Lord et al., <xref ref-type="bibr" rid="B143">2000</xref>). Moreover, it has been reported that the paternal inheritance of a cytogenetical abnormality leads to a normal phenotype; maternal inheritance leads to autism or atypical autism (Tabet et al., <xref ref-type="bibr" rid="B225">2015</xref>). Furthermore, previous efforts revealed that 16p13.1 micro duplication syndrome is caused by interstitial duplications encompassing 16p13.1, which is a risk factor for a range of neuropsychiatric disorders, including ASD, intellectual disability, SCH, and ADHD (Ullmann et al., <xref ref-type="bibr" rid="B228">2007</xref>; Mefford et al., <xref ref-type="bibr" rid="B158">2009</xref>; Ramalingam et al., <xref ref-type="bibr" rid="B194">2011</xref>; Grozeva et al., <xref ref-type="bibr" rid="B82">2012</xref>). There are, also, monogenic diseases that have been associated with ASD and display its characteristic features: tuberous sclerosis, fragile X syndrome, Rett syndrome and neurofibromatosis 1 (Wetmore and Garner, <xref ref-type="bibr" rid="B241">2010</xref>; Hulbert and Jiang, <xref ref-type="bibr" rid="B111">2016</xref>). Accordingly, single gene mutation gave rise to several human syndromes leading to an increase in the risk for developing ASD. Moreover, autistic traits are also connected to copy-number variants that lead to inheritance of maternal 15q11–13 duplication, resulting in Prader-Willi syndrome (Ogata et al., <xref ref-type="bibr" rid="B177">2014</xref>). Furthermore, the developed strategies for the identification of genetic variants has led to the description of novel syndromic forms of ASD and facilitated the relationship between genetic traits and phenotype. Consequently, these genetic dissimilarities identified so far, along with the newly developed strategies for genetic engineering, improved the expansion of genetic animal models for ASD. Accordingly, mice are the major animal model for ASD due to their genetic manipulability and their talent to show behavioral deficits associated with ASD features (Chen et al., <xref ref-type="bibr" rid="B37">2015</xref>). Moreover, construct as well as face validity of mice ASD animal models together with the availability of well-established techniques to manipulate their genome and study brain function at numerous levels of analysis constitute to the overall validity of mice model (Hulbert and Jiang, <xref ref-type="bibr" rid="B111">2016</xref>). Also, mice as mammals are genetically and biologically similar to humans, however, their rapid reproduction and accelerated development allow for the testing of large numbers of animals at a relatively low cost (Hulbert and Jiang, <xref ref-type="bibr" rid="B111">2016</xref>). Accordingly, animal models for genes of a syndromic disorder were commonly found to present autistic traits including Fragile X (FMR1) with social interaction deficits, hyperactivity, and cognitive impairments (Willem Verhoeven, <xref ref-type="bibr" rid="B242">2011</xref>; Bhattacharya et al., <xref ref-type="bibr" rid="B19">2012</xref>; Ronesi et al., <xref ref-type="bibr" rid="B201">2012</xref>; Hulbert and Jiang, <xref ref-type="bibr" rid="B111">2016</xref>; Hu et al., <xref ref-type="bibr" rid="B110">2017</xref>), Rett syndrome and MECP2 mutations with the resulted repetitive and stereotypic/restricted behaviors, abnormal gait and reduced anxiety, decreased pain and normal olfactory discrimination (Chao et al., <xref ref-type="bibr" rid="B36">2010</xref>; Samaco et al., <xref ref-type="bibr" rid="B207">2013</xref>), tuberous sclerosis TSC1 or TSC2 with social interactions deficits and repetitive/restricted behavior or interest (Chao et al., <xref ref-type="bibr" rid="B36">2010</xref>; Willem Verhoeven, <xref ref-type="bibr" rid="B242">2011</xref>), Timothy syndrome (TS) CACNA1C with impairments in social interactions, repetitive/stereotypic behaviors, and increased fear conditioning (Ergaz et al., <xref ref-type="bibr" rid="B60">2016</xref>), Phelan-McDermid syndrome with restricted interest as well as cognitive and motor deficits (Giza et al., <xref ref-type="bibr" rid="B74">2010</xref>; Ergaz et al., <xref ref-type="bibr" rid="B60">2016</xref>), PTEN mutations, cortical dysplasia focal epilepsy with deficits in regard to social interactions, restricted interest, sensory sensitivity, elevated anxiety, and seizures (Scott-Van Zeeland et al., <xref ref-type="bibr" rid="B212">2010</xref>) (Cook and Scherer, <xref ref-type="bibr" rid="B48">2008</xref>; LaSalle et al., <xref ref-type="bibr" rid="B135">2015</xref>; Piochon et al., <xref ref-type="bibr" rid="B189">2015</xref>) as behavioral features of the above described syndromes which are associated with the ASD (Table <xref ref-type="table" rid="T3">3</xref>). Numerous inbred mouse strains show face validity as ASD models in addition to the genetically modified animal models of ASD, as such inbred strains display robust and well-replicated social deficits and repetitive behaviors (Kazdoba et al., <xref ref-type="bibr" rid="B121">2016</xref>). These inbred strains are found to display idiopathic autism, as their ASD-relevant behaviors are not caused by known genetic mutations (Kazdoba et al., <xref ref-type="bibr" rid="B121">2016</xref>). For instance and while assessing sociability, inbred strains like A/J, BALB/cByJ (BALB), BTBR T+Itpr3tf/J (BTBR), C58/J (C58), and 129S1/SvImJ mice showed lack of sociability, as compared to inbred mouse strains with high sociability, such as C57BL/6J (B6) and FVB/NJ mice (Brodkin, <xref ref-type="bibr" rid="B24">2007</xref>; Moy et al., <xref ref-type="bibr" rid="B164">2007</xref>, <xref ref-type="bibr" rid="B163">2008</xref>; McFarlane et al., <xref ref-type="bibr" rid="B157">2008</xref>; Kazdoba et al., <xref ref-type="bibr" rid="B121">2016</xref>; Hu et al., <xref ref-type="bibr" rid="B110">2017</xref>). Moreover, it has been shown that several mouse strains, e.g. BTBR and C58, also demonstrate explicit motoric stereotypies or repetitive behaviors, such as jumping, digging, and high levels of self-grooming and marble burying (Pasciuto et al., <xref ref-type="bibr" rid="B182">2015</xref>; Kazdoba et al., <xref ref-type="bibr" rid="B121">2016</xref>).</p>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>Most relevant ASD mouse models induced by targeting ASD-associated genes.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Mouse model</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Associated syndrome</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Targeted mutant gene (Chromosome)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Observed behavioral symptoms</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fmr1 KO mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Fragile X syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">FMR1 (Xq27)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Social interaction deficits, hyperactivity, cognitive impairments.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Willem Verhoeven, <xref ref-type="bibr" rid="B242">2011</xref>; Bhattacharya et al., <xref ref-type="bibr" rid="B19">2012</xref>; Ronesi et al., <xref ref-type="bibr" rid="B201">2012</xref>; Hulbert and Jiang, <xref ref-type="bibr" rid="B111">2016</xref>; Hu et al., <xref ref-type="bibr" rid="B110">2017</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cntnap2−/− mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cortical dysplasia-focal epilepsy syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">CNTNAP2 (7q35)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Social interactions impairments, stereotypic behavior, sensory sensitivity, elevated motor activity, nest-building impairments. Normal olfactory discrimination and seizures.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cook and Scherer, <xref ref-type="bibr" rid="B48">2008</xref>; Scott-Van Zeeland et al., <xref ref-type="bibr" rid="B212">2010</xref>; LaSalle et al., <xref ref-type="bibr" rid="B135">2015</xref>; Piochon et al., <xref ref-type="bibr" rid="B189">2015</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tsc1+/− mice Tsc2+/− mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tuberous Sclerosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">TSC1 (9q34) TSC2 (16p13)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Social interactions deficits, normal olfaction. No difference in motor and sensory functions. Repetitive/restricted behavior or interest.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Chao et al., <xref ref-type="bibr" rid="B36">2010</xref>; Willem Verhoeven, <xref ref-type="bibr" rid="B242">2011</xref>; Ergaz et al., <xref ref-type="bibr" rid="B60">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Viaat-Mecp2 conditional mutant mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rett syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">MeCP2 (Xq28)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Repetitive and stereotypic/restricted behaviors, abnormal gait and reduced anxiety, irregular breathing, reduced pain and normal olfactory discrimination.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Amir et al., <xref ref-type="bibr" rid="B4">1999</xref>; Chao et al., <xref ref-type="bibr" rid="B36">2010</xref>; Katz et al., <xref ref-type="bibr" rid="B120">2012</xref>; Kron et al., <xref ref-type="bibr" rid="B132">2012</xref>; Samaco et al., <xref ref-type="bibr" rid="B207">2013</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Shank3B mutant mice Shank3A mutant mice Shank3(e4-9) mutant</td>
<td align="left" colspan="1" rowspan="1" valign="top">Phelan-McDermid syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">SHANK3 (22q13)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Restricted interest but no repetitive behavior, social interactions, learning, sensory, cognitive and motor deficits.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Giza et al., <xref ref-type="bibr" rid="B74">2010</xref>; Phelan and McDermid, <xref ref-type="bibr" rid="B188">2012</xref>; Ergaz et al., <xref ref-type="bibr" rid="B60">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ube3A−/− mice (transgenic mice with triple dosage of Ube3A)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Angelman syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">UBE3A (15q11)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Impaired social interactions, repetitive behavior and restricted interest.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Kishino et al., <xref ref-type="bibr" rid="B126">1997</xref>; Matsuura et al., <xref ref-type="bibr" rid="B150">1997</xref>; Buiting et al., <xref ref-type="bibr" rid="B29">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TS2 mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Timothy syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">CACNA1C (16p13)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Social interactions impairments, repetitive/stereotypic behaviors, and increased fear conditioning.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Chao et al., <xref ref-type="bibr" rid="B36">2010</xref>; Willem Verhoeven, <xref ref-type="bibr" rid="B242">2011</xref>; Ergaz et al., <xref ref-type="bibr" rid="B60">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PTEN mutant mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not defined</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTEN (10)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Social interactions deficits, restricted interest, sensory sensitivity, elevated anxiety, normal motor activity and seizures.</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cook and Scherer, <xref ref-type="bibr" rid="B48">2008</xref>; LaSalle et al., <xref ref-type="bibr" rid="B135">2015</xref>; Piochon et al., <xref ref-type="bibr" rid="B189">2015</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T4" position="float">
<label>Table 4</label>
<caption>
<p>Preclinical representation of several H3R antagonists in different animal models of SCH.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Ligand</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Dose (mg/kg)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Species</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Pharmacological effect observed</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Thioperamide</td>
<td align="left" colspan="1" rowspan="1" valign="top">10 and 30 (i.p.)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increase of prepulse inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">Browman et al., <xref ref-type="bibr" rid="B25">2004</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ciproxifan</td>
<td align="left" colspan="1" rowspan="1" valign="top">1, 3, and 10 (i.p.)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increase of prepulse inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">Browman et al., <xref ref-type="bibr" rid="B25">2004</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ABT-239</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.3-3.0 (i.p.)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rats</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decrease of cognitive deficits induced by ketamine and MK-801</td>
<td align="left" colspan="1" rowspan="1" valign="top">Brown et al., <xref ref-type="bibr" rid="B27">2013</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">A-431404</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.3-3.0 (i.p.)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decrease of cognitive deficits induced by ketamine and MK-801</td>
<td align="left" colspan="1" rowspan="1" valign="top">Browman et al., <xref ref-type="bibr" rid="B25">2004</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SAR110894</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.3-3 (p.o.)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decrease in Impaired social behaviors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Griebel et al., <xref ref-type="bibr" rid="B81">2012</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">0.3-1 (p.o.)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rats</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decrease in Impaired social behaviors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Griebel et al., <xref ref-type="bibr" rid="B81">2012</xref>; Sadek et al., <xref ref-type="bibr" rid="B205">2016</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Non-genetic animal models of ASD</title>
<p>Environmental animal models are induced by prenatal exposure of pregnant animals to certain chemical compounds, infections, or inflammations. The environmental inducing factor is only of significance if the chemicals used in the animal model cause the same effects in humans. Accordingly, the antiepileptic drug, VPA was found to significantly increase the ASD degree in offspring of treated mothers (Christianson et al., <xref ref-type="bibr" rid="B44">1994</xref>; Moore et al., <xref ref-type="bibr" rid="B162">2000</xref>), and similarly showed to induce ASD-like behaviors in mice and rats (Rodier et al., <xref ref-type="bibr" rid="B200">1997</xref>; Anshu et al., <xref ref-type="bibr" rid="B8">2017</xref>; Nicolini and Fahnestock, <xref ref-type="bibr" rid="B173">2017</xref>). Therefore, the ASD-like animal model induced by in utero exposure to the anticonvulsant drug VPA has been well established and recognized to study ASD features (Nicolini and Fahnestock, <xref ref-type="bibr" rid="B173">2017</xref>). Moreover, the immunomodulatory drug thalidomide, which was used by pregnant women in the 1950s, was revealed to be associated with a marked escalation in the incidence of ASD in their offspring (Strömland et al., <xref ref-type="bibr" rid="B223">1994</xref>). Furthermore, several reports revealed that methylmercury, which is formed from inorganic mercury by the action of microbes that live in aquatic systems including lakes, rivers, wetlands, sediments, and soils, exposure during childhood caused a variety of neuropsychological abnormalities, e.g., memory, attention, and language, (Grandjean et al., <xref ref-type="bibr" rid="B78">1999</xref>; Falluel-Morel et al., <xref ref-type="bibr" rid="B62">2007</xref>; Davidson et al., <xref ref-type="bibr" rid="B51">2011</xref>). Also, a previous study has shown that acute systemic administration methylmercury during developmental phases elicited hippocampal cell death, reductions in neurogenesis, and severe learning impairments (Grandjean et al., <xref ref-type="bibr" rid="B78">1999</xref>). Thimerosal was a widely used preservative in numerous biological and drug products since 1930s, including many vaccines. It is a mercury-containing organic compound which contains ethylmercury, a compound supposed to be the cause for several adverse neurodevelopmental deficits, including ASD (Hviid et al., <xref ref-type="bibr" rid="B112">2003</xref>). Also, a previous study in which 10,000 cases have been examined showed that there is a significant association between maternal viral infection in the first trimester and ASD in the offspring (Atladóttir et al., <xref ref-type="bibr" rid="B11">2010</xref>). Indeed, when animals were exposed to the maternal immune activation with polyinosine:cytosine (poly I:C) at embryonic day 9.5, the offspring displayed histological and behavioral abnormalities that resembled ASD (Shi et al., <xref ref-type="bibr" rid="B217">2009</xref>; Hsiao et al., <xref ref-type="bibr" rid="B106">2012</xref>; Garay et al., <xref ref-type="bibr" rid="B70">2013</xref>). On behavioral level, these animals demonstrated impaired sociability, communication differences, and increased repetitive stereotyped behaviors and had smaller brain sizes at birth, followed by macroencephaly in adulthood. In line with these observations, it has been shown that viral infections in the mother can prompt substantial changes in the immune system in both mother and fetus, leading to long-term epigenetic alterations in the offspring (Kong et al., <xref ref-type="bibr" rid="B130">2012</xref>). Consequently, the timing of immune insults during developmental phase may be one source of the heterogeneity in the phenotypic features observed in ASD (Kong et al., <xref ref-type="bibr" rid="B130">2012</xref>). Accordingly, male rats treated with thalidomide/VPA demonstrated immunological changes such as decreased splenocyte proliferative response to mitogenic stimulation, lower thymus weight, and decreased interferon (IFN)-β/IL-10 ratio in peritoneal macrophages, whereas female rats in this study failed to show many of these behavioral and immunological changes, indicating that sex-specific responses to some environmental factors might play a significant role on the phenotypic outcomes of several ASD features (Schneider et al., <xref ref-type="bibr" rid="B211">2008</xref>). Also and subsequent to viral infection, the immune response was found to produce various cytokines, such as interleukins (IL)-1,-2 and -6 which modulate the release of several monoamines such as 5-HT in the hippocampus and other brain regions (Libbey et al., <xref ref-type="bibr" rid="B141">2005</xref>). Indeed, maternal infection was found to lead to elevated levels of cytokines and chemokines including interleukin-1β (IL-β), IL-6, IL-8, and IL-12p40 in the plasma of ASD children, and such increases were reported to be associated with more reduced communication skills and abnormal behaviors (Patterson, <xref ref-type="bibr" rid="B183">2012</xref>). Also, the offspring of infected animal mothers given poly (I:C) exhibited both ASD-like behavioral and neuropathological deficits as described above (Shi et al., <xref ref-type="bibr" rid="B217">2009</xref>; Hsiao et al., <xref ref-type="bibr" rid="B106">2012</xref>; Patterson, <xref ref-type="bibr" rid="B183">2012</xref>; Gadad et al., <xref ref-type="bibr" rid="B69">2013</xref>; Garay et al., <xref ref-type="bibr" rid="B70">2013</xref>). Based on the aforementioned results, environmental influences both <italic>during</italic> and <italic>after</italic> pregnancy can significantly influence the immune system and the developing nervous system to play a role in constructing several neurodevelopmental disorders including ASD.</p>
<p>It should be stressed that experimental animal models (genetically manipulated animal models, animal models obtained by destruction of certain CNS areas, and animal models obtained by using maternal factors) are indispensable for exploring the pathophysiologic causes of brain disorders, e.g., ASD, although they do not reflect the entire state of ASD disease. Moreover, animal models (mostly rodents) are widely used to study the development of cortical neurocircuit, genetic analysis and molecular mechanisms underlying ASD, and the palliative effects of newly developed drugs on core as well as associated symptoms of ASD. Notably, rat has become the most extensively used animals in the context of SCH and ASD neuroscience (Brudzynski, <xref ref-type="bibr" rid="B28">2013</xref>). Accordingly, and as compared to mice, rats provide more experimental advantages including the fact that rats demonstrate richer social behavioral skills, show various types of social behaviors, and use a rich CNS communication system (Brudzynski, <xref ref-type="bibr" rid="B28">2013</xref>). Furthermore, genetic as well as non-genetic rodent models have the capability of being the major objects of pharmaceutical industry in testing drug efficacy, dosage and acute as well as (sub)chronic toxicology.</p>
</sec>
</sec>
<sec id="s6" sec-type="conclusions">
<title>Conclusion</title>
<p>The disciplines of neurochemistry, neuroanatomy, neuropsychopharmacology, genetics and molecular biology are encouraged to work simultaneously to further help uncover more details of the biological bases of ASD. It is motivating that numerous genes identified so far in human ASD genetic studies generate several valuable transgenic ASD rodent models, which display both ASD-like abnormalities in neuropathology as well as in behavioral phenotypic features. Moreover, several of the abnormalities involve the dysfunction of various neurotransmitter systems. Furthermore, a variety of multiple genetic and environmental factors induce alterations in brain development, leading to ASDs. Notably, there are associated behavioral abnormalities, e.g., anxiety-like behavior, seizure susceptibility, sensory processing, and motor abnormalities, which have been recognised in both the genetic and non-genetic rodent models of ASDs. Consequently, broader understanding of how the trajectory of patients affected with ASDs fits into several subcategories, with specific endophenotype concepts, will expedite both understanding of the causes of the disorders and can provide insight into specific possible future treatments. Preclinical experimental rodent models are supportive to determine the mechanistic pathways associated with the genetic and environmental targeted insults to the CNS and the pathogenesis of ASD. In recent times these animal models are also continuing to proliferate to assess the potential of different drugs and other related treatment modalities. Consequently, this is of valuable significance, as it may close a gap in our understanding of the effects of therapy and may suggest new and effective methods for ASD treatment. The experimental results observed so far clearly show that ASD involves cascade of complex gene-environmental interactions which requires experts of these research areas to work in collaboration together that may lead hopefully to improved pharmacological interventions, if not to cure but at least to reduce the impact of symptoms of this disorder. The majority of pharmacological interventions to date have focused on antipsychotics, antidepressants and psychostimulants that are the most commonly utilized medication classes for ASD. However, several other drug classes, e.g. SSRIs, glutamate antagonists, and antiepileptics, are currently progressing in clinical trials for their future potential use in ASD. In addition, future research in the ASD area needs to address individual differences within the ASD population in order to better account for etiological and phenotypic heterogeneity, and to emphasize on mechanistic processes as well as neurotransmitter dysfunctions and neurodevelopmental routes rather than outcomes or endpoints of the disorder. Moreover, understanding the high level of psychiatric comorbidities and overlapping features shared with other neurodevelopmental disorders together with integration of different research methodologies (e.g., neuropharmacological, behavioral, and brain imaging measures) could encourage further advances of the current level of knowledge in the field of therapeutic ASD intervention. Furthermore, it is becoming progressively obligatory to prospectively evaluate the co-occurrence of, and commonalities between SCH and ASD at the trait level applying the multifactorial data obtainable from large clinical samples, since undiagnosed co-occurring brain disorders in respective individuals may be the consequence of not receiving suitable facilities, assistances, or even pharmacological treatments. Given the similarities between several brain disorders, e.g., SCH and ASD, misdiagnosis is, also, possible. Therefore, it is imperative that future research efforts account for the heterogeneity of both disorders, and inspect evidence on several levels to categorize endophenotypic markers considering the dimensional nature of such brain disorders. In addition, future studies assessing new pharmacological treatment approaches combined with non-pharmacologic therapies are necessary to ensure that target core behaviors of ASD are properly managed.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>NE and BS: Idea, design, writing, and submission. MA-H, AS, SO, and AS: Substantial contribution to the conception, formulation, and critical revision of the manuscript. All authors gave approval for the final submission of the review and agreed be accountable for all aspects of the work.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>The Office of Graduate Studies and Research of UAE University as well as ADEK Award for Research Excellence (AARE) 2017 are highly thanked for the support provided to BS and MA-H in form of intramural College of Medicine and Health Sciences (Zayed Center for Health Sciences) as well as extramural funds from ADEK.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alachkar</surname><given-names>A.</given-names></name><name><surname>Lazewska</surname><given-names>D.</given-names></name><name><surname>Kiec-Kononowicz</surname><given-names>K.</given-names></name><name><surname>Sadek</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>The histamine H3 receptor antagonist E159 reverses memory deficits induced by dizocilpine in passive avoidance and novel object recognition paradigm in rats</article-title>. <source/>Front. Pharmacol.
<volume>8</volume>:<fpage>709</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00709</pub-id><pub-id pub-id-type="pmid">29075190</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AlOlaby</surname><given-names>R. R.</given-names></name><name><surname>Sweha</surname><given-names>S. R.</given-names></name><name><surname>Silva</surname><given-names>M.</given-names></name><name><surname>Durbin-Johnson</surname><given-names>B.</given-names></name><name><surname>Yrigollen</surname><given-names>C. M.</given-names></name><name><surname>Pretto</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome</article-title>. <source/>Brain Dev.
<volume>39</volume>, <fpage>483</fpage>–<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2017.01.012</pub-id><pub-id pub-id-type="pmid">28242040</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aman</surname><given-names>M. G.</given-names></name></person-group> (<year>2004</year>). <article-title>Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder</article-title>. <source/>Semin. Pediatr. Neurol.
<volume>11</volume>, <fpage>225</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.spen.2004.07.006</pub-id><pub-id pub-id-type="pmid">15575418</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname><given-names>R. E.</given-names></name><name><surname>Van den Veyver</surname><given-names>I. B.</given-names></name><name><surname>Wan</surname><given-names>M.</given-names></name><name><surname>Tran</surname><given-names>C. Q.</given-names></name><name><surname>Francke</surname><given-names>U.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>1999</year>). <article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2</article-title>. <source/>Nat. Genet.
<volume>23</volume>, <fpage>185</fpage>–<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1038/13810</pub-id><pub-id pub-id-type="pmid">10508514</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anagnostou</surname><given-names>E.</given-names></name><name><surname>Esposito</surname><given-names>K.</given-names></name><name><surname>Soorya</surname><given-names>L.</given-names></name><name><surname>Chaplin</surname><given-names>W.</given-names></name><name><surname>Wasserman</surname><given-names>S.</given-names></name><name><surname>Hollander</surname><given-names>E.</given-names></name></person-group> (<year>2006</year>). <article-title>Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder</article-title>. <source/>J. Clin. Psychopharmacol. <volume>26</volume>, <fpage>444</fpage>–<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1097/01.jcp.0000227703.72117.bc</pub-id><pub-id pub-id-type="pmid">16855475</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andolina</surname><given-names>D.</given-names></name><name><surname>Di Segni</surname><given-names>M.</given-names></name><name><surname>Ventura</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>MiRNA-34 and stress response</article-title>. <source/>Oncotarget
<volume>8</volume>, <fpage>5658</fpage>–<lpage>5659</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.13923</pub-id><pub-id pub-id-type="pmid">28086203</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andres</surname><given-names>C.</given-names></name></person-group> (<year>2002</year>). <article-title>Molecular genetics and animal models in autistic disorder</article-title>. <source/>Brain Res. Bull.
<volume>57</volume>, <fpage>109</fpage>–<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/S0361-9230(01)00642-6</pub-id><pub-id pub-id-type="pmid">11827743</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anshu</surname><given-names>K.</given-names></name><name><surname>Nair</surname><given-names>A. K.</given-names></name><name><surname>Kumaresan</surname><given-names>U. D.</given-names></name><name><surname>Kutty</surname><given-names>B. M.</given-names></name><name><surname>Srinath</surname><given-names>S.</given-names></name><name><surname>Laxmi</surname><given-names>T. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Altered attentional processing in male and female rats in a prenatal valproic acid exposure model of autism spectrum disorder</article-title>. <source/>Autism Res.
<volume>10</volume>, <fpage>1929</fpage>–<lpage>1944</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1852</pub-id><pub-id pub-id-type="pmid">28851114</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>H. M.</given-names></name><name><surname>Burk</surname><given-names>J. A.</given-names></name><name><surname>Hodgson</surname><given-names>E. M.</given-names></name><name><surname>Sarter</surname><given-names>M.</given-names></name><name><surname>Bruno</surname><given-names>J. P.</given-names></name></person-group> (<year>2002</year>). <article-title>Differential cortical acetylcholine release in rats performing a sustained attention task versus behavioral control tasks that do not explicitly tax attention</article-title>. <source/>Neuroscience
<volume>114</volume>, <fpage>451</fpage>–<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1016/S0306-4522(02)00292-0</pub-id><pub-id pub-id-type="pmid">12204214</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvidsson</surname><given-names>O.</given-names></name><name><surname>Gillberg</surname><given-names>C.</given-names></name><name><surname>Lichtenstein</surname><given-names>P.</given-names></name><name><surname>Lundstrom</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Secular changes in the symptom level of clinically diagnosed autism</article-title>. <source/>J. Child. Psychol. Psychiatry. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1111/jcpp.12864</pub-id><pub-id pub-id-type="pmid">29377119</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atladóttir</surname><given-names>H. O.</given-names></name><name><surname>Thorsen</surname><given-names>P.</given-names></name><name><surname>Østergaard</surname><given-names>L.</given-names></name><name><surname>Schendel</surname><given-names>D. E.</given-names></name><name><surname>Lemcke</surname><given-names>S.</given-names></name><name><surname>Abdallah</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders</article-title>. <source/>J. Autism Dev. Disord.
<volume>40</volume>, <fpage>1423</fpage>–<lpage>1430</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-010-1006-y</pub-id><pub-id pub-id-type="pmid">20414802</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avale</surname><given-names>M. E.</given-names></name><name><surname>Chabout</surname><given-names>J.</given-names></name><name><surname>Pons</surname><given-names>S.</given-names></name><name><surname>Serreau</surname><given-names>P.</given-names></name><name><surname>De Chaumont</surname><given-names>F.</given-names></name><name><surname>Olivo-Marin</surname><given-names>J. C.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Prefrontal nicotinic receptors control novel social interaction between mice</article-title>. <source/>FASEB J.
<volume>25</volume>, <fpage>2145</fpage>–<lpage>2155</lpage>. <pub-id pub-id-type="doi">10.1096/fj.10-178558</pub-id><pub-id pub-id-type="pmid">21402717</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacchelli</surname><given-names>E.</given-names></name><name><surname>Battaglia</surname><given-names>A.</given-names></name><name><surname>Cameli</surname><given-names>C.</given-names></name><name><surname>Lomartire</surname><given-names>S.</given-names></name><name><surname>Tancredi</surname><given-names>R.</given-names></name><name><surname>Thomson</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Analysis of CHRNA7 rare variants in autism spectrum disorder susceptibility</article-title>. <source/>Am. J. Med. Genet. A
<volume>167A</volume>, <fpage>715</fpage>–<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36847</pub-id><pub-id pub-id-type="pmid">25655306</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>J. A.</given-names></name><name><surname>Gu</surname><given-names>Z.</given-names></name><name><surname>Clark</surname><given-names>R. A.</given-names></name><name><surname>Reinert</surname><given-names>K.</given-names></name><name><surname>Samonte</surname><given-names>R. V.</given-names></name><name><surname>Schwartz</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Recent segmental duplications in the human genome</article-title>. <source/>Science
<volume>297</volume>, <fpage>1003</fpage>–<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1126/science.1072047</pub-id><pub-id pub-id-type="pmid">12169732</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramaniyan</surname><given-names>V.</given-names></name><name><surname>Boddeke</surname><given-names>E.</given-names></name><name><surname>Bakels</surname><given-names>R.</given-names></name><name><surname>Küst</surname><given-names>B.</given-names></name><name><surname>Kooistra</surname><given-names>S.</given-names></name><name><surname>Veneman</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse neural stem cells</article-title>. <source/>Neuroscience
<volume>143</volume>, <fpage>939</fpage>–<lpage>951</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.08.082</pub-id><pub-id pub-id-type="pmid">17084985</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballaban-Gil</surname><given-names>K.</given-names></name><name><surname>Tuchman</surname><given-names>R.</given-names></name></person-group> (<year>2000</year>). <article-title>Epilepsy and epileptiform EEG: association with autism and language disorders</article-title>. <source/>Ment. Retard Dev. Disabil. Res. Rev.
<volume>6</volume>, <fpage>300</fpage>–<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1002/1098-2779(2000)6:4&lt;300::AID-MRDD9&gt;3.0.CO;2-R</pub-id><pub-id pub-id-type="pmid">11107195</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baronio</surname><given-names>D.</given-names></name><name><surname>Castro</surname><given-names>K.</given-names></name><name><surname>Gonchoroski</surname><given-names>T.</given-names></name><name><surname>de Melo</surname><given-names>G. M.</given-names></name><name><surname>Nunes</surname><given-names>G. D.</given-names></name><name><surname>Bambini-Junior</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid</article-title>. <source/>PLoS ONE
<volume>10</volume>:<fpage>e0116363</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0116363</pub-id><pub-id pub-id-type="pmid">25560049</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baronio</surname><given-names>D.</given-names></name><name><surname>Gonchoroski</surname><given-names>T.</given-names></name><name><surname>Castro</surname><given-names>K.</given-names></name><name><surname>Zanatta</surname><given-names>G.</given-names></name><name><surname>Gottfried</surname><given-names>C.</given-names></name><name><surname>Riesgo</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Histaminergic system in brain disorders: lessons from the translational approach and future perspectives</article-title>. <source/>Ann. Gen. Psychiatry
<volume>13</volume>, <fpage>34</fpage>. <pub-id pub-id-type="doi">10.1186/s12991-014-0034-y</pub-id><pub-id pub-id-type="pmid">25426159</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A.</given-names></name><name><surname>Kaphzan</surname><given-names>H.</given-names></name><name><surname>Alvarez-Dieppa</surname><given-names>A. C.</given-names></name><name><surname>Murphy</surname><given-names>J. P.</given-names></name><name><surname>Pierre</surname><given-names>P.</given-names></name><name><surname>Klann</surname><given-names>E.</given-names></name></person-group> (<year>2012</year>). <article-title>Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice</article-title>. <source/>Neuron
<volume>76</volume>, <fpage>325</fpage>–<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.07.022</pub-id><pub-id pub-id-type="pmid">23083736</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bishara</surname><given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>Once-monthly paliperidone injection for the treatment of schizophrenia</article-title>. <source/>Neuropsychiatr. Dis. Treat.
<volume>6</volume>, <fpage>561</fpage>–<lpage>572</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S8505</pub-id><pub-id pub-id-type="pmid">20856919</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boellner</surname><given-names>S. W.</given-names></name><name><surname>Pennick</surname><given-names>M.</given-names></name><name><surname>Fiske</surname><given-names>K.</given-names></name><name><surname>Lyne</surname><given-names>A.</given-names></name><name><surname>Shojaei</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder</article-title>. <source/>Pharmacotherapy
<volume>27</volume>, <fpage>1253</fpage>–<lpage>1262</lpage>. <pub-id pub-id-type="doi">10.1592/phco.27.9.1253</pub-id><pub-id pub-id-type="pmid">17723079</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvard</surname><given-names>M. P.</given-names></name><name><surname>Leboyer</surname><given-names>M.</given-names></name><name><surname>Launay</surname><given-names>J. M.</given-names></name><name><surname>Recasens</surname><given-names>C.</given-names></name><name><surname>Plumet</surname><given-names>M. H.</given-names></name><name><surname>Waller-Perotte</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>1995</year>). <article-title>Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study</article-title>. <source/>Psychiatry Res.
<volume>58</volume>, <fpage>191</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/0165-1781(95)02601-R</pub-id><pub-id pub-id-type="pmid">8570775</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowton</surname><given-names>E.</given-names></name><name><surname>Saunders</surname><given-names>C.</given-names></name><name><surname>Reddy</surname><given-names>I. A.</given-names></name><name><surname>Campbell</surname><given-names>N. G.</given-names></name><name><surname>Hamilton</surname><given-names>P. J.</given-names></name><name><surname>Henry</surname><given-names>L. K.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking</article-title>. <source/>Transl. Psychiatry
<volume>4</volume>, <fpage>e464</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2014.90</pub-id><pub-id pub-id-type="pmid">25313507</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodkin</surname><given-names>E. S.</given-names></name></person-group> (<year>2007</year>). <article-title>BALB/c mice: low sociability and other phenotypes that may be relevant to autism</article-title>. <source/>Behav. Brain Res.
<volume>176</volume>, <fpage>53</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2006.06.025</pub-id><pub-id pub-id-type="pmid">16890300</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browman</surname><given-names>K. E.</given-names></name><name><surname>Komater</surname><given-names>V. A.</given-names></name><name><surname>Curzon</surname><given-names>P.</given-names></name><name><surname>Rueter</surname><given-names>L. E.</given-names></name><name><surname>Hancock</surname><given-names>A. A.</given-names></name><name><surname>Decker</surname><given-names>M. W.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan</article-title>. <source/>Behav. Brain Res.
<volume>153</volume>, <fpage>69</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2003.11.001</pub-id><pub-id pub-id-type="pmid">15219708</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J. T.</given-names></name><name><surname>Eum</surname><given-names>S.</given-names></name><name><surname>Cook</surname><given-names>E. H.</given-names></name><name><surname>Bishop</surname><given-names>J. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Pharmacogenomics of autism spectrum disorder</article-title>. <source/>Pharmacogenomics
<volume>18</volume>, <fpage>403</fpage>–<lpage>414</lpage>. <pub-id pub-id-type="doi">10.2217/pgs-2016-0167</pub-id><pub-id pub-id-type="pmid">28244813</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J. W.</given-names></name><name><surname>Whitehead</surname><given-names>C. A.</given-names></name><name><surname>Basso</surname><given-names>A. M.</given-names></name><name><surname>Rueter</surname><given-names>L. E.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia</article-title>. <source/>Int. J. Neuropsychopharmacol.
<volume>16</volume>, <fpage>889</fpage>–<lpage>904</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145712000739</pub-id><pub-id pub-id-type="pmid">22906530</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brudzynski</surname><given-names>S. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Ethotransmission: communication of emotional states through ultrasonic vocalization in rats</article-title>. <source/>Curr. Opin. Neurobiol.
<volume>23</volume>, <fpage>310</fpage>–<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2013.01.014</pub-id><pub-id pub-id-type="pmid">23375168</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buiting</surname><given-names>K.</given-names></name><name><surname>Williams</surname><given-names>C.</given-names></name><name><surname>Horsthemke</surname><given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>Angelman syndrome - insights into a rare neurogenetic disorder</article-title>. <source/>Nat. Rev. Neurol.
<volume>12</volume>, <fpage>584</fpage>–<lpage>593</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2016.133</pub-id><pub-id pub-id-type="pmid">27615419</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>M.</given-names></name><name><surname>Fish</surname><given-names>B.</given-names></name><name><surname>Shapiro</surname><given-names>T.</given-names></name><name><surname>Floyd</surname><given-names>A.</given-names><suffix>Jr.</suffix></name></person-group> (<year>1971</year>). <article-title>Imipramine in preschool autistic and schizophrenic children</article-title>. <source/>J. Autism Child. Schizophr.
<volume>1</volume>, <fpage>267</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1007/BF01557348</pub-id><pub-id pub-id-type="pmid">5172531</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carminati</surname><given-names>G. G.</given-names></name><name><surname>Deriaz</surname><given-names>N.</given-names></name><name><surname>Bertschy</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms</article-title>. <source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
<volume>30</volume>, <fpage>312</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.10.002</pub-id><pub-id pub-id-type="pmid">16307837</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carminati</surname><given-names>G. G.</given-names></name><name><surname>Gerber</surname><given-names>F.</given-names></name><name><surname>Darbellay</surname><given-names>B.</given-names></name><name><surname>Kosel</surname><given-names>M. M.</given-names></name><name><surname>Deriaz</surname><given-names>N.</given-names></name><name><surname>Chabert</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder</article-title>. <source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
<volume>65</volume>, <fpage>85</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2015.09.002</pub-id><pub-id pub-id-type="pmid">26361994</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>L. S.</given-names></name><name><surname>Owen</surname><given-names>M. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Genetic overlap between autism, schizophrenia and bipolar disorder</article-title>. <source/>Genome Med.
<volume>1</volume>, <fpage>102</fpage>. <pub-id pub-id-type="doi">10.1186/gm102</pub-id><pub-id pub-id-type="pmid">19886976</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadman</surname><given-names>K. K.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Crawley</surname><given-names>J. N.</given-names></name></person-group> (<year>2009</year>). <article-title>Criteria for validating mouse models of psychiatric diseases</article-title>. <source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
<volume>150B</volume>, <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.30777</pub-id><pub-id pub-id-type="pmid">18484083</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Gilman</surname><given-names>S. R.</given-names></name><name><surname>Chiang</surname><given-names>A. H.</given-names></name><name><surname>Sanders</surname><given-names>S. J.</given-names></name><name><surname>Vitkup</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Genotype to phenotype relationships in autism spectrum disorders</article-title>. <source/>Nat. Neurosci.
<volume>18</volume>, <fpage>191</fpage>–<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3907</pub-id><pub-id pub-id-type="pmid">25531569</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>H. T.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Samaco</surname><given-names>R. C.</given-names></name><name><surname>Xue</surname><given-names>M.</given-names></name><name><surname>Chahrour</surname><given-names>M.</given-names></name><name><surname>Yoo</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes</article-title>. <source/>Nature
<volume>468</volume>, <fpage>263</fpage>–<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1038/nature09582</pub-id><pub-id pub-id-type="pmid">21068835</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J. A.</given-names></name><name><surname>Peñagarikano</surname><given-names>O.</given-names></name><name><surname>Belgard</surname><given-names>T. G.</given-names></name><name><surname>Swarup</surname><given-names>V.</given-names></name><name><surname>Geschwind</surname><given-names>D. H.</given-names></name></person-group> (<year>2015</year>). <article-title>The emerging picture of autism spectrum disorder: genetics and pathology</article-title>. <source/>Annu. Rev. Pathol.
<volume>10</volume>, <fpage>111</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathol-012414-040405</pub-id><pub-id pub-id-type="pmid">25621659</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N. C.</given-names></name><name><surname>Bedair</surname><given-names>H. S.</given-names></name><name><surname>McKay</surname><given-names>B.</given-names></name><name><surname>Bowers</surname><given-names>M. B.</given-names><suffix>Jr.</suffix></name><name><surname>Mazure</surname><given-names>C.</given-names></name></person-group> (<year>2001</year>). <article-title>Clozapine in the treatment of aggression in an adolescent with autistic disorder</article-title>. <source/>J. Clin. Psychiatry
<volume>62</volume>, <fpage>479</fpage>–<lpage>480</lpage>. <pub-id pub-id-type="doi">10.4088/JCP.v62n0612h</pub-id><pub-id pub-id-type="pmid">11465533</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Davis</surname><given-names>L. K.</given-names></name><name><surname>Guter</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Jacob</surname><given-names>S.</given-names></name><name><surname>Potter</surname><given-names>M. H.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Leveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism</article-title>. <source/>Mol. Autism
<volume>8</volume>, <fpage>14</fpage>. <pub-id pub-id-type="doi">10.1186/s13229-017-0130-3</pub-id><pub-id pub-id-type="pmid">28344757</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chez</surname><given-names>M. G.</given-names></name><name><surname>Burton</surname><given-names>Q.</given-names></name><name><surname>Dowling</surname><given-names>T.</given-names></name><name><surname>Chang</surname><given-names>M.</given-names></name><name><surname>Khanna</surname><given-names>P.</given-names></name><name><surname>Kramer</surname><given-names>C.</given-names></name></person-group> (<year>2007</year>). <article-title>Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability</article-title>. <source/>J. Child Neurol.
<volume>22</volume>, <fpage>574</fpage>–<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1177/0883073807302611</pub-id><pub-id pub-id-type="pmid">17690064</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chisholm</surname><given-names>K.</given-names></name><name><surname>Lin</surname><given-names>A.</given-names></name><name><surname>Abu-Akel</surname><given-names>A.</given-names></name><name><surname>Wood</surname><given-names>S. J.</given-names></name></person-group> (<year>2015</year>). <article-title>The association between autism and schizophrenia spectrum disorders: a review of eight alternate models of co-occurrence</article-title>. <source/>Neurosci. Biobehav. Rev.
<volume>55</volume>, <fpage>173</fpage>–<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.04.012</pub-id><pub-id pub-id-type="pmid">25956249</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chomiak</surname><given-names>T.</given-names></name><name><surname>Turner</surname><given-names>N.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name></person-group> (<year>2013</year>). <article-title>What we have learned about autism spectrum disorder from valproic acid</article-title>. <source/>Patholog. Res. Int.
<volume>2013</volume>, <fpage>712758</fpage>
<pub-id pub-id-type="doi">10.1155/2013/712758</pub-id><pub-id pub-id-type="pmid">24381784</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christian</surname><given-names>S. L.</given-names></name><name><surname>Fantes</surname><given-names>J. A.</given-names></name><name><surname>Mewborn</surname><given-names>S. K.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Ledbetter</surname><given-names>D. H.</given-names></name></person-group> (<year>1999</year>). <article-title>Large genomic duplicons map to sites of instability in the Prader-Willi/Angelman syndrome chromosome region (15q11-q13)</article-title>. <source/>Hum. Mol. Genet.
<volume>8</volume>, <fpage>1025</fpage>–<lpage>1037</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/8.6.1025</pub-id><pub-id pub-id-type="pmid">10332034</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christianson</surname><given-names>A. L.</given-names></name><name><surname>Chesler</surname><given-names>N.</given-names></name><name><surname>Kromberg</surname><given-names>J. G.</given-names></name></person-group> (<year>1994</year>). <article-title>Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs</article-title>. <source/>Dev. Med. Child Neurol.
<volume>36</volume>, <fpage>361</fpage>–<lpage>369</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.1994.tb11858.x</pub-id><pub-id pub-id-type="pmid">7512516</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname><given-names>S.</given-names></name><name><surname>Dissanayake</surname><given-names>C.</given-names></name><name><surname>Bui</surname><given-names>Q. M.</given-names></name><name><surname>Huggins</surname><given-names>R.</given-names></name><name><surname>Taylor</surname><given-names>A. K.</given-names></name><name><surname>Loesch</surname><given-names>D. Z.</given-names></name></person-group> (<year>2007</year>). <article-title>Autism spectrum phenotype in males and females with fragile X full mutation and premutation</article-title>. <source/>J. Autism Dev. Disord.
<volume>37</volume>, <fpage>738</fpage>–<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-006-0205-z</pub-id><pub-id pub-id-type="pmid">17031449</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coghlan</surname><given-names>S.</given-names></name><name><surname>Horder</surname><given-names>J.</given-names></name><name><surname>Inkster</surname><given-names>B.</given-names></name><name><surname>Mendez</surname><given-names>M. A.</given-names></name><name><surname>Murphy</surname><given-names>D. G.</given-names></name><name><surname>Nutt</surname><given-names>D. J.</given-names></name></person-group> (<year>2012</year>). <article-title>GABA system dysfunction in autism and related disorders: from synapse to symptoms</article-title>. <source/>Neurosci. Biobehav. Rev.
<volume>36</volume>, <fpage>2044</fpage>–<lpage>2055</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.07.005</pub-id><pub-id pub-id-type="pmid">22841562</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>E. H.</given-names><suffix>Jr.</suffix></name><name><surname>Courchesne</surname><given-names>R. Y.</given-names></name><name><surname>Cox</surname><given-names>N. J.</given-names></name><name><surname>Lord</surname><given-names>C.</given-names></name><name><surname>Gonen</surname><given-names>D.</given-names></name><name><surname>Guter</surname><given-names>S. J.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers</article-title>. <source/>Am. J. Hum. Genet.
<volume>62</volume>, <fpage>1077</fpage>–<lpage>1083</lpage>. <pub-id pub-id-type="doi">10.1086/301832</pub-id><pub-id pub-id-type="pmid">9545402</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>E. H.</given-names><suffix>Jr.</suffix></name><name><surname>Scherer</surname><given-names>S. W.</given-names></name></person-group> (<year>2008</year>). <article-title>Copy-number variations associated with neuropsychiatric conditions</article-title>. <source/>Nature
<volume>455</volume>, <fpage>919</fpage>–<lpage>923</lpage>. <pub-id pub-id-type="doi">10.1038/nature07458</pub-id><pub-id pub-id-type="pmid">18923514</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coruzzi</surname><given-names>G.</given-names></name><name><surname>Pozzoli</surname><given-names>C.</given-names></name><name><surname>Adami</surname><given-names>M.</given-names></name><name><surname>Grandi</surname><given-names>D.</given-names></name><name><surname>Guido</surname><given-names>N.</given-names></name><name><surname>Smits</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Strain-dependent effects of the histamine H<sub>4</sub> receptor antagonist JNJ7777120 in a murine model of acute skin inflammation</article-title>. <source/>Exp. Dermatol.
<volume>21</volume>, <fpage>32</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0625.2011.01396.x</pub-id><pub-id pub-id-type="pmid">22151388</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davanzo</surname><given-names>P. A.</given-names></name><name><surname>Belin</surname><given-names>T. R.</given-names></name><name><surname>Widawski</surname><given-names>M. H.</given-names></name><name><surname>King</surname><given-names>B. H.</given-names></name></person-group> (<year>1998</year>). <article-title>Paroxetine treatment of aggression and self-injury in persons with mental retardation</article-title>. <source/>Am. J. Ment. Retard
<volume>102</volume>, <fpage>427</fpage>–<lpage>437</lpage>. <pub-id pub-id-type="doi">10.1352/0895-8017(1998)102&lt;0427:PTOAAS&gt;2.0.CO;2</pub-id><pub-id pub-id-type="pmid">9544340</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>P. W.</given-names></name><name><surname>Cory-Slechta</surname><given-names>D. A.</given-names></name><name><surname>Thurston</surname><given-names>S. W.</given-names></name><name><surname>Huang</surname><given-names>L. S.</given-names></name><name><surname>Shamlaye</surname><given-names>C. F.</given-names></name><name><surname>Gunzler</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Fish consumption and prenatal methylmercury exposure: cognitive and behavioral outcomes in the main cohort at 17 years from the Seychelles child development study</article-title>. <source/>Neurotoxicology
<volume>32</volume>, <fpage>711</fpage>–<lpage>717</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2011.08.003</pub-id><pub-id pub-id-type="pmid">21889535</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLong</surname><given-names>G. R.</given-names></name><name><surname>Ritch</surname><given-names>C. R.</given-names></name><name><surname>Burch</surname><given-names>S.</given-names></name></person-group> (<year>2002</year>). <article-title>Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement</article-title>. <source/>Dev. Med. Child Neurol.
<volume>44</volume>, <fpage>652</fpage>–<lpage>659</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.2002.tb00266.x</pub-id><pub-id pub-id-type="pmid">12418789</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devor</surname><given-names>A.</given-names></name><name><surname>Andreassen</surname><given-names>O. A.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Mäki-Marttunen</surname><given-names>T.</given-names></name><name><surname>Smeland</surname><given-names>O. B.</given-names></name><name><surname>Fan</surname><given-names>C. C.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia</article-title>. <source/>Mol. Psychiatry
<volume>22</volume>, <fpage>792</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2017.33</pub-id><pub-id pub-id-type="pmid">28348379</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Martino</surname><given-names>A.</given-names></name><name><surname>Melis</surname><given-names>G.</given-names></name><name><surname>Cianchetti</surname><given-names>C.</given-names></name><name><surname>Zuddas</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study</article-title>. <source/>J. Child Adolesc. Psychopharmacol.
<volume>14</volume>, <fpage>207</fpage>–<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1089/1044546041649011</pub-id><pub-id pub-id-type="pmid">15319018</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doxakis</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>12726</fpage>–<lpage>12734</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.086827</pub-id><pub-id pub-id-type="pmid">20106983</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eissa</surname><given-names>N.</given-names></name><name><surname>Khan</surname><given-names>N.</given-names></name><name><surname>Ojha</surname><given-names>S. K.</given-names></name><name><surname>Lazewska</surname><given-names>D.</given-names></name><name><surname>Kiec-Kononowicz</surname><given-names>K.</given-names></name><name><surname>Sadek</surname><given-names>B.</given-names></name></person-group> (<year>2018</year>). <article-title>The histamine H3 receptor antagonist DL77 ameliorates MK801-induced memory deficits in rats</article-title>. <source/>Front. Neurosci.
<volume>12</volume>:<fpage>42</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2018.00042</pub-id><pub-id pub-id-type="pmid">29483860</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elchaar</surname><given-names>G. M.</given-names></name><name><surname>Maisch</surname><given-names>N. M.</given-names></name><name><surname>Augusto</surname><given-names>L. M.</given-names></name><name><surname>Wehring</surname><given-names>H. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Efficacy and safety of naltrexone use in pediatric patients with autistic disorder</article-title>. <source/>Ann. Pharmacother.
<volume>40</volume>, <fpage>1086</fpage>–<lpage>1095</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1G499</pub-id><pub-id pub-id-type="pmid">16735648</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellenbroek</surname><given-names>B. A.</given-names></name><name><surname>August</surname><given-names>C.</given-names></name><name><surname>Youn</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Does prenatal valproate interact with a genetic reduction in the serotonin transporter? A rat study on anxiety and cognition</article-title>. <source/>Front. Neurosci.
<volume>10</volume>:<fpage>424</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2016.00424</pub-id><pub-id pub-id-type="pmid">27708559</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellenbroek</surname><given-names>B. A.</given-names></name><name><surname>Ghiabi</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?</article-title>
<source/>Curr. Pharm. Des.
<volume>21</volume>, <fpage>3760</fpage>–<lpage>3770</lpage>. <pub-id pub-id-type="doi">10.2174/1381612821666150605105325</pub-id><pub-id pub-id-type="pmid">26044979</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ergaz</surname><given-names>Z.</given-names></name><name><surname>Weinstein-Fudim</surname><given-names>L.</given-names></name><name><surname>Ornoy</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Genetic and non-genetic animal models for autism spectrum disorders (ASD)</article-title>. <source/>Reprod. Toxicol.
<volume>64</volume>, <fpage>116</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.reprotox.2016.04.024</pub-id><pub-id pub-id-type="pmid">27142188</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbenshade</surname><given-names>T. A.</given-names></name><name><surname>Browman</surname><given-names>K. E.</given-names></name><name><surname>Bitner</surname><given-names>R. S.</given-names></name><name><surname>Strakhova</surname><given-names>M.</given-names></name><name><surname>Cowart</surname><given-names>M. D.</given-names></name><name><surname>Brioni</surname><given-names>J. D.</given-names></name></person-group> (<year>2008</year>). <article-title>The histamine H3 receptor: an attractive target for the treatment of cognitive disorders</article-title>. <source/>Br. J. Pharmacol.
<volume>154</volume>, <fpage>1166</fpage>–<lpage>1181</lpage>. <pub-id pub-id-type="doi">10.1038/bjp.2008.147</pub-id><pub-id pub-id-type="pmid">18469850</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falluel-Morel</surname><given-names>A.</given-names></name><name><surname>Sokolowski</surname><given-names>K.</given-names></name><name><surname>Sisti</surname><given-names>H. M.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Shors</surname><given-names>T. J.</given-names></name><name><surname>Dicicco-Bloom</surname><given-names>E.</given-names></name></person-group> (<year>2007</year>). <article-title>Developmental mercury exposure elicits acute hippocampal cell death, reductions in neurogenesis, and severe learning deficits during puberty</article-title>. <source/>J. Neurochem.
<volume>103</volume>, <fpage>1968</fpage>–<lpage>1981</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.04882.x</pub-id><pub-id pub-id-type="pmid">17760861</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fankhauser</surname><given-names>M. P.</given-names></name><name><surname>Karumanchi</surname><given-names>V. C.</given-names></name><name><surname>German</surname><given-names>M. L.</given-names></name><name><surname>Yates</surname><given-names>A.</given-names></name><name><surname>Karumanchi</surname><given-names>S. D.</given-names></name></person-group> (<year>1992</year>). <article-title>A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism</article-title>. <source/>J. Clin. Psychiatry
<volume>53</volume>, <fpage>77</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="pmid">1548248</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatemi</surname><given-names>S. H.</given-names></name><name><surname>Halt</surname><given-names>A. R.</given-names></name><name><surname>Stary</surname><given-names>J. M.</given-names></name><name><surname>Kanodia</surname><given-names>R.</given-names></name><name><surname>Schulz</surname><given-names>S. C.</given-names></name><name><surname>Realmuto</surname><given-names>G. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices</article-title>. <source/>Biol. Psychiatry
<volume>52</volume>, <fpage>805</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-3223(02)01430-0</pub-id><pub-id pub-id-type="pmid">12372652</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatemi</surname><given-names>S. H.</given-names></name><name><surname>Realmuto</surname><given-names>G. M.</given-names></name><name><surname>Khan</surname><given-names>L.</given-names></name><name><surname>Thuras</surname><given-names>P.</given-names></name></person-group> (<year>1998</year>). <article-title>Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial</article-title>. <source/>J. Autism Dev. Disord.
<volume>28</volume>, <fpage>303</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1023/A:1026008602540</pub-id><pub-id pub-id-type="pmid">9711486</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Findling</surname><given-names>R. L.</given-names></name><name><surname>McNamara</surname><given-names>N. K.</given-names></name><name><surname>Gracious</surname><given-names>B. L.</given-names></name><name><surname>O'Riordan</surname><given-names>M. A.</given-names></name><name><surname>Reed</surname><given-names>M. D.</given-names></name><name><surname>Demeter</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Quetiapine in nine youths with autistic disorder</article-title>. <source/>J. Child Adoles. Psychopharmacol.
<volume>14</volume>, <fpage>287</fpage>–<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1089/1044546041649129</pub-id><pub-id pub-id-type="pmid">15319025</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fregeac</surname><given-names>J.</given-names></name><name><surname>Colleaux</surname><given-names>L.</given-names></name><name><surname>Nguyen</surname><given-names>L. S.</given-names></name></person-group> (<year>2016</year>). <article-title>The emerging roles of MicroRNAs in autism spectrum disorders</article-title>. <source/>Neurosci. Biobehav. Rev.
<volume>71</volume>, <fpage>729</fpage>–<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.10.018</pub-id><pub-id pub-id-type="pmid">27793596</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>S. D.</given-names></name><name><surname>Shaw</surname><given-names>D. W.</given-names></name><name><surname>Artru</surname><given-names>A. A.</given-names></name><name><surname>Dawson</surname><given-names>G.</given-names></name><name><surname>Petropoulos</surname><given-names>H.</given-names></name><name><surname>Dager</surname><given-names>S. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Gray and white matter brain chemistry in young children with autism</article-title>. <source/>Arch. Gen. Psychiatry
<volume>63</volume>, <fpage>786</fpage>–<lpage>794</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.63.7.786</pub-id><pub-id pub-id-type="pmid">16818868</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gadad</surname><given-names>B. S.</given-names></name><name><surname>Hewitson</surname><given-names>L.</given-names></name><name><surname>Young</surname><given-names>K. A.</given-names></name><name><surname>German</surname><given-names>D. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuropathology and animal models of autism: genetic and environmental factors</article-title>. <source/>Autism Res. Treat.
<volume>2013</volume>:<fpage>731935</fpage>. <pub-id pub-id-type="doi">10.1155/2013/731935</pub-id><pub-id pub-id-type="pmid">24151553</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garay</surname><given-names>P. A.</given-names></name><name><surname>Hsiao</surname><given-names>E. Y.</given-names></name><name><surname>Patterson</surname><given-names>P. H.</given-names></name><name><surname>McAllister</surname><given-names>A. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development</article-title>. <source/>Brain Behav. Immun.
<volume>31</volume>, <fpage>54</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2012.07.008</pub-id><pub-id pub-id-type="pmid">22841693</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardener</surname><given-names>H.</given-names></name><name><surname>Spiegelman</surname><given-names>D.</given-names></name><name><surname>Buka</surname><given-names>S. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis</article-title>. <source/>Pediatrics
<volume>128</volume>, <fpage>344</fpage>–<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2010-1036</pub-id><pub-id pub-id-type="pmid">21746727</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geschwind</surname><given-names>D. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Genetics of autism spectrum disorders</article-title>. <source/>Trends Cogn. Sci.
<volume>15</volume>, <fpage>409</fpage>–<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1016/j.tics.2011.07.003</pub-id><pub-id pub-id-type="pmid">21855394</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillberg</surname><given-names>C.</given-names></name><name><surname>Lundström</surname><given-names>S.</given-names></name><name><surname>Fernell</surname><given-names>E.</given-names></name><name><surname>Nilsson</surname><given-names>G.</given-names></name><name><surname>Neville</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Febrile seizures and epilepsy: association with autism and other neurodevelopmental disorders in the child and adolescent twin study in Sweden</article-title>. <source/>Pediatr. Neurol.
<volume>74</volume>, <fpage>80 e82</fpage>–<lpage>86 e82</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2017.05.027</pub-id><pub-id pub-id-type="pmid">28754226</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giza</surname><given-names>J.</given-names></name><name><surname>Urbanski</surname><given-names>M. J.</given-names></name><name><surname>Prestori</surname><given-names>F.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>B.</given-names></name><name><surname>Yam</surname><given-names>A.</given-names></name><name><surname>Friedrich</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Behavioral and cerebellar transmission deficits in mice lacking the autism-linked gene islet brain-2</article-title>. <source/>J. Neurosci.
<volume>30</volume>, <fpage>14805</fpage>–<lpage>14816</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1161-10.2010</pub-id><pub-id pub-id-type="pmid">21048139</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glasson</surname><given-names>E. J.</given-names></name><name><surname>Bower</surname><given-names>C.</given-names></name><name><surname>Petterson</surname><given-names>B.</given-names></name><name><surname>de Klerk</surname><given-names>N.</given-names></name><name><surname>Chaney</surname><given-names>G.</given-names></name><name><surname>Hallmayer</surname><given-names>J. F.</given-names></name></person-group> (<year>2004</year>). <article-title>Perinatal factors and the development of autism: a population study</article-title>. <source/>Arch. Gen. Psychiatry
<volume>61</volume>, <fpage>618</fpage>–<lpage>627</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.61.6.618</pub-id><pub-id pub-id-type="pmid">15184241</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobbi</surname><given-names>G.</given-names></name><name><surname>Pulvirenti</surname><given-names>L.</given-names></name></person-group> (<year>2001</year>). <article-title>Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour</article-title>. <source/>J. Psychiatry Neurosci.
<volume>26</volume>, <fpage>340</fpage>–<lpage>341</lpage>. <pub-id pub-id-type="pmid">11590976</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>C. T.</given-names></name><name><surname>State</surname><given-names>R. C.</given-names></name><name><surname>Nelson</surname><given-names>J. E.</given-names></name><name><surname>Hamburger</surname><given-names>S. D.</given-names></name><name><surname>Rapoport</surname><given-names>J. L.</given-names></name></person-group> (<year>1993</year>). <article-title>A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder</article-title>. <source/>Arch. Gen. Psychiatry
<volume>50</volume>, <fpage>441</fpage>–<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.1993.01820180039004</pub-id><pub-id pub-id-type="pmid">8498878</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandjean</surname><given-names>P.</given-names></name><name><surname>Budtz-Jørgensen</surname><given-names>E.</given-names></name><name><surname>White</surname><given-names>R. F.</given-names></name><name><surname>Jørgensen</surname><given-names>P. J.</given-names></name><name><surname>Weihe</surname><given-names>P.</given-names></name><name><surname>Debes</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>Methylmercury exposure biomarkers as indicators of neurotoxicity in children aged 7 years</article-title>. <source/>Am. J. Epidemiol.
<volume>150</volume>, <fpage>301</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a010002</pub-id><pub-id pub-id-type="pmid">10430235</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granon</surname><given-names>S.</given-names></name><name><surname>Faure</surname><given-names>P.</given-names></name><name><surname>Changeux</surname><given-names>J. P.</given-names></name></person-group> (<year>2003</year>). <article-title>Executive and social behaviors under nicotinic receptor regulation</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>100</volume>, <fpage>9596</fpage>–<lpage>9601</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1533498100</pub-id><pub-id pub-id-type="pmid">12876201</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregor</surname><given-names>A.</given-names></name><name><surname>Albrecht</surname><given-names>B.</given-names></name><name><surname>Bader</surname><given-names>I.</given-names></name><name><surname>Bijlsma</surname><given-names>E. K.</given-names></name><name><surname>Ekici</surname><given-names>A. B.</given-names></name><name><surname>Engels</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1</article-title>. <source/>BMC Med. Genet.
<volume>12</volume>:<fpage>106</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2350-12-106</pub-id><pub-id pub-id-type="pmid">21827697</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griebel</surname><given-names>G.</given-names></name><name><surname>Pichat</surname><given-names>P.</given-names></name><name><surname>Pruniaux</surname><given-names>M. P.</given-names></name><name><surname>Beeske</surname><given-names>S.</given-names></name><name><surname>Lopez-Grancha</surname><given-names>M.</given-names></name><name><surname>Genet</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>SAR110894, a potent histamine H(3)-receptor antagonist, displays procognitive effects in rodents</article-title>. <source/>Pharmacol. Biochem. Behav.
<volume>102</volume>, <fpage>203</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2012.04.004</pub-id><pub-id pub-id-type="pmid">22542742</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grozeva</surname><given-names>D.</given-names></name><name><surname>Conrad</surname><given-names>D. F.</given-names></name><name><surname>Barnes</surname><given-names>C. P.</given-names></name><name><surname>Hurles</surname><given-names>M.</given-names></name><name><surname>Owen</surname><given-names>M. J.</given-names></name><name><surname>O'Donovan</surname><given-names>M. C.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Independent estimation of the frequency of rare CNVs in the UK population confirms their role in schizophrenia</article-title>. <source/>Schizophr. Res.
<volume>135</volume>, <fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2011.11.004</pub-id><pub-id pub-id-type="pmid">22130109</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinchat</surname><given-names>V.</given-names></name><name><surname>Thorsen</surname><given-names>P.</given-names></name><name><surname>Laurent</surname><given-names>C.</given-names></name><name><surname>Cans</surname><given-names>C.</given-names></name><name><surname>Bodeau</surname><given-names>N.</given-names></name><name><surname>Cohen</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Pre-, peri- and neonatal risk factors for autism</article-title>. <source/>Acta Obstet. Gynecol. Scand.
<volume>91</volume>, <fpage>287</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0412.2011.01325.x</pub-id><pub-id pub-id-type="pmid">22085436</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>H. L.</given-names></name><name><surname>Sergeeva</surname><given-names>O. A.</given-names></name><name><surname>Selbach</surname><given-names>O.</given-names></name></person-group> (<year>2008</year>). <article-title>Histamine in the nervous system</article-title>. <source/>Physiol. Rev.
<volume>88</volume>, <fpage>1183</fpage>–<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00043.2007</pub-id><pub-id pub-id-type="pmid">18626069</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallmayer</surname><given-names>J.</given-names></name><name><surname>Cleveland</surname><given-names>S.</given-names></name><name><surname>Torres</surname><given-names>A.</given-names></name><name><surname>Phillips</surname><given-names>J.</given-names></name><name><surname>Cohen</surname><given-names>B.</given-names></name><name><surname>Torigoe</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Genetic heritability and shared environmental factors among twin pairs with autism</article-title>. <source/>Arch. Gen. Psychiatry
<volume>68</volume>, <fpage>1095</fpage>–<lpage>1102</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.76</pub-id><pub-id pub-id-type="pmid">21727249</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>P. J.</given-names></name><name><surname>Campbell</surname><given-names>N. G.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Erreger</surname><given-names>K.</given-names></name><name><surname>Herborg Hansen</surname><given-names>F.</given-names></name><name><surname>Saunders</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title><italic>De novo</italic> mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder</article-title>. <source/>Mol. Psychiatry
<volume>18</volume>, <fpage>1315</fpage>–<lpage>1323</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2013.102</pub-id><pub-id pub-id-type="pmid">23979605</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handen</surname><given-names>B. L.</given-names></name><name><surname>Johnson</surname><given-names>C. R.</given-names></name><name><surname>Lubetsky</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder</article-title>. <source/>J. Autism Dev. Disord.
<volume>30</volume>, <fpage>245</fpage>–<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1023/A:1005548619694</pub-id><pub-id pub-id-type="pmid">11055460</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>E.</given-names></name><name><surname>Kalish</surname><given-names>L. A.</given-names></name><name><surname>Bunce</surname><given-names>E.</given-names></name><name><surname>Curtis</surname><given-names>C.</given-names></name><name><surname>McDaniel</surname><given-names>S.</given-names></name><name><surname>Ware</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder</article-title>. <source/>J. Autism Dev. Disord.
<volume>37</volume>, <fpage>628</fpage>–<lpage>636</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-006-0192-0</pub-id><pub-id pub-id-type="pmid">16977497</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>Y.</given-names></name><name><surname>Ago</surname><given-names>Y.</given-names></name><name><surname>Taruta</surname><given-names>A.</given-names></name><name><surname>Hasebe</surname><given-names>S.</given-names></name><name><surname>Kawase</surname><given-names>H.</given-names></name><name><surname>Tanabe</surname><given-names>W.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice</article-title>. <source/>Psychopharmacology (Berl).
<volume>234</volume>, <fpage>3217</fpage>–<lpage>3228</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-017-4703-9</pub-id><pub-id pub-id-type="pmid">28798977</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardan</surname><given-names>A. Y.</given-names></name><name><surname>Handen</surname><given-names>B. L.</given-names></name></person-group> (<year>2002</year>). <article-title>A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder</article-title>. <source/>J. Child Adolesc. Psychopharmacol.
<volume>12</volume>, <fpage>237</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1089/104454602760386923</pub-id><pub-id pub-id-type="pmid">12427297</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellings</surname><given-names>J. A.</given-names></name><name><surname>Arnold</surname><given-names>L. E.</given-names></name><name><surname>Han</surname><given-names>J. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline</article-title>. <source/>Expert Opin. Pharmacother.
<volume>18</volume>, <fpage>581</fpage>–<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1080/14656566.2017.1308483</pub-id><pub-id pub-id-type="pmid">28335658</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellings</surname><given-names>J. A.</given-names></name><name><surname>Kelley</surname><given-names>L. A.</given-names></name><name><surname>Gabrielli</surname><given-names>W. F.</given-names></name><name><surname>Kilgore</surname><given-names>E.</given-names></name><name><surname>Shah</surname><given-names>P.</given-names></name></person-group> (<year>1996</year>). <article-title>Sertraline response in adults with mental retardation and autistic disorder</article-title>. <source/>J. Clin. Psychiatry
<volume>57</volume>, <fpage>333</fpage>–<lpage>336</lpage>. <pub-id pub-id-type="pmid">8778118</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellings</surname><given-names>J. A.</given-names></name><name><surname>Reed</surname><given-names>G.</given-names></name><name><surname>Cain</surname><given-names>S. E.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Barth</surname><given-names>F. X.</given-names></name><name><surname>Aman</surname><given-names>M. G.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability</article-title>. <source/>J. Child Adolesc. Psychopharmacol.
<volume>25</volume>, <fpage>150</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2014.0003</pub-id><pub-id pub-id-type="pmid">25782098</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellmer</surname><given-names>K.</given-names></name><name><surname>Nyström</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Infant acetylcholine, dopamine, and melatonin dysregulation: neonatal biomarkers and causal factors for ASD and ADHD phenotypes</article-title>. <source/>Med. Hypotheses
<volume>100</volume>, <fpage>64</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2017.01.015</pub-id><pub-id pub-id-type="pmid">28236851</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriksen</surname><given-names>J. G.</given-names></name><name><surname>Klinkenberg</surname><given-names>S.</given-names></name><name><surname>Collin</surname><given-names>P.</given-names></name><name><surname>Wong</surname><given-names>B.</given-names></name><name><surname>Niks</surname><given-names>E. H.</given-names></name><name><surname>Vles</surname><given-names>J. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Diagnosis and treatment of obsessive compulsive behavior in a boy with Duchenne muscular dystrophy and autism spectrum disorder: a case report</article-title>. <source/>Neuromuscul. Disord.
<volume>26</volume>, <fpage>659</fpage>–<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1016/j.nmd.2016.08.003</pub-id><pub-id pub-id-type="pmid">27612598</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hettinger</surname><given-names>J. A.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Schwartz</surname><given-names>C. E.</given-names></name><name><surname>Michaelis</surname><given-names>R. C.</given-names></name><name><surname>Holden</surname><given-names>J. J.</given-names></name></person-group> (<year>2008</year>). <article-title>A DRD1 haplotype is associated with risk for autism spectrum disorders in male-only affected sib-pair families</article-title>. <source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
<volume>147b</volume>, <fpage>628</fpage>–<lpage>636</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.30655</pub-id><pub-id pub-id-type="pmid">18205172</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>L. E.</given-names></name><name><surname>Pringsheim</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Aripiprazole for autism spectrum disorders (ASD)</article-title>. <source/>Cochrane Database Syst Rev,
<fpage>Cd009043</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD009043.pub3</pub-id><pub-id pub-id-type="pmid">27344135</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>K.</given-names></name><name><surname>Weisskopf</surname><given-names>M. G.</given-names></name><name><surname>Roberts</surname><given-names>A. L.</given-names></name><name><surname>Raz</surname><given-names>R.</given-names></name><name><surname>Hart</surname><given-names>J. E.</given-names></name><name><surname>Lyall</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Geographic patterns of autism spectrum disorder among children of participants in nurses' health study II</article-title>. <source/>Am. J. Epidemiol.
<volume>186</volume>, <fpage>834</fpage>–<lpage>842</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwx158</pub-id><pub-id pub-id-type="pmid">28525627</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogart</surname><given-names>A.</given-names></name><name><surname>Nagarajan</surname><given-names>R. P.</given-names></name><name><surname>Patzel</surname><given-names>K. A.</given-names></name><name><surname>Yasui</surname><given-names>D. H.</given-names></name><name><surname>Lasalle</surname><given-names>J. M.</given-names></name></person-group> (<year>2007</year>). <article-title>15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders</article-title>. <source/>Hum. Mol. Genet.
<volume>16</volume>, <fpage>691</fpage>–<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddm014</pub-id><pub-id pub-id-type="pmid">17339270</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogart</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>LaSalle</surname><given-names>J. M.</given-names></name><name><surname>Schanen</surname><given-names>N. C.</given-names></name></person-group> (<year>2010</year>). <article-title>The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13</article-title>. <source/>Neurobiol. Dis.
<volume>38</volume>, <fpage>181</fpage>–<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2008.08.011</pub-id><pub-id pub-id-type="pmid">18840528</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollander</surname><given-names>E.</given-names></name><name><surname>Chaplin</surname><given-names>W.</given-names></name><name><surname>Soorya</surname><given-names>L.</given-names></name><name><surname>Wasserman</surname><given-names>S.</given-names></name><name><surname>Novotny</surname><given-names>S.</given-names></name><name><surname>Rusoff</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders</article-title>. <source/>Neuropsychopharmacology
<volume>35</volume>, <fpage>990</fpage>–<lpage>998</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2009.202</pub-id><pub-id pub-id-type="pmid">20010551</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollander</surname><given-names>E.</given-names></name><name><surname>Phillips</surname><given-names>A.</given-names></name><name><surname>Chaplin</surname><given-names>W.</given-names></name><name><surname>Zagursky</surname><given-names>K.</given-names></name><name><surname>Novotny</surname><given-names>S.</given-names></name><name><surname>Wasserman</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism</article-title>. <source/>Neuropsychopharmacology
<volume>30</volume>, <fpage>582</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300627</pub-id><pub-id pub-id-type="pmid">15602505</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollander</surname><given-names>E.</given-names></name><name><surname>Soorya</surname><given-names>L.</given-names></name><name><surname>Wasserman</surname><given-names>S.</given-names></name><name><surname>Esposito</surname><given-names>K.</given-names></name><name><surname>Chaplin</surname><given-names>W.</given-names></name><name><surname>Anagnostou</surname><given-names>E.</given-names></name></person-group> (<year>2006</year>). <article-title>Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder</article-title>. <source/>Int. J. Neuropsychopharmacol.
<volume>9</volume>, <fpage>209</fpage>–<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145705005791</pub-id><pub-id pub-id-type="pmid">16316486</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>S. Y.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>J. C.</given-names></name><name><surname>Lee</surname><given-names>Y. J.</given-names></name><name><surname>Hwangbo</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Prescription trends of psychotropics in children and adolescents with autism based on nationwide health insurance data</article-title>. <source/>J. Korean Med. Sci.
<volume>32</volume>, <fpage>1687</fpage>–<lpage>1693</lpage>. <pub-id pub-id-type="doi">10.3346/jkms.2017.32.10.1687</pub-id><pub-id pub-id-type="pmid">28875615</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howes</surname><given-names>O. D.</given-names></name><name><surname>Rogdaki</surname><given-names>M.</given-names></name><name><surname>Findon</surname><given-names>J. L.</given-names></name><name><surname>Wichers</surname><given-names>R. H.</given-names></name><name><surname>Charman</surname><given-names>T.</given-names></name><name><surname>King</surname><given-names>B. H.</given-names></name><etal></etal></person-group>. (<year>2018</year>). <article-title>Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for psychopharmacology</article-title>. <source/>J. Psychopharmacol.
<volume>32</volume>, <fpage>3</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1177/0269881117741766</pub-id><pub-id pub-id-type="pmid">29237331</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>E. Y.</given-names></name><name><surname>McBride</surname><given-names>S. W.</given-names></name><name><surname>Chow</surname><given-names>J.</given-names></name><name><surname>Mazmanian</surname><given-names>S. K.</given-names></name><name><surname>Patterson</surname><given-names>P. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Modeling an autism risk factor in mice leads to permanent immune dysregulation</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>12776</fpage>–<lpage>12781</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1202556109</pub-id><pub-id pub-id-type="pmid">22802640</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>G. C.</given-names></name><name><surname>Chandran</surname><given-names>P.</given-names></name><name><surname>Salyers</surname><given-names>A. K.</given-names></name><name><surname>Pai</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>C. Z.</given-names></name><name><surname>Wensink</surname><given-names>E. J.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats</article-title>. <source/>Pharmacol. Biochem. Behav.
<volume>95</volume>, <fpage>41</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2009.12.004</pub-id><pub-id pub-id-type="pmid">20004681</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>J.</given-names></name><name><surname>Gage</surname><given-names>F. H.</given-names></name></person-group> (<year>2004</year>). <article-title>Epigenetic control of neural stem cell fate</article-title>. <source/>Curr. Opin. Genet. Dev.
<volume>14</volume>, <fpage>461</fpage>–<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2004.07.006</pub-id><pub-id pub-id-type="pmid">15380235</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>J.</given-names></name><name><surname>Gage</surname><given-names>F. H.</given-names></name></person-group> (<year>2005</year>). <article-title>Chromatin remodeling in neural development and plasticity</article-title>. <source/>Curr. Opin. Cell Biol.
<volume>17</volume>, <fpage>664</fpage>–<lpage>671</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceb.2005.09.002</pub-id><pub-id pub-id-type="pmid">16226449</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Ehli</surname><given-names>E. A.</given-names></name><name><surname>Boomsma</surname><given-names>D. I.</given-names></name></person-group> (<year>2017</year>). <article-title>MicroRNAs as biomarkers for psychiatric disorders with a focus on autism spectrum disorder: current progress in genetic association studies, expression profiling, and translational research</article-title>. <source/>Autism Res.
<volume>10</volume>, <fpage>1184</fpage>–<lpage>1203</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1789</pub-id><pub-id pub-id-type="pmid">28419777</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulbert</surname><given-names>S. W.</given-names></name><name><surname>Jiang</surname><given-names>Y. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Monogenic mouse models of autism spectrum disorders: common mechanisms and missing links</article-title>. <source/>Neuroscience
<volume>321</volume>, <fpage>3</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.12.040</pub-id><pub-id pub-id-type="pmid">26733386</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hviid</surname><given-names>A.</given-names></name><name><surname>Stellfeld</surname><given-names>M.</given-names></name><name><surname>Wohlfahrt</surname><given-names>J.</given-names></name><name><surname>Melbye</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Association between thimerosal-containing vaccine and autism</article-title>. <source/>JAMA
<volume>290</volume>, <fpage>1763</fpage>–<lpage>1766</lpage>. <pub-id pub-id-type="doi">10.1001/jama.290.13.1763</pub-id><pub-id pub-id-type="pmid">14519711</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahromi</surname><given-names>L. B.</given-names></name><name><surname>Kasari</surname><given-names>C. L.</given-names></name><name><surname>McCracken</surname><given-names>J. T.</given-names></name><name><surname>Lee</surname><given-names>L. S.</given-names></name><name><surname>Aman</surname><given-names>M. G.</given-names></name><name><surname>McDougle</surname><given-names>C. J.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity</article-title>. <source/>J. Autism Dev. Disord.
<volume>39</volume>, <fpage>395</fpage>–<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-008-0636-9</pub-id><pub-id pub-id-type="pmid">18752063</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamain</surname><given-names>S.</given-names></name><name><surname>Betancur</surname><given-names>C.</given-names></name><name><surname>Quach</surname><given-names>H.</given-names></name><name><surname>Philippe</surname><given-names>A.</given-names></name><name><surname>Fellous</surname><given-names>M.</given-names></name><name><surname>Giros</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Linkage and association of the glutamate receptor 6 gene with autism</article-title>. <source/>Mol. Psychiatry
<volume>7</volume>, <fpage>302</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4000979</pub-id><pub-id pub-id-type="pmid">11920157</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>S. J.</given-names></name><name><surname>Melnyk</surname><given-names>S.</given-names></name><name><surname>Fuchs</surname><given-names>G.</given-names></name><name><surname>Reid</surname><given-names>T.</given-names></name><name><surname>Jernigan</surname><given-names>S.</given-names></name><name><surname>Pavliv</surname><given-names>O.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism</article-title>. <source/>Am. J. Clin. Nutr.
<volume>89</volume>, <fpage>425</fpage>–<lpage>430</lpage>. <pub-id pub-id-type="doi">10.3945/ajcn.2008.26615</pub-id><pub-id pub-id-type="pmid">19056591</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jessberger</surname><given-names>S.</given-names></name><name><surname>Nakashima</surname><given-names>K.</given-names></name><name><surname>Clemenson</surname><given-names>G. D.</given-names><suffix>Jr.</suffix></name><name><surname>Mejia</surname><given-names>E.</given-names></name><name><surname>Mathews</surname><given-names>E.</given-names></name><name><surname>Ure</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Epigenetic modulation of seizure-induced neurogenesis and cognitive decline</article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>5967</fpage>–<lpage>5975</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0110-07.2007</pub-id><pub-id pub-id-type="pmid">17537967</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobski</surname><given-names>K.</given-names></name><name><surname>Höfer</surname><given-names>J.</given-names></name><name><surname>Hoffmann</surname><given-names>F.</given-names></name><name><surname>Bachmann</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review</article-title>. <source/>Acta Psychiatr. Scand.
<volume>135</volume>, <fpage>8</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1111/acps.12644</pub-id><pub-id pub-id-type="pmid">27624381</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karvat</surname><given-names>G.</given-names></name><name><surname>Kimchi</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism</article-title>. <source/>Neuropsychopharmacology
<volume>39</volume>, <fpage>831</fpage>–<lpage>840</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2013.274</pub-id><pub-id pub-id-type="pmid">24096295</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kataoka</surname><given-names>S.</given-names></name><name><surname>Takuma</surname><given-names>K.</given-names></name><name><surname>Hara</surname><given-names>Y.</given-names></name><name><surname>Maeda</surname><given-names>Y.</given-names></name><name><surname>Ago</surname><given-names>Y.</given-names></name><name><surname>Matsuda</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>). <article-title>Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid</article-title>. <source/>Int. J. Neuropsychopharmacol.
<volume>16</volume>, <fpage>91</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145711001714</pub-id><pub-id pub-id-type="pmid">22093185</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>D. M.</given-names></name><name><surname>Berger-Sweeney</surname><given-names>J. E.</given-names></name><name><surname>Eubanks</surname><given-names>J. H.</given-names></name><name><surname>Justice</surname><given-names>M. J.</given-names></name><name><surname>Neul</surname><given-names>J. L.</given-names></name><name><surname>Pozzo-Miller</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Preclinical research in Rett syndrome: setting the foundation for translational success</article-title>. <source/>Dis. Model. Mech.
<volume>5</volume>, <fpage>733</fpage>–<lpage>745</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.011007</pub-id><pub-id pub-id-type="pmid">23115203</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazdoba</surname><given-names>T. M.</given-names></name><name><surname>Leach</surname><given-names>P. T.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Silverman</surname><given-names>J. L.</given-names></name><name><surname>Solomon</surname><given-names>M.</given-names></name><name><surname>Crawley</surname><given-names>J. N.</given-names></name></person-group> (<year>2016</year>). <article-title>Translational mouse models of autism: advancing toward pharmacological therapeutics</article-title>. <source/>Curr. Top. Behav. Neurosci.
<volume>28</volume>, <fpage>1</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1007/7854_2015_5003</pub-id><pub-id pub-id-type="pmid">27305922</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kemper</surname><given-names>T. L.</given-names></name><name><surname>Bauman</surname><given-names>M.</given-names></name></person-group> (<year>1998</year>). <article-title>Neuropathology of infantile autism</article-title>. <source/>J. Neuropathol. Exp. Neurol.
<volume>57</volume>, <fpage>645</fpage>–<lpage>652</lpage>. <pub-id pub-id-type="doi">10.1097/00005072-199807000-00001</pub-id><pub-id pub-id-type="pmid">9690668</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>J. K.</given-names></name><name><surname>Jones</surname><given-names>A. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Evidence of toxicity, oxidative stress, and neuronal insult in autism</article-title>. <source/>J. Toxicol. Environ. Health B Crit. Rev.
<volume>9</volume>, <fpage>485</fpage>–<lpage>499</lpage>. <pub-id pub-id-type="doi">10.1080/10937400600882079</pub-id><pub-id pub-id-type="pmid">17090484</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. J.</given-names></name><name><surname>Shonka</surname><given-names>S.</given-names></name><name><surname>French</surname><given-names>W. P.</given-names></name><name><surname>Strickland</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>L.</given-names></name><name><surname>Stein</surname><given-names>M. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Dose-response effects of long-acting liquid methylphenidate in children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): a pilot study</article-title>. <source/>J. Autism Dev. Disord.
<volume>47</volume>, <fpage>2307</fpage>–<lpage>2313</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-017-3125-1</pub-id><pub-id pub-id-type="pmid">28474229</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>B. H.</given-names></name><name><surname>Wright</surname><given-names>D. M.</given-names></name><name><surname>Handen</surname><given-names>B. L.</given-names></name><name><surname>Sikich</surname><given-names>L.</given-names></name><name><surname>Zimmerman</surname><given-names>A. W.</given-names></name><name><surname>McMahon</surname><given-names>W.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder</article-title>. <source/>J. Am. Acad. Child Adolesc. Psychiatry
<volume>40</volume>, <fpage>658</fpage>–<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1097/00004583-200106000-00010</pub-id><pub-id pub-id-type="pmid">11392343</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishino</surname><given-names>T.</given-names></name><name><surname>Lalande</surname><given-names>M.</given-names></name><name><surname>Wagstaff</surname><given-names>J.</given-names></name></person-group> (<year>1997</year>). <article-title>UBE3A/E6-AP mutations cause Angelman syndrome</article-title>. <source/>Nat. Genet.
<volume>15</volume>, <fpage>70</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/ng0197-70</pub-id><pub-id pub-id-type="pmid">8988171</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>S. J.</given-names></name><name><surname>Regan</surname><given-names>R.</given-names></name><name><surname>Nicod</surname><given-names>A.</given-names></name><name><surname>Horsley</surname><given-names>S. W.</given-names></name><name><surname>Kearney</surname><given-names>L.</given-names></name><name><surname>Homfray</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>Subtle chromosomal rearrangements in children with unexplained mental retardation</article-title>. <source/>Lancet
<volume>354</volume>, <fpage>1676</fpage>–<lpage>1681</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(99)03070-6</pub-id><pub-id pub-id-type="pmid">10568569</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolevzon</surname><given-names>A.</given-names></name><name><surname>Gross</surname><given-names>R.</given-names></name><name><surname>Reichenberg</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Prenatal and perinatal risk factors for autism: a review and integration of findings</article-title>. <source/>Arch. Pediatr. Adolesc. Med.
<volume>161</volume>, <fpage>326</fpage>–<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.161.4.326</pub-id><pub-id pub-id-type="pmid">17404128</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolmen</surname><given-names>B. K.</given-names></name><name><surname>Feldman</surname><given-names>H. M.</given-names></name><name><surname>Handen</surname><given-names>B. L.</given-names></name><name><surname>Janosky</surname><given-names>J. E.</given-names></name></person-group> (<year>1995</year>). <article-title>Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study</article-title>. <source/>J. Am. Acad. Child Adolesc. Psychiatry
<volume>34</volume>, <fpage>223</fpage>–<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1097/00004583-199502000-00018</pub-id><pub-id pub-id-type="pmid">7896655</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>A.</given-names></name><name><surname>Frigge</surname><given-names>M. L.</given-names></name><name><surname>Masson</surname><given-names>G.</given-names></name><name><surname>Besenbacher</surname><given-names>S.</given-names></name><name><surname>Sulem</surname><given-names>P.</given-names></name><name><surname>Magnusson</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Rate of de novo mutations and the importance of father's age to disease risk</article-title>. <source/>Nature
<volume>488</volume>, <fpage>471</fpage>–<lpage>475</lpage>. <pub-id pub-id-type="doi">10.1038/nature11396</pub-id><pub-id pub-id-type="pmid">22914163</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konstantareas</surname><given-names>M. M.</given-names></name><name><surname>Hewitt</surname><given-names>T.</given-names></name></person-group> (<year>2001</year>). <article-title>Autistic disorder and schizophrenia: diagnostic overlaps</article-title>. <source/>J. Autism Dev. Disord.
<volume>31</volume>, <fpage>19</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1023/A:1005605528309</pub-id><pub-id pub-id-type="pmid">11439750</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kron</surname><given-names>M.</given-names></name><name><surname>Howell</surname><given-names>C. J.</given-names></name><name><surname>Adams</surname><given-names>I. T.</given-names></name><name><surname>Ransbottom</surname><given-names>M.</given-names></name><name><surname>Christian</surname><given-names>D.</given-names></name><name><surname>Ogier</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment</article-title>. <source/>J. Neurosci.
<volume>32</volume>, <fpage>13860</fpage>–<lpage>13872</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2159-12.2012</pub-id><pub-id pub-id-type="pmid">23035095</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>B.</given-names></name><name><surname>Prakash</surname><given-names>A.</given-names></name><name><surname>Sewal</surname><given-names>R. K.</given-names></name><name><surname>Medhi</surname><given-names>B.</given-names></name><name><surname>Modi</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Drug therapy in autism: a present and future perspective</article-title>. <source/>Pharmacol. Rep.
<volume>64</volume>, <fpage>1291</fpage>–<lpage>1304</lpage>. <pub-id pub-id-type="doi">10.1016/S1734-1140(12)70927-1</pub-id><pub-id pub-id-type="pmid">23406740</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtis</surname><given-names>L. B.</given-names></name></person-group> (<year>1966</year>). <article-title>Clinical study of the response to nortriptyline on autistic children</article-title>. <source/>Int. J. Neuropsychiatry
<volume>2</volume>, <fpage>298</fpage>–<lpage>301</lpage>. <pub-id pub-id-type="pmid">5338335</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaSalle</surname><given-names>J. M.</given-names></name><name><surname>Reiter</surname><given-names>L. T.</given-names></name><name><surname>Chamberlain</surname><given-names>S. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders</article-title>. <source/>Epigenomics
<volume>7</volume>, <fpage>1213</fpage>–<lpage>1228</lpage>. <pub-id pub-id-type="doi">10.2217/epi.15.70</pub-id><pub-id pub-id-type="pmid">26585570</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leblond</surname><given-names>C. S.</given-names></name><name><surname>Heinrich</surname><given-names>J.</given-names></name><name><surname>Delorme</surname><given-names>R.</given-names></name><name><surname>Proepper</surname><given-names>C.</given-names></name><name><surname>Betancur</surname><given-names>C.</given-names></name><name><surname>Huguet</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders</article-title>. <source/>PLoS Genet.
<volume>8</volume>:<fpage>e1002521</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1002521</pub-id><pub-id pub-id-type="pmid">22346768</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>B. H.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Howes</surname><given-names>O. D.</given-names></name><name><surname>Cho</surname><given-names>K. I. K.</given-names></name><name><surname>Yoon</surname><given-names>Y. B.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: a [(11) C]DASB PET study</article-title>. <source/>Hum. Psychopharmacol.
<volume>33</volume>:<fpage>e2642</fpage>
<pub-id pub-id-type="doi">10.1002/hup.2642</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>J. E.</given-names></name><name><surname>Park</surname><given-names>J. Y.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>J. E.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Excessive D1 dopamine receptor activation in the dorsal striatum promotes autistic-like behaviors</article-title>. <source/>Mol. Neurobiol.
<volume>12</volume>, <fpage>1</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-017-0770-5</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lejeune</surname><given-names>J.</given-names></name><name><surname>Gautier</surname><given-names>M.</given-names></name><name><surname>Turpin</surname><given-names>R.</given-names></name></person-group> (<year>1959</year>). <article-title>[Study of somatic chromosomes from 9 mongoloid children]</article-title>. <source/>C. R. Hebd. Seances Acad. Sci.
<volume>248</volume>, <fpage>1721</fpage>–<lpage>1722</lpage>. <pub-id pub-id-type="pmid">13639368</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levisohn</surname><given-names>P. M.</given-names></name></person-group> (<year>2007</year>). <article-title>The autism-epilepsy connection</article-title>. <source/>Epilepsia
<volume>48</volume>(<issue>Suppl. 9</issue>), <fpage>33</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.01399.x</pub-id><pub-id pub-id-type="pmid">18047599</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libbey</surname><given-names>J. E.</given-names></name><name><surname>Sweeten</surname><given-names>T. L.</given-names></name><name><surname>McMahon</surname><given-names>W. M.</given-names></name><name><surname>Fujinami</surname><given-names>R. S.</given-names></name></person-group> (<year>2005</year>). <article-title>Autistic disorder and viral infections</article-title>. <source/>J. Neurovirol.
<volume>11</volume>, <fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/13550280590900553</pub-id><pub-id pub-id-type="pmid">15804954</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligneau</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Vanni-Mercier</surname><given-names>G.</given-names></name><name><surname>Jouvet</surname><given-names>M.</given-names></name><name><surname>Muir</surname><given-names>J. L.</given-names></name><name><surname>Ganellin</surname><given-names>C. R.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>287</volume>, <fpage>658</fpage>–<lpage>666</lpage>. <pub-id pub-id-type="pmid">9808693</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>C.</given-names></name><name><surname>Cook</surname><given-names>E. H.</given-names></name><name><surname>Leventhal</surname><given-names>B. L.</given-names></name><name><surname>Amaral</surname><given-names>D. G.</given-names></name></person-group> (<year>2000</year>). <article-title>Autism spectrum disorders</article-title>. <source/>Neuron
<volume>28</volume>, <fpage>355</fpage>–<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/S0896-6273(00)00115-X</pub-id><pub-id pub-id-type="pmid">11144346</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyall</surname><given-names>K.</given-names></name><name><surname>Croen</surname><given-names>L.</given-names></name><name><surname>Daniels</surname><given-names>J.</given-names></name><name><surname>Fallin</surname><given-names>M. D.</given-names></name><name><surname>Ladd-Acosta</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>B. K.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>The changing epidemiology of autism spectrum disorders</article-title>. <source/>Annu. Rev. Public Health
<volume>38</volume>, <fpage>81</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-publhealth-031816-044318</pub-id><pub-id pub-id-type="pmid">28068486</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmood</surname><given-names>D.</given-names></name><name><surname>Khanam</surname><given-names>R.</given-names></name><name><surname>Pillai</surname><given-names>K. K.</given-names></name><name><surname>Akhtar</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Reversal of oxidative stress by histamine H<sub>3</sub> receptor-ligands in experimental models of schizophrenia</article-title>. <source/>Arzneimittelforschung.
<volume>62</volume>, <fpage>222</fpage>–<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1055/s-0031-1301326</pub-id><pub-id pub-id-type="pmid">22331799</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maramara</surname><given-names>L. A.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Ming</surname><given-names>X.</given-names></name></person-group> (<year>2014</year>). <article-title>Pre- and perinatal risk factors for autism spectrum disorder in a New Jersey cohort</article-title>. <source/>J. Child Neurol.
<volume>29</volume>, <fpage>1645</fpage>–<lpage>1651</lpage>. <pub-id pub-id-type="doi">10.1177/0883073813512899</pub-id><pub-id pub-id-type="pmid">24413357</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>R. N.</given-names></name><name><surname>Owen</surname><given-names>R.</given-names></name><name><surname>Kamen</surname><given-names>L.</given-names></name><name><surname>Manos</surname><given-names>G.</given-names></name><name><surname>McQuade</surname><given-names>R. D.</given-names></name><name><surname>Carson</surname><given-names>W. H.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder</article-title>. <source/>J. Am. Acad. Child Adolesc. Psychiatry
<volume>48</volume>, <fpage>1110</fpage>–<lpage>1119</lpage>. <pub-id pub-id-type="doi">10.1097/CHI.0b013e3181b76658</pub-id><pub-id pub-id-type="pmid">19797985</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>A.</given-names></name><name><surname>Koenig</surname><given-names>K.</given-names></name><name><surname>Anderson</surname><given-names>G. M.</given-names></name><name><surname>Scahill</surname><given-names>L.</given-names></name></person-group> (<year>2003</year>). <article-title>Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study</article-title>. <source/>J. Autism Dev. Disord.
<volume>33</volume>, <fpage>77</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1023/A:1022234605695</pub-id><pub-id pub-id-type="pmid">12708582</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matson</surname><given-names>J. L.</given-names></name><name><surname>Sipes</surname><given-names>M.</given-names></name><name><surname>Fodstad</surname><given-names>J. C.</given-names></name><name><surname>Fitzgerald</surname><given-names>M. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Issues in the management of challenging behaviours of adults with autism spectrum disorder</article-title>. <source/>CNS Drugs
<volume>25</volume>, <fpage>597</fpage>–<lpage>606</lpage>. <pub-id pub-id-type="doi">10.2165/11591700-000000000-00000</pub-id><pub-id pub-id-type="pmid">21699271</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuura</surname><given-names>T.</given-names></name><name><surname>Sutcliffe</surname><given-names>J. S.</given-names></name><name><surname>Fang</surname><given-names>P.</given-names></name><name><surname>Galjaard</surname><given-names>R. J.</given-names></name><name><surname>Jiang</surname><given-names>Y. H.</given-names></name><name><surname>Benton</surname><given-names>C. S.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome</article-title>. <source/>Nat. Genet.
<volume>15</volume>, <fpage>74</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/ng0197-74</pub-id><pub-id pub-id-type="pmid">8988172</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConville</surname><given-names>B. J.</given-names></name><name><surname>Sanberg</surname><given-names>P. R.</given-names></name><name><surname>Fogelson</surname><given-names>M. H.</given-names></name><name><surname>King</surname><given-names>J.</given-names></name><name><surname>Cirino</surname><given-names>P.</given-names></name><name><surname>Parker</surname><given-names>K. W.</given-names></name><etal></etal></person-group>. (<year>1992</year>). <article-title>The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder</article-title>. <source/>Biol. Psychiatry
<volume>31</volume>, <fpage>832</fpage>–<lpage>840</lpage>. <pub-id pub-id-type="doi">10.1016/0006-3223(92)90315-Q</pub-id><pub-id pub-id-type="pmid">1643197</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCool</surname><given-names>M. F.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Talati</surname><given-names>R.</given-names></name><name><surname>Ragozzino</surname><given-names>M. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Differential involvement of M1-type and M4-type muscarinic cholinergic receptors in the dorsomedial striatum in task switching</article-title>. <source/>Neurobiol. Learn. Mem.
<volume>89</volume>, <fpage>114</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2007.06.005</pub-id><pub-id pub-id-type="pmid">17709264</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCracken</surname><given-names>J. T.</given-names></name><name><surname>McGough</surname><given-names>J.</given-names></name><name><surname>Shah</surname><given-names>B.</given-names></name><name><surname>Cronin</surname><given-names>P.</given-names></name><name><surname>Hong</surname><given-names>D.</given-names></name><name><surname>Aman</surname><given-names>M. G.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Risperidone in children with autism and serious behavioral problems</article-title>. <source/>N. Engl. J. Med.
<volume>347</volume>, <fpage>314</fpage>–<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa013171</pub-id><pub-id pub-id-type="pmid">12151468</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDougle</surname><given-names>C. J.</given-names></name><name><surname>Brodkin</surname><given-names>E. S.</given-names></name><name><surname>Naylor</surname><given-names>S. T.</given-names></name><name><surname>Carlson</surname><given-names>D. C.</given-names></name><name><surname>Cohen</surname><given-names>D. J.</given-names></name><name><surname>Price</surname><given-names>L. H.</given-names></name></person-group> (<year>1998a</year>). <article-title>Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation</article-title>. <source/>J. Clin. Psychopharmacol.
<volume>18</volume>, <fpage>62</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1097/00004714-199802000-00010</pub-id><pub-id pub-id-type="pmid">9472844</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDougle</surname><given-names>C. J.</given-names></name><name><surname>Holmes</surname><given-names>J. P.</given-names></name><name><surname>Carlson</surname><given-names>D. C.</given-names></name><name><surname>Pelton</surname><given-names>G. H.</given-names></name><name><surname>Cohen</surname><given-names>D. J.</given-names></name><name><surname>Price</surname><given-names>L. H.</given-names></name></person-group> (<year>1998b</year>). <article-title>A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders</article-title>. <source/>Arch. Gen. Psychiatry
<volume>55</volume>, <fpage>633</fpage>–<lpage>641</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.55.7.633</pub-id><pub-id pub-id-type="pmid">9672054</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDougle</surname><given-names>C. J.</given-names></name><name><surname>Naylor</surname><given-names>S. T.</given-names></name><name><surname>Cohen</surname><given-names>D. J.</given-names></name><name><surname>Volkmar</surname><given-names>F. R.</given-names></name><name><surname>Heninger</surname><given-names>G. R.</given-names></name><name><surname>Price</surname><given-names>L. H.</given-names></name></person-group> (<year>1996</year>). <article-title>A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder</article-title>. <source/>Arch. Gen. Psychiatry
<volume>53</volume>, <fpage>1001</fpage>–<lpage>1008</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.1996.01830110037005</pub-id><pub-id pub-id-type="pmid">8911223</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarlane</surname><given-names>H. G.</given-names></name><name><surname>Kusek</surname><given-names>G. K.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Phoenix</surname><given-names>J. L.</given-names></name><name><surname>Bolivar</surname><given-names>V. J.</given-names></name><name><surname>Crawley</surname><given-names>J. N.</given-names></name></person-group> (<year>2008</year>). <article-title>Autism-like behavioral phenotypes in BTBR T+tf/J mice</article-title>. <source/>Genes Brain Behav.
<volume>7</volume>, <fpage>152</fpage>–<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2007.00330.x</pub-id><pub-id pub-id-type="pmid">17559418</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mefford</surname><given-names>H. C.</given-names></name><name><surname>Cooper</surname><given-names>G. M.</given-names></name><name><surname>Zerr</surname><given-names>T.</given-names></name><name><surname>Smith</surname><given-names>J. D.</given-names></name><name><surname>Baker</surname><given-names>C.</given-names></name><name><surname>Shafer</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>A method for rapid, targeted CNV genotyping identifies rare variants associated with neurocognitive disease</article-title>. <source/>Genome Res.
<volume>19</volume>, <fpage>1579</fpage>–<lpage>1585</lpage>. <pub-id pub-id-type="doi">10.1101/gr.094987.109</pub-id><pub-id pub-id-type="pmid">19506092</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikhail</surname><given-names>F. M.</given-names></name><name><surname>Lose</surname><given-names>E. J.</given-names></name><name><surname>Robin</surname><given-names>N. H.</given-names></name><name><surname>Descartes</surname><given-names>M. D.</given-names></name><name><surname>Rutledge</surname><given-names>K. D.</given-names></name><name><surname>Rutledge</surname><given-names>S. L.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorders</article-title>. <source/>Am. J. Med. Genet. A
<volume>155a</volume>, <fpage>2386</fpage>–<lpage>2396</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.34177</pub-id><pub-id pub-id-type="pmid">22031302</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>X.</given-names></name><name><surname>Gordon</surname><given-names>E.</given-names></name><name><surname>Kang</surname><given-names>N.</given-names></name><name><surname>Wagner</surname><given-names>G. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Use of clonidine in children with autism spectrum disorders</article-title>. <source/>Brain Dev.
<volume>30</volume>, <fpage>454</fpage>–<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2007.12.007</pub-id><pub-id pub-id-type="pmid">18280681</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>M. L.</given-names></name><name><surname>Eichner</surname><given-names>S. F.</given-names></name><name><surname>Jones</surname><given-names>J. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Treating functional impairment of autism with selective serotonin-reuptake inhibitors</article-title>. <source/>Ann. Pharmacother.
<volume>38</volume>, <fpage>1515</fpage>–<lpage>1519</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1D543</pub-id><pub-id pub-id-type="pmid">15292500</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>S. J.</given-names></name><name><surname>Turnpenny</surname><given-names>P.</given-names></name><name><surname>Quinn</surname><given-names>A.</given-names></name><name><surname>Glover</surname><given-names>S.</given-names></name><name><surname>Lloyd</surname><given-names>D. J.</given-names></name><name><surname>Montgomery</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>A clinical study of 57 children with fetal anticonvulsant syndromes</article-title>. <source/>J. Med. Genet.
<volume>37</volume>, <fpage>489</fpage>–<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.37.7.489</pub-id><pub-id pub-id-type="pmid">10882750</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moy</surname><given-names>S. S.</given-names></name><name><surname>Nadler</surname><given-names>J. J.</given-names></name><name><surname>Poe</surname><given-names>M. D.</given-names></name><name><surname>Nonneman</surname><given-names>R. J.</given-names></name><name><surname>Young</surname><given-names>N. B.</given-names></name><name><surname>Koller</surname><given-names>B. H.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Development of a mouse test for repetitive, restricted behaviors: relevance to autism</article-title>. <source/>Behav. Brain Res.
<volume>188</volume>, <fpage>178</fpage>–<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2007.10.029</pub-id><pub-id pub-id-type="pmid">18068825</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moy</surname><given-names>S. S.</given-names></name><name><surname>Nadler</surname><given-names>J. J.</given-names></name><name><surname>Young</surname><given-names>N. B.</given-names></name><name><surname>Perez</surname><given-names>A.</given-names></name><name><surname>Holloway</surname><given-names>L. P.</given-names></name><name><surname>Barbaro</surname><given-names>R. P.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains</article-title>. <source/>Behav. Brain Res.
<volume>176</volume>, <fpage>4</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2006.07.030</pub-id><pub-id pub-id-type="pmid">16971002</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muhle</surname><given-names>R.</given-names></name><name><surname>Trentacoste</surname><given-names>S. V.</given-names></name><name><surname>Rapin</surname><given-names>I.</given-names></name></person-group> (<year>2004</year>). <article-title>The genetics of autism</article-title>. <source/>Pediatrics
<volume>113</volume>, <fpage>e472</fpage>–<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1542/peds.113.5.e472</pub-id><pub-id pub-id-type="pmid">15121991</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukaetova-Ladinska</surname><given-names>E. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Silent lives: why do we fail community-dwelling people with dementia?</article-title>
<source/>Age Ageing
<volume>46</volume>, <fpage>341</fpage>–<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1093/ageing/afx028</pub-id><pub-id pub-id-type="pmid">28338848</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naaijen</surname><given-names>J.</given-names></name><name><surname>Bralten</surname><given-names>J.</given-names></name><name><surname>Poelmans</surname><given-names>G.</given-names></name><name><surname>consortium</surname><given-names>I.</given-names></name><name><surname>Glennon</surname><given-names>J. C.</given-names></name><name><surname>Franke</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism</article-title>. <source/>Transl. Psychiatry
<volume>7</volume>, <fpage>e999</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2016.273</pub-id><pub-id pub-id-type="pmid">28072412</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naddafi</surname><given-names>F.</given-names></name><name><surname>Mirshafiey</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>The neglected role of histamine in Alzheimer's disease</article-title>. <source/>Am. J. Alzheimers. Dis. Other Demen.
<volume>28</volume>, <fpage>327</fpage>–<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1177/1533317513488925</pub-id><pub-id pub-id-type="pmid">23677734</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>N.</given-names></name><name><surname>Nagano</surname><given-names>M.</given-names></name><name><surname>Saitow</surname><given-names>F.</given-names></name><name><surname>Watanabe</surname><given-names>Y.</given-names></name><name><surname>Kawamura</surname><given-names>Y.</given-names></name><name><surname>Kawamoto</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Serotonin rebalances cortical tuning and behavior linked to autism symptoms in 15q11-13 CNV mice</article-title>. <source/>Sci. Adv.
<volume>3</volume>:<fpage>e1603001</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.1603001</pub-id><pub-id pub-id-type="pmid">28691086</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>K.</given-names></name><name><surname>Carter</surname><given-names>K. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Treatment options for the management of pervasive developmental disorders</article-title>. <source/>Int. J. Psychiatry Med.
<volume>51</volume>, <fpage>201</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1177/0091217416636600</pub-id><pub-id pub-id-type="pmid">27079778</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestler</surname><given-names>E. J.</given-names></name><name><surname>Hyman</surname><given-names>S. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Animal models of neuropsychiatric disorders</article-title>. <source/>Nat. Neurosci.
<volume>13</volume>, <fpage>1161</fpage>–<lpage>1169</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2647</pub-id><pub-id pub-id-type="pmid">20877280</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>M.</given-names></name><name><surname>Roth</surname><given-names>A.</given-names></name><name><surname>Kyzar</surname><given-names>E. J.</given-names></name><name><surname>Poudel</surname><given-names>M. K.</given-names></name><name><surname>Wong</surname><given-names>K.</given-names></name><name><surname>Stewart</surname><given-names>A. M.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD)</article-title>. <source/>Neurochem. Int.
<volume>66</volume>, <fpage>15</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2014.01.002</pub-id><pub-id pub-id-type="pmid">24412511</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolini</surname><given-names>C.</given-names></name><name><surname>Fahnestock</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>The valproic acid-induced rodent model of autism</article-title>. <source/>Exp. Neurol. <volume>299</volume>(<issue>Pt A</issue>):<fpage>217</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2017.04.017</pub-id><pub-id pub-id-type="pmid">28472621</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolson</surname><given-names>R.</given-names></name><name><surname>Craven-Thuss</surname><given-names>B.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name></person-group> (<year>2006</year>). <article-title>A prospective, open-label trial of galantamine in autistic disorder</article-title>. <source/>J. Child Adolesc. Psychopharmacol.
<volume>16</volume>, <fpage>621</fpage>–<lpage>629</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2006.16.621</pub-id><pub-id pub-id-type="pmid">17069550</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niederhofer</surname><given-names>H.</given-names></name><name><surname>Staffen</surname><given-names>W.</given-names></name><name><surname>Mair</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Galantamine may be effective in treating autistic disorder</article-title>. <source/>BMJ
<volume>325</volume>:<fpage>1422</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.325.7377.1422/a</pub-id><pub-id pub-id-type="pmid">12480867</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nord</surname><given-names>A. S.</given-names></name><name><surname>Roeb</surname><given-names>W.</given-names></name><name><surname>Dickel</surname><given-names>D. E.</given-names></name><name><surname>Walsh</surname><given-names>T.</given-names></name><name><surname>Kusenda</surname><given-names>M.</given-names></name><name><surname>O'Connor</surname><given-names>K. L.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Reduced transcript expression of genes affected by inherited and de novo CNVs in autism</article-title>. <source/>Eur. J. Hum. Genet.
<volume>19</volume>, <fpage>727</fpage>–<lpage>731</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2011.24</pub-id><pub-id pub-id-type="pmid">21448237</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>H.</given-names></name><name><surname>Ihara</surname><given-names>H.</given-names></name><name><surname>Murakami</surname><given-names>N.</given-names></name><name><surname>Gito</surname><given-names>M.</given-names></name><name><surname>Kido</surname><given-names>Y.</given-names></name><name><surname>Nagai</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Autism spectrum disorders and hyperactive/impulsive behaviors in Japanese patients with Prader-Willi syndrome: a comparison between maternal uniparental disomy and deletion cases</article-title>. <source/>Am. J. Med. Genet. A
<volume>164A</volume>, <fpage>2180</fpage>–<lpage>2186</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.36615</pub-id><pub-id pub-id-type="pmid">24850752</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>R.</given-names></name><name><surname>Sikich</surname><given-names>L.</given-names></name><name><surname>Marcus</surname><given-names>R. N.</given-names></name><name><surname>Corey-Lisle</surname><given-names>P.</given-names></name><name><surname>Manos</surname><given-names>G.</given-names></name><name><surname>McQuade</surname><given-names>R. D.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder</article-title>. <source/>Pediatrics
<volume>124</volume>, <fpage>1533</fpage>–<lpage>1540</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2008-3782</pub-id><pub-id pub-id-type="pmid">19948625</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owley</surname><given-names>T.</given-names></name><name><surname>Salt</surname><given-names>J.</given-names></name><name><surname>Guter</surname><given-names>S.</given-names></name><name><surname>Grieve</surname><given-names>A.</given-names></name><name><surname>Walton</surname><given-names>L.</given-names></name><name><surname>Ayuyao</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders</article-title>. <source/>J. Child Adolesc. Psychopharmacol.
<volume>16</volume>, <fpage>517</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2006.16.517</pub-id><pub-id pub-id-type="pmid">17069541</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owley</surname><given-names>T.</given-names></name><name><surname>Walton</surname><given-names>L.</given-names></name><name><surname>Salt</surname><given-names>J.</given-names></name><name><surname>Guter</surname><given-names>S. J.</given-names><suffix>Jr.</suffix></name><name><surname>Winnega</surname><given-names>M.</given-names></name><name><surname>Leventhal</surname><given-names>B. L.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>An open-label trial of escitalopram in pervasive developmental disorders</article-title>. <source/>J. Am. Acad. Child Adolesc. Psychiatry
<volume>44</volume>, <fpage>343</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1097/01.chi.0000153229.80215.a0</pub-id><pub-id pub-id-type="pmid">15782081</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panksepp</surname><given-names>J.</given-names></name><name><surname>Lensing</surname><given-names>P.</given-names></name></person-group> (<year>1991</year>). <article-title>Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children</article-title>. <source/>J. Autism Dev. Disord.
<volume>21</volume>, <fpage>243</fpage>–<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1007/BF02284764</pub-id><pub-id pub-id-type="pmid">1864831</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasciuto</surname><given-names>E.</given-names></name><name><surname>Borrie</surname><given-names>S. C.</given-names></name><name><surname>Kanellopoulos</surname><given-names>A. K.</given-names></name><name><surname>Santos</surname><given-names>A. R.</given-names></name><name><surname>Cappuyns</surname><given-names>E.</given-names></name><name><surname>D'Andrea</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Autism spectrum disorders: translating human deficits into mouse behavior</article-title>. <source/>Neurobiol. Learn. Mem.
<volume>124</volume>, <fpage>71</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.nlm.2015.07.013</pub-id><pub-id pub-id-type="pmid">26220900</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>P. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Maternal infection and autism</article-title>. <source/>Brain Behav. Immun.
<volume>26</volume>, <fpage>393</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2011.09.008</pub-id><pub-id pub-id-type="pmid">22001185</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paval</surname><given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>A dopamine hypothesis of autism spectrum disorder</article-title>. <source/>Dev. Neurosci.
<volume>39</volume>, <fpage>355</fpage>–<lpage>360</lpage>. <pub-id pub-id-type="doi">10.1159/000478725</pub-id><pub-id pub-id-type="pmid">28750400</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paval</surname><given-names>D.</given-names></name><name><surname>Rad</surname><given-names>F.</given-names></name><name><surname>Rusu</surname><given-names>R.</given-names></name><name><surname>Niculae</surname><given-names>A. S.</given-names></name><name><surname>Colosi</surname><given-names>H. A.</given-names></name><name><surname>Dobrescu</surname><given-names>I.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Low retinal dehydrogenase 1 (RALDH1) level in prepubertal boys with autism spectrum disorder: a possible link to dopamine dysfunction?</article-title>
<source/>Clin. Psychopharmacol. Neurosci.
<volume>15</volume>, <fpage>229</fpage>–<lpage>236</lpage>. <pub-id pub-id-type="doi">10.9758/cpn.2017.15.3.229</pub-id><pub-id pub-id-type="pmid">28783931</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peñagarikano</surname><given-names>O.</given-names></name><name><surname>Abrahams</surname><given-names>B. S.</given-names></name><name><surname>Herman</surname><given-names>E. I.</given-names></name><name><surname>Winden</surname><given-names>K. D.</given-names></name><name><surname>Gdalyahu</surname><given-names>A.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits</article-title>. <source/>Cell
<volume>147</volume>, <fpage>235</fpage>–<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.08.040</pub-id><pub-id pub-id-type="pmid">21962519</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>E. K.</given-names></name><name><surname>Lee</surname><given-names>M. L.</given-names></name><name><surname>Martin-Ruiz</surname><given-names>C. M.</given-names></name><name><surname>Court</surname><given-names>J. A.</given-names></name><name><surname>Volsen</surname><given-names>S. G.</given-names></name><name><surname>Merrit</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain</article-title>. <source/>Am. J. Psychiatry
<volume>158</volume>, <fpage>1058</fpage>–<lpage>1066</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.158.7.1058</pub-id><pub-id pub-id-type="pmid">11431227</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phelan</surname><given-names>K.</given-names></name><name><surname>McDermid</surname><given-names>H. E.</given-names></name></person-group> (<year>2012</year>). <article-title>The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome)</article-title>. <source/>Mol. Syndromol.
<volume>2</volume>, <fpage>186</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1159/000334260</pub-id><pub-id pub-id-type="pmid">22670140</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piochon</surname><given-names>C.</given-names></name><name><surname>Kloth</surname><given-names>A. D.</given-names></name><name><surname>Grasselli</surname><given-names>G.</given-names></name><name><surname>Titley</surname><given-names>H. K.</given-names></name><name><surname>Nakayama</surname><given-names>H.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Corrigendum: cerebellar plasticity and motor learning deficits in a copy-number variation mouse model of autism</article-title>. <source/>Nat. Commun. <volume>6</volume>, <fpage>6014</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7014</pub-id><pub-id pub-id-type="pmid">25625889</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posey</surname><given-names>D. J.</given-names></name><name><surname>Puntney</surname><given-names>J. I.</given-names></name><name><surname>Sasher</surname><given-names>T. M.</given-names></name><name><surname>Kem</surname><given-names>D. L.</given-names></name><name><surname>McDougle</surname><given-names>C. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases</article-title>. <source/>J. Child Adolesc. Psychopharmacol.
<volume>14</volume>, <fpage>233</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1089/1044546041649084</pub-id><pub-id pub-id-type="pmid">15319020</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>A. E.</given-names></name><name><surname>Jeon</surname><given-names>O. H.</given-names></name><name><surname>Zimmerman</surname><given-names>A. W.</given-names></name><name><surname>Blue</surname><given-names>M. E.</given-names></name><name><surname>Pevsner</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>). <article-title>Postmortem brain abnormalities of the glutamate neurotransmitter system in autism</article-title>. <source/>Neurology
<volume>57</volume>, <fpage>1618</fpage>–<lpage>1628</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.57.9.1618</pub-id><pub-id pub-id-type="pmid">11706102</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Forssberg</surname><given-names>H.</given-names></name><name><surname>Diaz Heijtz</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Genetic variation in dopamine-related gene expression influences motor skill learning in mice</article-title>. <source/>Genes Brain Behav.
<volume>12</volume>, <fpage>604</fpage>–<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1111/gbb.12062</pub-id><pub-id pub-id-type="pmid">23819855</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragozzino</surname><given-names>M. E.</given-names></name><name><surname>Pal</surname><given-names>S. N.</given-names></name><name><surname>Unick</surname><given-names>K.</given-names></name><name><surname>Stefani</surname><given-names>M. R.</given-names></name><name><surname>Gold</surname><given-names>P. E.</given-names></name></person-group> (<year>1998</year>). <article-title>Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections</article-title>. <source/>J. Neurosci.
<volume>18</volume>, <fpage>1595</fpage>–<lpage>1601</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.18-04-01595.1998</pub-id><pub-id pub-id-type="pmid">9454864</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramalingam</surname><given-names>A.</given-names></name><name><surname>Zhou</surname><given-names>X. G.</given-names></name><name><surname>Fiedler</surname><given-names>S. D.</given-names></name><name><surname>Brawner</surname><given-names>S. J.</given-names></name><name><surname>Joyce</surname><given-names>J. M.</given-names></name><name><surname>Liu</surname><given-names>H. Y.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>16p13.11 duplication is a risk factor for a wide spectrum of neuropsychiatric disorders</article-title>. <source/>J. Hum. Genet.
<volume>56</volume>, <fpage>541</fpage>–<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1038/jhg.2011.42</pub-id><pub-id pub-id-type="pmid">21614007</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>P.</given-names></name><name><surname>Benito</surname><given-names>E.</given-names></name><name><surname>Fischer</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>MicroRNAs as biomarkers for CNS disease</article-title>. <source/>Front. Mol. Neurosci.
<volume>6</volume>:<fpage>39</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2013.00039</pub-id><pub-id pub-id-type="pmid">24324397</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravnan</surname><given-names>J. B.</given-names></name><name><surname>Tepperberg</surname><given-names>J. H.</given-names></name><name><surname>Papenhausen</surname><given-names>P.</given-names></name><name><surname>Lamb</surname><given-names>A. N.</given-names></name><name><surname>Hedrick</surname><given-names>J.</given-names></name><name><surname>Eash</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Subtelomere FISH analysis of 11 688 cases: an evaluation of the frequency and pattern of subtelomere rearrangements in individuals with developmental disabilities</article-title>. <source/>J. Med. Genet.
<volume>43</volume>, <fpage>478</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2005.036350</pub-id><pub-id pub-id-type="pmid">16199540</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>W. P.</given-names></name><name><surname>Bernasconi</surname><given-names>F.</given-names></name><name><surname>Mutirangura</surname><given-names>A.</given-names></name><name><surname>Ledbetter</surname><given-names>D. H.</given-names></name><name><surname>Langlois</surname><given-names>S.</given-names></name><name><surname>Malcolm</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>1993a</year>). <article-title>Nondisjunction of chromosome 15: origin and recombination</article-title>. <source/>Am. J. Hum. Genet.
<volume>53</volume>, <fpage>740</fpage>–<lpage>751</lpage>. <pub-id pub-id-type="pmid">8352279</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>W. P.</given-names></name><name><surname>Binkert</surname><given-names>F.</given-names></name><name><surname>Giné</surname><given-names>R.</given-names></name><name><surname>Vazquez</surname><given-names>C.</given-names></name><name><surname>Müller</surname><given-names>W.</given-names></name><name><surname>Rosenkranz</surname><given-names>W.</given-names></name><etal></etal></person-group>. (<year>1993b</year>). <article-title>Clinical and molecular analysis of five inv dup patients</article-title>. <source/>Eur. J. Hum. Genet.
<volume>1</volume>, <fpage>37</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1159/000472386</pub-id><pub-id pub-id-type="pmid">8069650</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>W. P.</given-names></name><name><surname>Spiegel</surname><given-names>R.</given-names></name><name><surname>Schinzel</surname><given-names>A. A.</given-names></name></person-group> (<year>1993c</year>). <article-title>Deletion breakpoints associated with the Prader-Willi and Angelman syndromes (15q11-q13) are not sites of high homologous recombination</article-title>. <source/>Hum. Genet.
<volume>91</volume>, <fpage>181</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1007/BF00222722</pub-id><pub-id pub-id-type="pmid">8462978</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodier</surname><given-names>P. M.</given-names></name><name><surname>Ingram</surname><given-names>J. L.</given-names></name><name><surname>Tisdale</surname><given-names>B.</given-names></name><name><surname>Croog</surname><given-names>V. J.</given-names></name></person-group> (<year>1997</year>). <article-title>Linking etiologies in humans and animal models: studies of autism</article-title>. <source/>Reprod. Toxicol.
<volume>11</volume>, <fpage>417</fpage>–<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1016/S0890-6238(97)80001-U</pub-id><pub-id pub-id-type="pmid">9100317</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronesi</surname><given-names>J. A.</given-names></name><name><surname>Collins</surname><given-names>K. A.</given-names></name><name><surname>Hays</surname><given-names>S. A.</given-names></name><name><surname>Tsai</surname><given-names>N. P.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Birnbaum</surname><given-names>S. G.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome</article-title>. <source/>Nat. Neurosci.
<volume>15</volume>, <fpage>431. s431</fpage>–<lpage>440. s431</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3033</pub-id><pub-id pub-id-type="pmid">22267161</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rugino</surname><given-names>T. A.</given-names></name><name><surname>Samsock</surname><given-names>T. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Levetiracetam in autistic children: an open-label study</article-title>. <source/>J. Dev. Behav. Pediatr.
<volume>23</volume>, <fpage>225</fpage>–<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1097/00004703-200208000-00006</pub-id><pub-id pub-id-type="pmid">12177568</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruhela</surname><given-names>R. K.</given-names></name><name><surname>Prakash</surname><given-names>A.</given-names></name><name><surname>Medhi</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>An urgent need for experimental animal model of autism in drug development</article-title>. <source/>Ann Neurosci
<volume>22</volume>, <fpage>44</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.5214/ans.0972.7531.220210</pub-id><pub-id pub-id-type="pmid">26124551</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadek</surname><given-names>B.</given-names></name><name><surname>Stark</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>Cherry-picked ligands at histamine receptor subtypes</article-title>. <source/>Neuropharmacology
<volume>106</volume>, <fpage>56</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.11.005</pub-id><pub-id pub-id-type="pmid">26581501</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadek</surname><given-names>B.</given-names></name><name><surname>Saad</surname><given-names>A.</given-names></name><name><surname>Sadeq</surname><given-names>A.</given-names></name><name><surname>Jalal</surname><given-names>F.</given-names></name><name><surname>Stark</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases</article-title>. <source/>Behav. Brain Res.
<volume>312</volume>, <fpage>415</fpage>–<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2016.06.051</pub-id><pub-id pub-id-type="pmid">27363923</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahoo</surname><given-names>S.</given-names></name><name><surname>Padhy</surname><given-names>S. K.</given-names></name><name><surname>Singla</surname><given-names>N.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Effectiveness of clozapine for the treatment of psychosis and disruptive behaviour in a child with Atypical Autism: a case report and a brief review of the evidence</article-title>. <source/>Asian J. Psychiatr.
<volume>29</volume>, <fpage>194</fpage>–<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajp.2017.07.012</pub-id><pub-id pub-id-type="pmid">28704788</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samaco</surname><given-names>R. C.</given-names></name><name><surname>McGraw</surname><given-names>C. M.</given-names></name><name><surname>Ward</surname><given-names>C. S.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Neul</surname><given-names>J. L.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>2013</year>). <article-title>Female Mecp2<sup>+/−</sup> mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies</article-title>. <source/>Hum. Mol. Genet.
<volume>22</volume>, <fpage>96</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/dds406</pub-id><pub-id pub-id-type="pmid">23026749</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>L. E.</given-names></name><name><surname>Campbell</surname><given-names>M.</given-names></name><name><surname>Small</surname><given-names>A. M.</given-names></name><name><surname>Cueva</surname><given-names>J. E.</given-names></name><name><surname>Armenteros</surname><given-names>J. L.</given-names></name><name><surname>Adams</surname><given-names>P. B.</given-names></name></person-group> (<year>1996</year>). <article-title>A pilot study of clomipramine in young autistic children</article-title>. <source/>J. Am. Acad. Child Adolesc. Psychiatry
<volume>35</volume>, <fpage>537</fpage>–<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1097/00004583-199604000-00021</pub-id><pub-id pub-id-type="pmid">8919717</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathe</surname><given-names>N.</given-names></name><name><surname>Andrews</surname><given-names>J. C.</given-names></name><name><surname>McPheeters</surname><given-names>M. L.</given-names></name><name><surname>Warren</surname><given-names>Z. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Nutritional and dietary interventions for autism spectrum disorder: a systematic review</article-title>. <source/>Pediatrics
<volume>139</volume>:<fpage>e20170346</fpage>. <pub-id pub-id-type="doi">10.1542/peds.2017-0346</pub-id><pub-id pub-id-type="pmid">28562286</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scahill</surname><given-names>L.</given-names></name><name><surname>Aman</surname><given-names>M. G.</given-names></name><name><surname>McDougle</surname><given-names>C. J.</given-names></name><name><surname>McCracken</surname><given-names>J. T.</given-names></name><name><surname>Tierney</surname><given-names>E.</given-names></name><name><surname>Dziura</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>A prospective open trial of guanfacine in children with pervasive developmental disorders</article-title>. <source/>J. Child Adolesc. Psychopharmacol.
<volume>16</volume>, <fpage>589</fpage>–<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2006.16.589</pub-id><pub-id pub-id-type="pmid">17069547</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>T.</given-names></name><name><surname>Roman</surname><given-names>A.</given-names></name><name><surname>Basta-Kaim</surname><given-names>A.</given-names></name><name><surname>Kubera</surname><given-names>M.</given-names></name><name><surname>Budziszewska</surname><given-names>B.</given-names></name><name><surname>Schneider</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid</article-title>. <source/>Psychoneuroendocrinology
<volume>33</volume>, <fpage>728</fpage>–<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2008.02.011</pub-id><pub-id pub-id-type="pmid">18396377</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott-Van Zeeland</surname><given-names>A. A.</given-names></name><name><surname>Abrahams</surname><given-names>B. S.</given-names></name><name><surname>Alvarez-Retuerto</surname><given-names>A. I.</given-names></name><name><surname>Sonnenblick</surname><given-names>L. I.</given-names></name><name><surname>Rudie</surname><given-names>J. D.</given-names></name><name><surname>Ghahremani</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Altered functional connectivity in frontal lobe circuits is associated with variation in the autism risk gene CNTNAP2</article-title>. <source/>Sci. Transl. Med.
<volume>2</volume>, <fpage>56ra80</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3001344</pub-id><pub-id pub-id-type="pmid">21048216</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeman</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Dopamine D2 receptors as treatment targets in schizophrenia</article-title>. <source/>Clin. Schizophr. Relat. Psychoses
<volume>4</volume>, <fpage>56</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.3371/CSRP.4.1.5</pub-id><pub-id pub-id-type="pmid">20643630</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>A.</given-names></name><name><surname>Wing</surname><given-names>L.</given-names></name></person-group> (<year>2006</year>). <article-title>Psychological approaches to chronic catatonia-like deterioration in autism spectrum disorders</article-title>. <source/>Int. Rev. Neurobiol.
<volume>72</volume>, <fpage>245</fpage>–<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1016/S0074-7742(05)72015-8</pub-id><pub-id pub-id-type="pmid">16697302</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>L.</given-names></name><name><surname>Bossers</surname><given-names>K.</given-names></name><name><surname>Luchetti</surname><given-names>S.</given-names></name><name><surname>Balesar</surname><given-names>R.</given-names></name><name><surname>Lethbridge</surname><given-names>N.</given-names></name><name><surname>Chazot</surname><given-names>P. L.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study</article-title>. <source/>Neurobiol. Aging
<volume>33</volume>, <fpage>1488.e1481</fpage>–<lpage>1488.e1413</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.10.016</pub-id><pub-id pub-id-type="pmid">22118942</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheldrick</surname><given-names>R. C.</given-names></name><name><surname>Carter</surname><given-names>A. S.</given-names></name></person-group> (<year>2018</year>). <article-title>State-level trends in the prevalence of Autism Spectrum Disorder (ASD) from 2000 to 2012: A reanalysis of findings from the autism and developmental disabilities network</article-title>. <source/>J. Autism Dev. Disord. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1007/s10803-018-3568-z</pub-id><pub-id pub-id-type="pmid">29654453</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Smith</surname><given-names>S. E.</given-names></name><name><surname>Malkova</surname><given-names>N.</given-names></name><name><surname>Tse</surname><given-names>D.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Patterson</surname><given-names>P. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Activation of the maternal immune system alters cerebellar development in the offspring</article-title>. <source/>Brain Behav. Immun.
<volume>23</volume>, <fpage>116</fpage>–<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2008.07.012</pub-id><pub-id pub-id-type="pmid">18755264</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soghomonian</surname><given-names>J. J.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Reprakash</surname><given-names>S.</given-names></name><name><surname>Blatt</surname><given-names>G. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Decreased parvalbumin mRNA levels in cerebellar Purkinje cells in autism</article-title>. <source/>Autism Res. <volume>10</volume>, <fpage>1787</fpage>–<lpage>1796</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1835</pub-id><pub-id pub-id-type="pmid">28707805</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokol</surname><given-names>D. K.</given-names></name><name><surname>Dunn</surname><given-names>D. W.</given-names></name><name><surname>Edwards-Brown</surname><given-names>M.</given-names></name><name><surname>Feinberg</surname><given-names>J.</given-names></name></person-group> (<year>2002</year>). <article-title>Hydrogen proton magnetic resonance spectroscopy in autism: preliminary evidence of elevated choline/creatine ratio</article-title>. <source/>J. Child Neurol.
<volume>17</volume>, <fpage>245</fpage>–<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1177/088307380201700401</pub-id><pub-id pub-id-type="pmid">12088077</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>H.</given-names></name><name><surname>Sadek</surname><given-names>B.</given-names></name><name><surname>Krause</surname><given-names>M.</given-names></name><name><surname>Hüls</surname><given-names>A.</given-names></name><name><surname>Ligneau</surname><given-names>X.</given-names></name><name><surname>Ganellin</surname><given-names>C. R.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Novel histamine H(3)-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds</article-title>. <source/>J. Med. Chem.
<volume>43</volume>, <fpage>3987</fpage>–<lpage>3994</lpage>. <pub-id pub-id-type="doi">10.1021/jm000966l</pub-id><pub-id pub-id-type="pmid">11052804</pub-id></mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>S. D.</given-names></name><name><surname>Minshew</surname><given-names>N. J.</given-names></name><name><surname>Luna</surname><given-names>B.</given-names></name><name><surname>Sweeney</surname><given-names>J. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Spatial working memory deficits in autism</article-title>. <source/>J. Autism Dev. Disord.
<volume>37</volume>, <fpage>605</fpage>–<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-006-0202-2</pub-id><pub-id pub-id-type="pmid">16909311</pub-id></mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephan</surname><given-names>D. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Unraveling autism</article-title>. <source/>Am. J. Hum. Genet.
<volume>82</volume>, <fpage>7</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2007.12.003</pub-id><pub-id pub-id-type="pmid">18179879</pub-id></mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strömland</surname><given-names>K.</given-names></name><name><surname>Nordin</surname><given-names>V.</given-names></name><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>Akerström</surname><given-names>B.</given-names></name><name><surname>Gillberg</surname><given-names>C.</given-names></name></person-group> (<year>1994</year>). <article-title>Autism in thalidomide embryopathy: a population study</article-title>. <source/>Dev. Med. Child Neurol.
<volume>36</volume>, <fpage>351</fpage>–<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.1994.tb11856.x</pub-id><pub-id pub-id-type="pmid">8157157</pub-id></mixed-citation>
</ref>
<ref id="B224">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubbs</surname><given-names>G.</given-names></name><name><surname>Henley</surname><given-names>K.</given-names></name><name><surname>Green</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Autism: will vitamin D supplementation during pregnancy and early childhood reduce the recurrence rate of autism in newborn siblings?</article-title>
<source/>Med. Hypotheses
<volume>88</volume>, <fpage>74</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2016.01.015</pub-id><pub-id pub-id-type="pmid">26880644</pub-id></mixed-citation>
</ref>
<ref id="B225">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabet</surname><given-names>A. C.</given-names></name><name><surname>Verloes</surname><given-names>A.</given-names></name><name><surname>Pilorge</surname><given-names>M.</given-names></name><name><surname>Delaby</surname><given-names>E.</given-names></name><name><surname>Delorme</surname><given-names>R.</given-names></name><name><surname>Nygren</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Complex nature of apparently balanced chromosomal rearrangements in patients with autism spectrum disorder</article-title>. <source/>Mol. Autism
<volume>6</volume>, <fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s13229-015-0015-2</pub-id><pub-id pub-id-type="pmid">25844147</pub-id></mixed-citation>
</ref>
<ref id="B226">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takuma</surname><given-names>K.</given-names></name><name><surname>Hara</surname><given-names>Y.</given-names></name><name><surname>Kataoka</surname><given-names>S.</given-names></name><name><surname>Kawanai</surname><given-names>T.</given-names></name><name><surname>Maeda</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism</article-title>. <source/>Pharmacol. Biochem. Behav.
<volume>126</volume>, <fpage>43</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2014.08.013</pub-id><pub-id pub-id-type="pmid">25240644</pub-id></mixed-citation>
</ref>
<ref id="B227">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiligada</surname><given-names>E.</given-names></name><name><surname>Kyriakidis</surname><given-names>K.</given-names></name><name><surname>Chazot</surname><given-names>P. L.</given-names></name><name><surname>Passani</surname><given-names>M. B.</given-names></name></person-group> (<year>2011</year>). <article-title>Histamine pharmacology and new CNS drug targets</article-title>. <source/>CNS Neurosci. Ther.
<volume>17</volume>, <fpage>620</fpage>–<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5949.2010.00212.x</pub-id><pub-id pub-id-type="pmid">22070192</pub-id></mixed-citation>
</ref>
<ref id="B228">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullmann</surname><given-names>R.</given-names></name><name><surname>Turner</surname><given-names>G.</given-names></name><name><surname>Kirchhoff</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Tonge</surname><given-names>B.</given-names></name><name><surname>Rosenberg</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation</article-title>. <source/>Hum. Mutat.
<volume>28</volume>, <fpage>674</fpage>–<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1002/humu.20546</pub-id><pub-id pub-id-type="pmid">17480035</pub-id></mixed-citation>
</ref>
<ref id="B229">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uvebrant</surname><given-names>P.</given-names></name><name><surname>Bauzienè</surname><given-names>R.</given-names></name></person-group> (<year>1994</year>). <article-title>Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits</article-title>. <source/>Neuropediatrics
<volume>25</volume>, <fpage>284</fpage>–<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1055/s-2008-1073041</pub-id><pub-id pub-id-type="pmid">7770124</pub-id></mixed-citation>
</ref>
<ref id="B230">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veenstra-VanderWeele</surname><given-names>J.</given-names></name><name><surname>Muller</surname><given-names>C. L.</given-names></name><name><surname>Iwamoto</surname><given-names>H.</given-names></name><name><surname>Sauer</surname><given-names>J. E.</given-names></name><name><surname>Owens</surname><given-names>W. A.</given-names></name><name><surname>Shah</surname><given-names>C. R.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>5469</fpage>–<lpage>5474</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1112345109</pub-id><pub-id pub-id-type="pmid">22431635</pub-id></mixed-citation>
</ref>
<ref id="B231">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viktorin</surname><given-names>A.</given-names></name><name><surname>Uher</surname><given-names>R.</given-names></name><name><surname>Reichenberg</surname><given-names>A.</given-names></name><name><surname>Levine</surname><given-names>S. Z.</given-names></name><name><surname>Sandin</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Autism risk following antidepressant medication during pregnancy</article-title>. <source/>Psychol. Med.
<volume>47</volume>, <fpage>2787</fpage>–<lpage>2796</lpage>. <pub-id pub-id-type="doi">10.1017/S0033291717001301</pub-id><pub-id pub-id-type="pmid">28528584</pub-id></mixed-citation>
</ref>
<ref id="B232">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voineagu</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Johnston</surname><given-names>P.</given-names></name><name><surname>Lowe</surname><given-names>J. K.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Horvath</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Transcriptomic analysis of autistic brain reveals convergent molecular pathology</article-title>. <source/>Nature
<volume>474</volume>, <fpage>380</fpage>–<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1038/nature10110</pub-id><pub-id pub-id-type="pmid">21614001</pub-id></mixed-citation>
</ref>
<ref id="B233">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkmar</surname><given-names>F.</given-names></name><name><surname>Cook</surname><given-names>E. H.</given-names><suffix>Jr.</suffix></name><name><surname>Pomeroy</surname><given-names>J.</given-names></name><name><surname>Realmuto</surname><given-names>G.</given-names></name><name><surname>Tanguay</surname><given-names>P.</given-names></name></person-group> (<year>1999</year>). <article-title>Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of child and adolescent psychiatry working group on quality issues</article-title>. <source/>J. Am. Acad. Child Adolesc. Psychiatry
<volume>38</volume>(<issue>12 Suppl.</issue>), <fpage>32s</fpage>–<lpage>54s</lpage>. <pub-id pub-id-type="doi">10.1016/S0890-8567(99)80003-3</pub-id><pub-id pub-id-type="pmid">10624084</pub-id></mixed-citation>
</ref>
<ref id="B234">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Coburg</surname><given-names>Y.</given-names></name><name><surname>Kottke</surname><given-names>T.</given-names></name><name><surname>Weizel</surname><given-names>L.</given-names></name><name><surname>Ligneau</surname><given-names>X.</given-names></name><name><surname>Stark</surname><given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics</article-title>. <source/>Bioorg. Med. Chem. Lett.
<volume>19</volume>, <fpage>538</fpage>–<lpage>542</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2008.09.012</pub-id><pub-id pub-id-type="pmid">19091563</pub-id></mixed-citation>
</ref>
<ref id="B235">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorstman</surname><given-names>J. A. S.</given-names></name><name><surname>Parr</surname><given-names>J. R.</given-names></name><name><surname>Moreno-De-Luca</surname><given-names>D.</given-names></name><name><surname>Anney</surname><given-names>R. J. L.</given-names></name><name><surname>Nurnberger</surname><given-names>J. I.</given-names><suffix>Jr.</suffix></name><name><surname>Hallmayer</surname><given-names>J. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Autism genetics: opportunities and challenges for clinical translation</article-title>. <source/>Nat. Rev. Genet.
<volume>18</volume>, <fpage>362</fpage>–<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1038/nrg.2017.4</pub-id><pub-id pub-id-type="pmid">28260791</pub-id></mixed-citation>
</ref>
<ref id="B236">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>B. R.</given-names></name><name><surname>Diefenbach</surname><given-names>K. S.</given-names></name><name><surname>Parikh</surname><given-names>T. N.</given-names></name></person-group> (<year>2007</year>). <article-title>Inhibition within the nucleus tractus solitarius (NTS) ameliorates environmental exploration deficits due to cerebellum lesions in an animal model for autism</article-title>. <source/>Behav. Brain Res.
<volume>176</volume>, <fpage>109</fpage>–<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2006.08.008</pub-id><pub-id pub-id-type="pmid">16971000</pub-id></mixed-citation>
</ref>
<ref id="B237">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zong</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-beta type II receptor</article-title>. <source/>Brain Res.
<volume>1357</volume>, <fpage>166</fpage>–<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2010.08.023</pub-id><pub-id pub-id-type="pmid">20709030</pub-id></mixed-citation>
</ref>
<ref id="B238">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Almeida</surname><given-names>L. E.</given-names></name><name><surname>Spornick</surname><given-names>N. A.</given-names></name><name><surname>Kenyon</surname><given-names>N.</given-names></name><name><surname>Kamimura</surname><given-names>S.</given-names></name><name><surname>Khaibullina</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Modulation of social deficits and repetitive behaviors in a mouse model of autism: the role of the nicotinic cholinergic system</article-title>. <source/>Psychopharmacology (Berl)
<volume>232</volume>, <fpage>4303</fpage>–<lpage>4316</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-015-4058-z</pub-id><pub-id pub-id-type="pmid">26337613</pub-id></mixed-citation>
</ref>
<ref id="B239">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Detection of circulating miRNA levels in schizophrenia</article-title>. <source/>Am. J. Psychiatry
<volume>172</volume>, <fpage>1141</fpage>–<lpage>1147</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2015.14030273</pub-id><pub-id pub-id-type="pmid">26183697</pub-id></mixed-citation>
</ref>
<ref id="B240">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitlauf</surname><given-names>A. S.</given-names></name><name><surname>Sathe</surname><given-names>N.</given-names></name><name><surname>McPheeters</surname><given-names>M. L.</given-names></name><name><surname>Warren</surname><given-names>Z. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Interventions targeting sensory challenges in autism spectrum disorder: a systematic review</article-title>. <source/>Pediatrics
<volume>139</volume>:<fpage>e20170347</fpage>. <pub-id pub-id-type="doi">10.1542/peds.2017-0347</pub-id><pub-id pub-id-type="pmid">28562287</pub-id></mixed-citation>
</ref>
<ref id="B241">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetmore</surname><given-names>D. Z.</given-names></name><name><surname>Garner</surname><given-names>C. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Emerging pharmacotherapies for neurodevelopmental disorders</article-title>. <source/>J. Dev. Behav. Pediatr.
<volume>31</volume>, <fpage>564</fpage>–<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1097/DBP.0b013e3181ee3833</pub-id><pub-id pub-id-type="pmid">20814256</pub-id></mixed-citation>
</ref>
<ref id="B242">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Willem Verhoeven</surname><given-names>J. E. A. I. F.</given-names></name></person-group> (<year>2011</year>). <source/>Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment. <publisher-loc>Rijeka</publisher-loc>: <publisher-name>InTech Janeza Trdine</publisher-name>.</mixed-citation>
</ref>
<ref id="B243">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkin</surname><given-names>J. M.</given-names></name><name><surname>Nelson</surname><given-names>D. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system</article-title>. <source/>Pharmacol. Ther.
<volume>103</volume>, <fpage>1</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2004.05.001</pub-id><pub-id pub-id-type="pmid">15251226</pub-id></mixed-citation>
</ref>
<ref id="B244">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>H. H.</given-names></name><name><surname>Smith</surname><given-names>R. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders</article-title>. <source/>J. Autism Dev. Disord.
<volume>36</volume>, <fpage>901</fpage>–<lpage>909</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-006-0131-0</pub-id><pub-id pub-id-type="pmid">16897395</pub-id></mixed-citation>
</ref>
<ref id="B245">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>C.</given-names></name><name><surname>Shin</surname><given-names>J. H.</given-names></name><name><surname>Rajpurohit</surname><given-names>A.</given-names></name><name><surname>Deep-Soboslay</surname><given-names>A.</given-names></name><name><surname>Collado-Torres</surname><given-names>L.</given-names></name><name><surname>Brandon</surname><given-names>N. J.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Altered expression of histamine signaling genes in autism spectrum disorder</article-title>. <source/>Transl. Psychiatry
<volume>7</volume>:<fpage>e1126</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2017.87</pub-id><pub-id pub-id-type="pmid">28485729</pub-id></mixed-citation>
</ref>
<ref id="B246">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>S.</given-names></name><name><surname>Heuvelman</surname><given-names>H.</given-names></name><name><surname>Magnusson</surname><given-names>C.</given-names></name><name><surname>Rai</surname><given-names>D.</given-names></name><name><surname>Lyall</surname><given-names>K.</given-names></name><name><surname>Newschaffer</surname><given-names>C. J.</given-names></name><etal></etal></person-group>. (<year>2017</year>). <article-title>Prevalence of autism spectrum disorders with and without intellectual disability by gestational age at birth in the Stockholm youth cohort: a register linkage study</article-title>. <source/>Paediatr. Perinat. Epidemiol.
<volume>31</volume>, <fpage>586</fpage>–<lpage>594</lpage>. <pub-id pub-id-type="doi">10.1111/ppe.12413</pub-id><pub-id pub-id-type="pmid">28898924</pub-id></mixed-citation>
</ref>
<ref id="B247">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>Strathearn</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Bao</surname><given-names>W.</given-names></name></person-group> (<year>2018</year>). <article-title>Prevalence of Autism spectrum disorder among US children and adolescents, 2014–2016</article-title>. <source/>JAMA
<volume>319</volume>, <fpage>81</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.17812</pub-id><pub-id pub-id-type="pmid">29297068</pub-id></mixed-citation>
</ref>
<ref id="B248">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X. L.</given-names></name><name><surname>Zong</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Biswas</surname><given-names>M. H.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Nelson</surname><given-names>D. L.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>FXR1P but not FMRP regulates the levels of mammalian brain-specific microRNA-9 and microRNA-124</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>13705</fpage>–<lpage>13709</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2827-11.2011</pub-id><pub-id pub-id-type="pmid">21957233</pub-id></mixed-citation>
</ref>
<ref id="B249">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuddas</surname><given-names>A.</given-names></name><name><surname>Ledda</surname><given-names>M. G.</given-names></name><name><surname>Fratta</surname><given-names>A.</given-names></name><name><surname>Muglia</surname><given-names>P.</given-names></name><name><surname>Cianchetti</surname><given-names>C.</given-names></name></person-group> (<year>1996</year>). <article-title>Clinical effects of clozapine on autistic disorder</article-title>. <source/>Am. J. Psychiatry
<volume>153</volume>, <fpage>738</fpage>. <pub-id pub-id-type="doi">10.1176/ajp.153.5.738a</pub-id><pub-id pub-id-type="pmid">8615435</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>